NZ758264B2 - Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same - Google Patents

Abstract

The disclosure relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

Description

MULTISPECIFIC PTIDE UCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME This application claims priority from US. ional application No. 62/484,217 ?led April 1 l, 2017, entitled "MULTISPECIFIC POLYPEPTIDES HAVING DUAL EFFECTOR FUNCTION AND METHODS OF USING THE SAME," the contents ofWhich are incorporated by reference in their entirety.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING The present application is being ?led along with a Sequence Listing in onic format. The Sequence Listing is provided as a ?le entitled 74495200014OSeqList.TXT, created April 11, 2018 which is 174,179 bytes in size. The information in the electronic format of the Sequence Listing is incorporated by nce in its entirety.

FIELD OF THE DISCLOSURE The invention relates generally to multispeciflc polypeptides having constrained CD3 binding. In some embodiments, the multispeciflc polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also ed are methods of making and using these multispeciflc polypeptides in a variety of therapeutic, stic and prophylactic indications.

BACKGROUND OF THE DISCLOSURE eutic antibodies that cause target cell ion generally rely on effector functions mediated via interaction with Fc-gamma-receptors (Fm/Rs) and complement proteins. or cells expressing FcyRs are predominately those of the innate immune system. T-cells are not direct effector cells involved in antibody mediated target cell depletion.

CD3 (Cluster of Differentiation 3) T-cell co-receptor is a multimeric protein composed of four distinct polypeptide chains, referred to as the a, y, 6, and C chains. The CD3 complex serves as the signaling module of the T cell receptor that ates non-covalently with the antigen-binding a/b chains of T cell receptor (TCR).

Because direct engagement of CD3 results in T-cell activation, it is a desirable target for a variety of therapeutic and/or diagnostic indications. Accordingly, there exists a need for antibodies and therapeutics that target the CD3/TCR pathway.

SUMMARY OF THE SURE The present disclosure provides multispeci?c polypeptide constructs that exhibit constrained CD3 binding. In some embodiments, the multispeci?c polypeptide uct is composed of a ?rst component comprising an immunoglobulin Fc region and a second component comprising a CD3-binding region, wherein the ?rst and second components are d by a linker or operably linked, wherein the Fc region is positioned N—terrninal to the CD3-binding region; and one or both of the ?rst and second components comprises an antigen binding domain that binds a tumor associated antigen (TAA). In some embodiments, the peci?c polypeptide construct, in an inactive state, is composed of a ?rst component and a second component, wherein the ?rst and second ents are operably linked, wherein each of the ?rst and second components comprises an antigen binding domain that binds a tumor associated antigen (TAA), wherein the ?rst component comprises an Fc region, wherein the second ent comprises a CD3-binding region, and wherein the ?rst and second ents are d by a cleavable linker. In some embodiments, the CD3- binding region binds CD3 (CD38).

In some embodiments, the antigen binding domain is positioned terminally relative to the Fc region and/or carboxy-terminally relative to the CD3 binding region of the multispeci?c polypeptide construct. In some embodiments, the ?rst component comprises a ?rst antigen binding domain and the second component comprises a second antigen g domain, wherein each of the antigen binding domains bind a tumor associated antigen (TAA). In some cases, the ?rst antigen binding domain is positioned at the amino terminus of the multispeci?c construct and the second n g domain is oned at the carboxy terminus of the multispeci?c construct. In some embodiments, the ?rst antigen binding domain is positioned amino-terminally relative to the Fc region and/or carboxy- terminally relative to the CD3 binding region of the peci?c polypeptide construct.

Provided herein is a multispeci?c polypeptide construct, n the multi speci?c construct comprises in order, from inus to C—terminus: a ?rst antigen binding domain that binds to a tumor-associated antigen (TAA); an immunoglobulin Fc region, a linker, a CD3 binding region that binds CD3 (CD38), and a second antigen binding domain that binds a tumor-associated antigen (TAA). Also provided is a multispeci?c polypeptide construct, wherein the peciflc uct comprises in order, from N- terminus to C-terminus: an immunoglobulin Fc region; a linker; a CD3 binding region that binds CD3 (CD38); and an antigen binding domain that binds a tumor-associated antigen (TAA). Provided is a multispecific polypeptide construct, wherein the multispeciflc construct comprises in order, from N—terminus to C-terminus: an antigen binding domain that binds to a tumor-associated antigen (TAA); an immunoglobulin Fc ; a linker; and a CD3 binding region that binds CD3 (CD38).

Among embodiments of the t disclosure are multispeci?c polypeptide constructs that bind at least CD3 and a second n, such as a tumor associated antigen (TAA). The multispeciflc polypeptide constructs provided herein include at least a ?rst component that includes one or more copies of an n-binding domain that bind an antigen linked to an immunoglobulin Fc region, a second component that includes one or more copies of at least a binding domain that binds CD3 red to herein as an anti-CD3 binding domain or CD3 binding region, which are used interchangeably herein), and a linker, such as a cleavable linker, that joins the ?rst component and the second component.

The positioning of the Fc region N—terminal to the CD3 binding region reduces or prevents the ability of the CD3 binding region to bind CD3. In some embodiments, in the uncleaved/inactive state, the first component (component #1) and the second component (component #2) of the multispeciflc polypeptide constructs are linked and binding to CD3 is owed, unless the antigen binding domain(s) are bound to their cognate antigen. This is advantageous as it prevents systemic g of the CD3 binding region to T-cells and focuses it to site of n expression. This is bene?cial as it eliminates a major g sink of peripheral T-cells, allowing more favorable distribution and localization at site of antigen expression, e. g, tumor cells or the tumor microenvironment. In some cases, binding and/or engagement of CD3 is amplified or increased by inclusion of a cleavable linker joining component #1 and component # 2, in which upon cleavage of the cleavable linker, such as by proteolysis, increased g by the CD3 binding region is enabled.

In the inactive, 116., uncleaved state, component #1 and component #2 of the peciflc ptide constructs are operably linked and do not bind or otherwise engage CD3 unless the antigen binding (s) is bound to their cognate antigen. In some embodiments, the uncleaved multispeciflc polypeptide constructs are capable of interacting with FcyRs and mediating innate immune effector functions, for example antibody ent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). In some embodiments, the uncleaved multispeciflc polypeptide constructs are capable of interacting with complement proteins, namely Clq, and mediating ment dependent cytotoxicity.

The multispeciflc polypeptide constructs of the disclosure generally have more than one antigen-binding (s). In provided s in which the multispeciflc polypeptide constructs contain a cleavable linker, once the linker joining the ?rst and second ent is cleaved, such as by protease, each component maintains at least one antigen binding domain. The ?rst component (i.e., ent #1) contains at least an Fc region and n binding domain. The second component (i.e., component #2) contains at least an anti- CD3 binding domain and an antigen binding domain, Cleavage, such as by proteolysis, within the cleavable linker physically separates component #1 and component #2, each of which has therapeutic utility albeit rely on different effector cells. Component #1 contains at least one antigen binding domain and an Fc region.

In some embodiments, component #1 is capable of eliciting innate immune effector functions, for example ADCC, cytokine release, degranulation and/or phagocytosis.

Component #2 contains at least domain CD3 binding region and an antigen binding domain, the former of which is capable of binding CD3 (when separated from ent #1). ent #2 is capable of forming an immune synapse between an antigen expression cell and a T-cell. This co-engagement mediates antigen dependent T-cell activation, cytotoxicity, cytokine release, degranulation and proliferation. In the d/activated state component #2 is not ly linked to the Fc—region of component #1 and thereby component #2 does not interact with FcRn and has enhanced serum clearance if localized to a site without an antigen expressing cell. This is advantageous as it limits the systemic exposure of the activated anti- CD3 binding domain and focuses directly into antigen expressing tissues, e.g., tumor cells or the tumor microenvironment.

In some ments, the multispecific polypeptide is in an inactive state, i.e., uncleaved state, and binding of the CD3—binding region to CD3 is inhibited or substantially reduced when the multispeciflc polypeptide construct is in an ved state compared to a cleaved state. In some embodiments, the peciflc polypeptide is in an activated state, and the first and second components are not operably linked. In some embodiments, the multispeciflc polypeptide is in an activated state, 1'. e., cleaved state, and the second component binds the epsilon chain of CD3 (CD38) and a tumor associated antigen (TAA).

In some aspects, the antigen binding domain, or independently each of the antigen binding domains, is selected from an dy or antigen binding fragment, a natural cognate binding partner, an Anticalin (engineered lipocalin), a Darpin, a Fynomer, a Centyrin (engineered ?broneticin III domain), a cystine-knot domain, an Af?lin, an Af?body, or an engineered CH3 . In some embodiments, the natural cognate binding partner comprises an extracellular domain or binding fragment thereof of the native cognate binding partner of the TAA, or a variant thereof that exhibits binding activity to the TAA.

In some aspects, the antigen g domain, or independently each of the antigen binding domains, comprises an extracellular domain or binding nt thereof of the native cognate binding partner of the TAA, or a variant f that exhibits binding activity to the In some ments, the ?rst ent includes one or more copies of an antigen—binding domain. In some embodiments, the ?rst component contains at least two antigen binding domains, such as two antigen binding domains. In some embodiments, the at least two antigen binding domains of the ?rst component bind to the same TAA. In some cases, the at least two antigen binding domains of the ?rst component binds to a different epitope of the same TAA. In some instances, the at least two antigen binding domains of the ?rst ent binds to a different epitope of the same TAA. In some embodiments, the at least two antigen binding domain of the ?rst component bind to a different TAA.

In some embodiments, the n-binding domain of the ?rst component, which, in some cases is a ?rst antigen binding domain, includes one or more copies of an antibody or an antigen—binding fragment thereof. In some embodiments, the antigen binding domain of the ?rst component, such as the ?rst antigen-binding domain es one or more copies of an dy or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, an Fv fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the ?rst antigen-binding domain includes one or more copies of one or more single domain antibody (sdAb) fragments, for example VHH, VNAR, engineered VH or VK domains. VHHs can be generated from d heavy chain only antibodies. VNARs can be ted from cartilaginous ?sh heavy chain only antibodies. Various methods have been implemented to te monomeric sdAbs from conventionally heterodimeric VH and VK domains, including interface engineering and selection of speci?c geImline families.

In some embodiments, the n binding domain of the ?rst component, such as the ?rst n binding domain, binds an antigen, such as a tumor associated antigen (TAA).

In some embodiments, the TAA is selected from the group consisting of 1LFA-3, 5T4, Alpha-4 integrin, Alpha-V in, alpha4beta1 integrin, alpha4beta7 integrin, AGRZ, Anti- Lewis-Y, Apelin J receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), ic ase 9, CD2, CD3, CD6, CD9, CD11a, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD40L, CD41, CD44, CD44V6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD137, CD138, CD166, CD172A, CD248, CDH6, CEACAM5 (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, , CTLA-4, CTGF, CXCLIO, CXCL13, CXCRI, CXCR2, CXCR4, CYR61, DL44, DLK1,DLL3, DLL4, DPP-4, DSGl, EDA, EDB, EGFR, ii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-Z, FGF8, FGFRI, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FRoc), GAL3ST1, G—C SF, G-CSFR, GD2, GITR, GLUTl, GLUT4, , R, GP IIb/IIIa receptors, Gp130, GPIIB/IIIA, GPNMB, GRP78, HER2/neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGFlR, ILlB, ILlR, 1L2, IL] 1, IL12, ILlZp40, , IL-12Rbeta1, ILl3, IL13R, 1L15, ILl7, ILl8, IL21, IL23, IL23R, IL27/IL27R (wsxl), IL29, IL—3 1R, 1L3 1/IL31R, ILZR, IL4, IL4R, 1L6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISSl-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUC1, Mucin-16 (MUC16, CA-125), Na/K ATPase, NGF, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM— R, OX-40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, eta, PD-l, PD-Ll, PD-L2, Phosphatidyl-serine, PlGF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, , STEAPZ, TAG-72, TAPAl, TEM-8, TGFbeta, TIGIT, TIM-3, TLRZ, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, INFR, TNFRSl2A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAPl, VCAM-l, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFRI, VEGFRZ, VEGFR3, VISTA, WISP-l, WISP-2, and WISP-3.

In some embodiments, the Fc region is a homodimeric Fc region. In some ments, the Fc region is a heterodimeric Fc region.

In some embodiments, the immunoglobulin Fc region of the ?rst component is an IgG isotype selected from the group consisting of IgG1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 subclass. In some examples, the Fc region is an Fc region of a human IgG1,a human IgG2, a human IgG3, or a human IgG4, or is an immunologically active fragment thereof. In some embodiments, the Fc region comprises a ptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NOzl. In some cases, the Fc region comprises a polypeptide ses the amino acid sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO:2. In some of any such embodiments, the Fc region comprises a polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO:4. In some examples, the Fc region ses a polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 5 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence ty to SEQ ID N05 In some embodiments, the immunoglobulin Fc region is a polypeptide comprising an amino acid sequence selected from the group ting of SEQ ID NOS: 1-6.

In some embodiments, the immunoglobulin Fc region is a polypeptide sing an amino acid sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1—6.

In some embodiments, the immunoglobulin Fc region is a polypeptide comprising an amino acid sequence that is derived from an amino acid sequence selected from the group consisting of SEQ ID NOs: 1—6. In some ments, the immunoglobulin Fc region is a polypeptide comprising an amino acid ce that is derived from an amino acid sequence selected from the group consisting of SEQ ID NOs: l-6 comprising one or modi?cations. In some embodiments, the immunoglobulin Fc region is a polypeptide comprising an amino acid sequence that is derived from an amino acid sequence ed from the group consisting of SEQ ID NOs: l-6 comprising one or modi?cations to prevent glycosylation, to alter Fc receptor interactions, to reduce Fc receptor binding, to enhance the interaction with CD3 2A, to reduce the complement n Clq binding, to extend the half-life, to enhance FcRn binding, to alter antibody-dependent cellular cytotoxicity (ADCC) and/or complement- dependent cytotoxicity (CDC), to induce heterodimerization, to prevent dimerization, to stabilize the homodimerization at the CH3 :CH3 ace, and combinations thereof.

In some embodiments, the PC is a heterodimeric Fc. In some cases, one or both Fc polypeptides of the heterodimeric Fc region comprises at least one modi?cation to induce heterodimerization compared to a polypeptide of a homodimeric Fc region, optionally compared to the Fc polypeptide set forth in SEQ ID N01 or an immunologically active fragment thereof .

In some embodiments, each of the Fc polypeptides of the heterodimeric Fc independently comprise at least one amino acid ation. In some cases, each of the Fc polypeptides of the heterodimeric Fc comprise a knob-into-hole modi?cation or comprise a charge mutation to increase electrostatic complementarity of the polypeptides. In some examples, the amino acid modi?cation is a knob-into-hole modi?cation.

In some embodiments, the ?rst Fc ptide of the heterodimeric Fc comprises the ation selected from among Thr3668er, Leu368Ala, Tyr407Val, and combinations thereof and the second Fc polypeptide of the heterodimeric Fc comprises the modi?cation T366W. In some cases, the ?rst and second Fc polypeptides further comprise a modi?cation of a non-cysteine residue to a cysteine residue, wherein the ation of the ?rst polypeptide is at one of a position Ser354 and Y349 and the ation of the second Fc polypeptide is at the other of the on Ser354 and Y349.

In some examples, the amino acid modi?cation is a charge on to se electrostatic complementarity of the polypeptides. In some embodiments, the ?rst and/or second Fc polypeptides se a modi?cation in complementary positions, wherein the modi?cation is replacement with an amino acid having an opposite charge to the complementary amino acid of the other polypeptide. In some embodiments, the ?rst or second polypeptide comprise a modi?cation in complementary positions, wherein the modi?cation is replacement with an amino acid having an opposite charge to the complementary amino acid of the other polypeptide. In some embodiments, at least the ?rst or second Fc polypeptides each comprise a modi?cation in a complementary position, wherein the modi?cation is replacement with an amino acid having an opposite charge to the complementary amino acid of the other polypeptide. In some embodiments, the ?rst and second Fc polypeptides each se a modi?cation in complementary positions, n the modi?cation is replacement with an amino acid having an opposite charge to the complementary amino acid of the other polypeptide.

In some embodiments, one of the ?rst or second Fc polypeptide of the heterodimeric Fc r comprises a modi?cation at residue Ile253. In some instances, the modi?cation is Ile253Arg. In some embodiments, one of the ?rst or second Fc ptide of the heterodimeric Fc further comprises a modi?cation at e His435. In some instances, the modi?cation is His43 SArg. In some embodiments, the Fc region comprises a polypeptide that lacks Lys447.

In some embodiments, modi?cations within the Fc region reduce binding to Fc- receptor-gamma receptors while having minimal impact on binding to the neonatal Fc receptor (FcRn). In some embodiments, the mutated or modi?ed Fc polypeptide includes the following mutations: Tyr and Met428Leu or Met252Tyr and Met428Val (M252Y, M428L, or M252Y, M428V) using the Kabat ing system.

In some embodiments, the Fc region comprises a polypeptide comprising at least one modi?cation to enhance FcRn binding. In some examples, the modi?cation is at a position selected from the group consisting of Met252, Ser254, Thr256, Met428, Asn434, and combinations thereof. In some cases, the modi?cation is at a position selected from the group consisting of Met252Y, Ser254T, E, Met428L, V, Asn434S, and combinations thereof. In some particular embodiments, the modi?cation is at position Met252 and at position Met428. In some cases, the modi?cation is Met252Y and Met428L.

In some cases, the ation is Met252Y and Met428V.

In some embodiments, the ?rst polypeptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS:82, 86, 94 or 96, and the second polypeptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS:83, 87, 90, 92, 98 or 100.

In some embodiments, the Fc region comprises a polypeptide comprising at least one amino acid modi?cation that reduces effector function and/or reduces binding to an effector molecule selected from an Fc gamma receptor or Clq. In some examples, the one or more amino acid modi?cation is deletion of one or more of Glu233, Leu234 or Leu235. In some aspects, the ?rst polypeptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS: 84, 88, 95 or 97 and the second ptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS: 85, 89, 91, 93, 99 or 101.

In some embodiments, the Fc region ses a polypeptide sing at least one ation to enhance FcyR g. In some cases, the modi?cation is modi?cation at Ser239 or Ile332. In some embodiments, the glycosylation of the Fc region is modi?ed to enhance FcyR binding as compared to an unmodi?ed Fc region. In some examples, the Fc region lacks or has reduced fucose content.

In some embodiments, the CD3 binding region is an anti-CD3 dy or antigen-binding fragment. In some embodiments, the anti-CD3 antibody or antigen g fragment comprises a variable heavy chain region (VH) and a variable light chain region (VL). In some of any such embodiments, the CD3 binding region is monovalent.

In some embodiments, the anti-CD3 antibody or antigen binding fragment is not a single chain antibody, optionally is not a single chain variable fragment (scFV). In some embodiments, the Fc is a dimelic EC and the VH and VL that comprise the anti-CD3 dy or antigen binding fragment are linked to opposite polypeptides of the heterodimeric PC. In some embodiments, the CD3 binding region is not able to, or is not substantially able to, bind or engage CD3 unless at least one of the antigen binding domain is bound to its TAA.

In some aspects, the CD3 binding region is not able to, or is not substantially able, to bind or engage CD3 unless at least two of the antigen binding domain is bound to its TAA.

In some embodiments, the multispeci?c polypeptide construct contains a linker that is a ptide . In some embodiments, the linker is a polypeptide of up to 25 amino acids in length. In some cases, the linker is a polypeptide of from or from about 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 24 amino acids, 6 to amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 24 amino acids, 8 to 20 amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, 10 to 14 amino acids, 10 to 12 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 24 amino acids, 18 to 20 amino acids or 20 to 24 amino acids. In some embodiments, the linker is a polypeptide that is 3, 4,5, 6, 7, ,11,12,13,l4,15,l6,l7,l8,l9 or 20 amino acids in length. In some cases, the linker is a cleavable linker.

In some embodiments, the ?rst antigen binding domain and the immunoglobulin Fc polypeptide are operably linked Via amino acid linkers. In some embodiments, these intra- component linkers are ed predominately of the amino acids Glycine and Serine, denoted as GS—linkers herein. The GS—linkers of the fusion proteins of the t disclosure can be ofvarious lengths, for example 3, 4,5, 6, 7, 8, 9, 10, ll, 12, 13, 14, 15, 16, 17, 18, 19, amino acids in length.

In some embodiments, the GS-linker comprises an amino acid sequence selected from the group consisting of GGSGGS, i.e., (GGS); (SEQ ID NO: 10); GGSGGSGGS, 1'. e., (GGS)3 (SEQ ID NO: 11), GGSGGSGGSGGS, 1'. e., (GGS)4 (SEQ ID NO: 12), and GGSGGSGGSGGSGGS, i.e., (GGS)5 (SEQ ID NO: 13).

In some embodiments, the second component also includes one or more copies of an anti-CD3 binding domain. In some embodiments, the D3 binding domain includes one or more copies of an antibody or an antigen-binding fragment thereof. In some embodiments, the anti-CD3 binding domain includes one or more copies of an dy or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, an FV fragment, a scFV, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the anti-CD3 binding domain includes an FV antibody fragment that binds CD38 (referred to herein as an D38 FV fragment). In some embodiments, the anti-CD38 FV antibody fragment includes an amino acid sequence selected from the group of SEQ ID NO: 32-81. In some embodiments, the anti-CD33 FV antibody fragment includes an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 32-81. In some embodiments, the anti-CD38 FV antibody fragment includes a combination of an amino acid sequence ed from the group of SEQ ID NO: 32-62 and an amino acid sequence selected from the group consisting of SEQ ID NO: 63-81. In some embodiments, the D38 FV antibody fragment includes a combination of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group ting of SEQ ID NO: 32-62 and an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence ed from the group consisting of SEQ ID NO: 63-81 an amino acid ce.

In some embodiments, the anti-CD38 FV antibody fragment is a disulfide ized anti-CD3 binding FV fragment (dst).

In some embodiments, the second component also includes one or more copies of an antigen—binding domain. In n embodiments, the second component contain at least two antigen binding domains, such as two antigen binding s. In some ments, the at least two antigen binding s of the second component bind to the same TAA. In some cases, the at least two antigen binding domains of the second component binds to a different epitope of the same TAA. In some instances, the at least two antigen binding s of the second component binds to a different epitope of the same TAA. In some embodiments, the at least two antigen binding domain of the second component bind to a different TAA.

In some embodiments, the first component contains a first antigen binding domain and the antigen binding domain of the second component is a second antigen binding . In some embodiments, the second antigen-binding domain of the second ent binds the same antigen as the ?rst antigen-binding domain of the ?rst component. In some embodiments, the second antigen-binding domain of the second component binds a different epitope on the same antigen as the ?rst antigen-binding domain of the ?rst component. In some embodiments, the second antigen-binding domain of the second component binds the epitope on the same antigen as the ?rst antigen-binding domain of the ?rst ent.

In some embodiments, the antigen binding domain of the second component, such as the second antigen-binding domain, includes one or more copies of an antibody or an antigen-binding fragment thereof. In some embodiments, the second antigen-binding domain includes one or more copies of an antibody or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab‘)2 fragment, an Fv fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the second n-binding domain includes one or more copies of one or more single domain antibody (sdAb) nts, for example VHH, VNAR, engineered VH or VK domains. VHHs can be generated from camelid heavy chain only antibodies. VNARs can be ted from cartilaginous ?sh heavy chain only antibodies.

Various methods have been implemented to generate monomeric sdAbs from conventionally dimeric VH and VK domains, including interface engineering and ion of speci?c germline families.

In some embodiments, the antigen binding domain of the second component, such as the second antigen-binding domain,_binds an antigen, such as a tumor associated antigen (TAA). In some embodiments, the TAA is selected from the group consisting of 1- 92-LFA—3, 5T4, Alpha—4 integrin, Alpha—V integrin, alpha4beta1 integrin, alpha4beta7 integrin, AGR2, Anti-Lewis-Y, Apelin I receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CD11a, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD4OL, CD41, CD44, CD44v6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, G), CD133, CD137, CD138, CD166, CD172A, CD248, CDH6, CEACAMS (CEA), CEACAM6 (NCA-90), CLAUDIN—3, CLAUDIN—4, cMet, Collagen, Cripto, CSFR, CSFR-l, CTLA-4, CTGF, , CXCL13, CXCRl, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL3, DLL4, DPP- 4, DSGl, EDA, EDB, EGFR, ii, Endothelin B receptor , ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1,FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FRoc), GAL3ST1, G—CSF, G—CSFR, GD2, GITR, GLUTl, GLUT4, GM-CSF, GM-CSFR, GP IIb/IIIa receptors, Gp130, GPIIB/IIIA, GPNMB, GRP78, HERZ/neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICO S, ha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGFlR, lLlB, IL1R, ILZ, ILl 1, IL12, IL12p40,IL-12R,IL-12Rbeta1,IL13,IL13R,1LlS,ILl7,IL18,IL21,IL23,ILZ3R, IL27/IL27R(wsX1), IL29, IL-3 1R, IL31/IL31R, ILZR, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISSl-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUCl, Mucin-16 (MUC16, CA-125), Na/K ATPase, NGF, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, OX-40, PAR2, PDGF-AA, PDGF-BB, lpha, PDGFRbeta, PD-l, PD-Ll, PD-LZ, Phosphatidyl-serine, PlGF, PSCA, PSMA, PSGR, RAAGlZ, RAGE, SLC44A4, Sphingosine 1 Phosphate, STEAPl, STEAPZ, TAG—72, TAPAl, TEM—8, TGFbeta, TIGIT, THVI-3, TLRZ, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, TNFR, TNFRSlZA, R1, TRAIL-R2, Transferrin, errin or, TRK-A, TRK—B, uPAR, VAPl, VCAM—l, VEGF, VEGF-A, VEGF—B, VEGF-C, VEGF—D, VEGFRl, VEGFRZ, , VISTA, WISP-l, WISP-2, and WISP-3.

In some embodiments, the antigen binding domain of the second component, such as the second n g domain, and the anti—CD3—binding domain are operably linked via amino acid linkers. In some embodiments, these intra—component s are composed predominately of the amino acids e and Serine, denoted as GS-linkers herein. The GS—linkers of the fusion proteins of the present disclosure can be of various lengths, for example 5, 6, 7, 8, 9, 10, ll, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acids in length.

In some embodiments, the GS—linker comprises an amino acid sequence selected from the group consisting of GGSGGS, i.e., (GGS); (SEQ ID NO: 10); GGSGGSGGS, 1'. e., (GGS)3 (SEQ ID NO: 11), GGSGGSGGSGGS, 1'. e., (GGS)4 (SEQ ID NO: 12), and GGSGGSGGSGGSGGS, i.e., (GGS)5 (SEQ ID NO: 13).

Provided herein is a pecific polypeptide construct, the multispeci?c polypeptide construct comprising a ?rst component comprising a dimeric Fc region and a second component comprising an anti-CD3 antibody or antigen-binding fragment comprising a variable heavy chain region (VH) and a variable light chain region (VL), wherein: the VH and VL that comprise the anti-CD3 antibody or n binding fragment are linked to opposite polypeptides of the heterodimeric Fc, the ?rst and second components are coupled by a cleavable linker, wherein the heterodimeric Fc region is positioned N- terminal to the anti-CD3 antibody; and one or both of the first and second components comprises an antigen binding domain that binds a tumor associated antigen (TAA).

In some embodiments, binding of the CD3-binding region to CD3 is substantially reduced when the multispecific polypeptide construct is in an uncleaved state compared to a cleaved state. In some embodiments, in a cleaved state, the first and second components are not .

In some embodiments, the cleavable linker is a polypeptide. In some ments, the cleavable linker is a polypeptide that is a substrate for a protease. In some embodiments, the protease is produced by an immune effector cell, by a tumor, or by cells present in the tumor microenvironment. In some embodiments, the protease is produced by a tumor that is in proximity to cells that express CD38 and/or is produced by a tumor that is co- localized with cells that express CD38 in a tissue, and wherein the protease s the cleavable linker in the multispeci?c polypeptide construct when the multispecific polypeptide construct is exposed to the protease. In some embodiments, the protease is produced by a tumor that is in proximity to cells that express one or more tumor associated antigens (TAA) and/or is produced by a tumor that is co-localized with cells that express the target TAA(s) in a tissue, and wherein the protease cleaves the cleavable linker in the multispeci?c polypeptide construct when the multispecific polypeptide construct is exposed to the protease. In some embodiments, the protease is produced by an immune or cell. In some embodiments, the se is produced by an immune effector cell that is in ity to cells that express the TAA. In some es, the protease is ed by an immune effector cell and the immune effector cell is an activated T cell, a natural killer (NK) cell, or an NK T cell.

In some embodiments, the protease cleaves the cleavable linker in the multispecific polypeptide construct when the multispecific polypeptide construct is exposed to the protease. In some embodiments, the protease is produced an immune effector cell that is in proximity to cells that s the TAA and n the protease cleaves the cleavable linker in the multispecific polypeptide construct when the multispecific polypeptide construct is exposed to the protease.

In some embodiments, the cleavable linker is a polypeptide of up to 50 amino acids in length. In some embodiments, the cleavable linker is a polypeptide of up to 25 amino acids in length. In some ments, the ble linker is a ptide of up to 15 amino acids in length.

In some embodiments, the cleavable linker is a substrate for a protease selected from the proteases described herein. In some embodiments, the cleavable linker is a substrate for a protease ed from the group consisting of uPA, legumain, tase (also referred to herein as MT-SPlor MTSPI), ADAM17, BMP-l, TMPRSS3, TMPRSS4, MMP-9, MMP- 12, MMP-l3, MMP-14, and any combination thereof. In some embodiments, the cleavable linker is a substrate for a protease selected from the group consisting of uPA, legumain, and matriptase. In some embodiments, the protease is selected from among tase, a matrix metalloprotease (MIVIP), granzyme B, and combinations f.

In some embodiments, the protease is granzyme B. In some examples, the cleavable linker comprises an amino acid sequence of the general formula P4 P3 P2 P1 ] P1’ (SEQ ID NO: 150), wherein P4 is amino acid I, L, Y, M, F, V, or A; P3 is amino acid A, G, S, V, E, D, Q, N, or Y, P2 is amino acid H, P, A, V, G, S, or T, P1 is amino acid D or E; and P1’ is amino acid I, L, Y, M, F, V, T, S, G or A. In some embodiments, the cleavable linker comprises an amino acid sequence of the general formula P4 P3 P2 P1 i Pl’ (SEQ ID NO: 151), wherein P4 is amino acid I or L, P3 is amino acid E, P2 is amino acid P or A, P1 is amino acid D, and P1’ is amino acid I, V, T, S, or G. In some examples, the ble linker comprises the amino acid sequence [EPDI (SEQ 1D NO:136), LEPDG (SEQ ID NO: 152, LEADT (SEQ ID NO: 137), IEPDG (SEQ ID NO: 138), IEPDV (SEQ ID NO: 139), IEPDS (SEQ ID NO:140), IEPDT (SEQ ID NO:141) or LEADG (SEQ ID NO:153). In some cases, the cleavable linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOsz22, 105-112, 136-141, 148,150-153.

In some embodiments, the se is matriptase. In some cases, the ble linker comprises the sequence P1QAR](A/V) (SEQ ID NO: 154), wherein P1 is any amino acid; or the ble linker comprises the sequence RQAR(A/V) (SEQ ID NO: 155). In some examples, the cleavable linker comprises the sequence RQARV (SEQ ID NO: 156). In some cases, the cleavable linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 23, 6.

In some embodiments, the se is an MMP. In some examples, the MMP is MMP-2. In some embodiments, the cleavable linker comprises the l formula P3 P2 P1 iPl’ (SEQ ID NO: 157), wherein P3 is P, V or A, P2 is Q or D; P1 is A or N; and P1’ is L, I or M. In some cases, the cleavable linker comprises the general formula P3 P2 P1 ] Pl’ (SEQ ID NO: 158), wherein is P, P2 is Q or D, P1 is A or N, and P1’ is L or I. IN some embodiments, the cleavable linker comprises the sequence PAGL (SEQ ID NO:24). In some embodiments, the cleavable linker is a substrate for a matrix metalloprotease (MMP).

In some embodiments, the multispeci?c polypeptide construct comprises at least (i) a ?rst polypeptide comprising the ?rst Fc polypeptide of the dimeric Fc region, the linker and the VH domain of the anti-CD3 antibody or antigen binding fragment; and (ii) a second polypeptide sing the second Fc polypeptide of the heterodimeric Fc region, the linker and the VL domain of the anti-CD3 antibody or antigen binding fragment wherein one or both of the ?rst and second polypeptide comprise at least one antigen-binding domain that binds to a tumor ated antigen (TAA). In some instances, only one of the ?rst or second polypeptide comprises the at least one antigen-binding domain that binds a TAA.

In some of any of the provided embodiments, the antigen binding domain(s) results in monovalent, bivalent, trivalent, or tetravalent binding to the TAA. In some embodiments, the one or more antigen binding domains that bind TAA independently are selected from an sdAb, an scFv or a Fab. In some embodiments, the one or more antigen binding domains that binds a TAA is a TAA is a single chain le, such as a single chain antibody fragment containing a VH and a VL, for example an sdAb or an scFv. In some embodiments, at least one of the antigen binding domains is a Fab ning a ?rst chain comprising a VH-CHl (Fd) and a second chain comprising a VL-CL.

In some embodiments, the at least one antigen binding domain is positioned amino-terminally relative to the Fc region and/or is positioned carboxy-terminally relative to the CD3 binding region of one of the ?rst or second polypeptide of the multispeci?c polypeptide construct. In some cases, the at least one antigen binding domain is positioned amino-terminally ve to the Fc region of the multispeci?c construct and the second antigen binding domain is positioned carboxy-terminally relative to the CD3 binding region of the multispeci?c construct.

In some ments, the at least one of the antigen binding domain(s) is a Fab.

In some embodiments, the multispeci?c polypeptide construct comprises: (i) a ?rst ptide comprising the ?rst Fc polypeptide of the dimeric Fc region, the linker and the VH domain of the anti-CD3 dy or antigen binding fragment; (ii) a second polypeptide comprising the second Fc polypeptide of the heterodimeric Fc region, the linker and the VL domain of the anti-CD3 dy or antigen g fragment, and (iii) a third polypeptide comprising a VH-CHl (Fd) or VL-CL of a Fab antibody fragment that binds to a tumor-associated antigen, wherein the ?rst and/or second polypeptide r comprises the other of the VH-CHl (Fd) or VL-CL of the Fab antibody fragment. In some cases, only one of the ?rst or second polypeptide comprises the other of the VH—CHl (Fd) or VL-CL of the Fab dy fragment. In some embodiments, both the ?rst or second polypeptide comprises the other of the VH-CHl (Fd) or VL-CL of the Fab antibody fragment. In some cases, the other of the VH-CHl (Fd) or VL-CL of the Fab antibody nt is positioned amino- terminally relative to the Fc region and/or at the carboxy-tenninally ve to the CD3 binding region of one of the first or second polypeptide of the multispecific polypeptide construct. In some embodiments, the other of the VH-CHl (Fd) or VL-CL of the Fab antibody fragment is positioned amino-terminally relative to the Fc region of the ?rst polypeptide or second polypeptide and at the y-terminally relative to the CD3 binding region of the other of the first or second polypeptide.

In some examples, the antigen binding domain, or independently each of the antigen g s, binds to a tumor n selected from among 1LFA-3, 5T4, 4 integrin, Alpha—V integrin, alpha4beta1 integrin, alpha4beta7 integrin, AGR2, Anti— Lewis-Y, Apelin I receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CD11a, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD4OL, CD41, CD44, CD44v6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD137, CD138, CD166, CD172A, CD248, CDH6, CEACAM5 (CEA), CEACAM6 (NCA—90), CLAUDIN—3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR—l, CTLA-4, CTGF, CXCL10, CXCL13, CXCRl, CXCR2, CXCR4, CYR61, DL44, LL3, DLL4, DPP-4, DSGl, EDA, EDB, EGFR, EGFRviii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFRI, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FROL), GAL3 ST1, G—C SF, G-CSFR, GD2, GITR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP IIb/IIIa receptors, Gp130, GPIIB/IIIA, GPN1V?3, GRP78, HER2/neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGFlR, ILlB, IL1R, IL2, IL11, IL12, ILlZp40, IL-12R,IL-12Rbeta1, ILl3, IL13R, IL15, ILl7, ILlS, IL21, IL23, IL23R, ILZ7/IL27R (wsxl), IL29, 1L-31R, 1L3 1/1L3 1R, ILZR, 1L4, IL4R, 1L6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISSl-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, , Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUCl, Mucin-16 , CA-125), Na/K ATPase, NGF, rin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM- R, OX-40, PARZ, PDGF-AA, PDGF-BB, PDGFRalpha, eta, PD-l, PD-Ll, PD-L2, Phosphatidyl-serine, PlGF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, STEAPl, STEAPZ, TAG-72, TAPAl, TEM-S, TGFbeta, TIGIT, TIM-3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, INFR, TNFRSIZA, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAPl, VCAM-l, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, , , , VISTA, WISP-l, WISP-Z, and WISP-3.

In some embodiments, the multispeci?c antigen binding domain comprises at least a ?rst antigen g domain and a second antigen binding domain, wherein the ?rst antigen binding domain and second antigen g domain bind to the same TAA. In some cases, the ?rst antigen binding domain and the second antigen binding domain binds a different e of the same TAA. In some instances, the ?rst antigen binding domain and the second antigen binding domain binds the same epitope of the same TAA. In some embodiments, the multispeci?c antigen binding domain comprises at least a ?rst antigen binding domain and a second antigen binding domain wherein the ?rst antigen binding domain and the second antigen g domain bind a ent TAA.

In some embodiments, the multispeci?c polypeptide construct ses a ?rst linking peptide (LPl) between the ?rst n binding domain and the immunoglobulin Fc polypeptide region (Fc region). In some embodiments, the multispeci?c polypeptide construct comprises a second linking peptide (LPZ) between the anti—CD3 binding domain (CD3 binding region) and the second antigen binding domain. In some embodiments, the multispeci?c polypeptide construct comprises a ?rst linking peptide (LPl) between the ?rst antigen binding domain and the immunoglobulin Fc polypeptide region (Fc region) and a second g peptide (LP2) between the anti-CD3 binding domain (CD3 binding region) and the second antigen binding domain.

In some embodiments, the multispeci?c polypeptide construct in the uncleaved state has the structural arrangement from N—terminus to C-terminus as follows: ?rst antigen g domain — LPl-immunoglobulin Fc polypeptide linker region (Fc region) — linker (such as a cleavable linker) — anti—CD3 binding domain — LP2 — second antigen binding domain. In some embodiments, the multispeci?c ptide construct in the uncleaved state has the structural arrangement from N—terminus to C-terminus as follows: second antigen binding domain — LP2 — anti-CD3 binding domain (CD3 binding ) — linker (such as a ble linker) — immunoglobulin Fc polypeptide linker region — LPl — ?rst antigen binding domain. In some examples, the linker is a cleavable linker. In some embodiments, the two linking peptides are not identical to each other. In some cases, LPl or LP2 is independently a peptide of about 1 to 20 amino acids in length. In some examples, LPl or LP2 independently comprise a peptide that is or comprises any Gly-Ser linker as set forth in SEQ ID NOs: 10-13, 119, 135, 147, 149.

In some embodiments, the multispeci?c construct is a construct having any of the structural arrangements shown in In some embodiments, the multispeci?c construct is a i?c construct having the structural arrangement shown in In some embodiments, the bispeci?c construct has a structural arrangement from inus to C- terminus as follows. The N—terminal end of the bispeci?c construct includes a ?rst antigen binding domain that binds a tumor associated antigen (TAA). The ?rst binding domain binds a ?rst epitope on the TAA target, Coupled to the ?rst antigen binding domain is a central globulin Fc ptide region that regulates FcyR interactions and/or FcRn interaction. In some embodiments, the central immunoglobulin Fc polypeptide region is dimeric. The immunoglobulin Fc polypeptide region is d to a cleavable linker that contains one or more lytic cleavage sites located at a position inal to the end of the globulin Fc polypeptide . In some embodiments, the one or more proteolytic cleavage sites is a substrate for matriptase, a matrix metalloprotease (MMP), or granzyme B. The ble linker is attached to an anti—CD3 binding sequence located C— terminal from the Fc region and in some cases, at the distal end of the second component.

In some embodiments, the anti-CD3 antibody or antigen binding fragment is an Fv antibody fragment. In some embodiments, the Fv antibody fragment comprises a de stabilized anti-CD3 binding Fv nt (dst). In some embodiments, the anti- CD3 binding ce is an Fv antibody fragment that has an engineered to e a disul?de linkage n the variable heavy chain (VH) and variable light chain (VL) regions, thereby producing a disul?de stabilized anti-CD3 binding Fv fragment (dst). In some embodiments, the VH and VL domains that comprise the anti-CD3 Fv are operably linked to opposite members of a heterodimeric Fc region. In these embodiments, the anti- CD3 Fv binds CD3 in a monovalent fashion. The anti-CD3 dst does not engage CD3 when the cleavable linkers are intact, i.e., in an uncleaved or inactive state. The C-terminus of the bispeci?c construct includes a second antigen binding domain that binds a TAA. In some embodiments, the second antigen binding domain binds the same TAA as the ?rst antigen binding domain located in within the ?rst component. In some embodiments, the second antigen binding domain binds a second epitope on the TAA, wherein the second epitope is non-competitive with the ?rst epitope on the TAA. In some embodiment, the second antigen binding domain binds a distinct TAA from that of the ?rst antigen binding domain.

In some embodiments, each of the ?rst antigen binding domain and the second antigen binding domain of the bispeci?c construct includes one or more copies of an antibody or an antigen-binding fragment thereof. In some embodiments, each of the ?rst n binding domain and the second antigen g domain of the i?c construct includes one or more copies of an dy or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, an Fv fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some ments, the antigen binding domain, or independently each of the antigen binding domains, is an dy or n-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, an Fv fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the each of the ?rst antigen binding domain and the second antigen binding domain of the bispeci?c construct includes one or more copies of one or more single domain antibody (sdAb) fragments, for example VHH, VNAR, engineered VH or VK domains. VHHs can be generated from natural camelid heavy chain only dies, genetically d rodents that produce heavy chain only antibodies, or naive/synthetic camelid or humanized camelid single domain antibody libraries. VNARS can be ted from cartilaginous ?sh heavy chain only antibodies. Various methods have been implemented to te monomeric sdAbs from conventionally heterodimeric VH and VK domains, including interface engineering and selection of speci?c germline families.

In some ments, the antibody or antigen-binding fragment is an sdAb. In some cases, the sdAb is a human or humanized sdAb. In some aspects, the sdAb is VHH, VNAR, an engineered VH domain or an engineered VK domain. In some examples, the antibody or antigen-binding fragment thereof is an scFv. In some cases, the antibody or antigen-binding fragment thereof is a Fab.

In some of any of the provided embodiments, the anti—CD3 dy or antigen— binding fragment comprises a VH CDRl comprising the amino acid sequence TYAMN (SEQ ID NO: 16), a VH CD2 comprising the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17), a VH CDR3 comprising the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDRl sing the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 19), a VL CDRZ comprising the amino acid sequence GTNKRAP (SEQ ID NO: 20), and a VL CDR3 comprising the amino acid sequence ALWYSNLWV (SEQ ID NO: 21).

In some embodiments, the anti-CD3 dst comprises: a VH having the amino acid sequence of any of SEQ ID NOS: 14, 44, and 32-62 or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOS: 14, 44, and 32-62, and a VL having the amino acid sequence of any of SEQ ID NOS: , 72, and 63-81 or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOS: 14, 44, and 32-62. In some cases, the anti-CD3 dst comprises the amino acid sequence of SEQ ID NO: 14 and the amino acid sequence of SEQ ID NO: 15. In some cases, the D3 dst ses the amino acid sequence of SEQ ID NO: 44 and the amino acid sequence of SEQ ID NO: 72.

In some embodiments, the immunoglobulin Fc region of the ?rst component is an IgG e selected from the group consisting of IgG1 e, IgG2 isotype, IgG3 isotype, and IgG4 subclass. In some embodiments, the immunoglobulin Fc region is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6.

In some embodiments, the immunoglobulin Fc region is a polypeptide comprising an amino acid sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid ce selected from the group consisting of SEQ 1D NOs: 1—6.

In some embodiments, the immunoglobulin Fc region is a polypeptide sing an amino acid sequence that is derived from an amino acid sequence selected from the group consisting of SEQ ID NOs: 1—6. In some ments, the immunoglobulin Fc region is a polypeptide sing an amino acid sequence that is derived from an amino acid sequence ed from the group consisting of SEQ ID NOs: 1-6 comprising one or modi?cations. In some embodiments, the immunoglobulin Fc region is a polypeptide comprising an amino acid sequence that is derived from an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6 comprising one or modi?cations to prevent glycosylation, to alter Fc receptor interactions, to reduce Fc receptor binding, to enhance the interaction with CD3 2A, to reduce the complement protein C1q binding, to extend the half-life, to enhance FcRn binding, to alter antibody-dependent cellular cytotoxicity (ADCC) and/or complement- dependent cytotoxicity (CDC), to induce heterodimerization, to prevent dimerization, to ize the homodimerization at the CH3 :CH3 interface, and combinations thereof. In some embodiments, modi?cations within the Fc region reduce binding to Fc-receptor-gamma receptors while have minimal impact on binding to the neonatal Fc or (FcRn). In some embodiments, the mutated or modi?ed Fc polypeptide includes the following mutations: Met252Tyr and Met428Leu or Met252Tyr and Met428Val (M252Y, M428L, or M252Y, M428V) using the Kabat numbering system.

In some embodiments, the first antigen binding domain and the globulin Fc polypeptide are operably linked Via amino acid linkers. In some embodiments, these intra- component s are composed predominately of the amino acids Glycine and Serine, denoted as GS-linkers herein. The GS-linkers of the fusion proteins of the t disclosure can be ofvarious lengths, for example 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20 amino acids in length.

In some embodiments, the GS-linker comprises an amino acid sequence ed from the group ting of GGSGGS, i.e., (GGS)2 (SEQ ID NO: 10), GGSGGSGGS, i.e., (GGS)3 (SEQ ID NO: 11); GGSGGSGGSGGS, 1'. e., (GGS)4 (SEQ ID NO: 12); and GGSGGSGGSGGSGGS, i.e., (GGS)5 (SEQ ID NO: 13).

In some embodiments, the anti-CD38 dsFV antibody fragment includes an amino acid sequence ed from the group consisting of SEQ ID NO: 32-81. In some ments, the anti-CD33 dsFV antibody fragment es an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 32-81. In some embodiments, the anti-CD33 FV antibody fragment includes a combination of an amino acid sequence selected from the group of SEQ ID NO: 32-62 and an amino acid sequence selected from the group consisting of SEQ ID NO: 63—81. In some ments, the anti—CD38 FV antibody fragment es a combination of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 32-62 and an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence ed from the group consisting of SEQ ID NO: 63-81 an amino acid sequence.

In some embodiments, the second antigen binding domain and the anti-CD3- binding domain are operably linked Via amino acid linkers. In some embodiments, these intra—component linkers are composed predominately of the amino acids Glycine and Serine, denoted as GS-linkers herein. The GS-linkers of the fusion proteins of the present disclosure can be ofvarious lengths, for example 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, l7, 18, 19, 20 amino acids in length.

In some embodiments, the GS-linker comprises an amino acid sequence selected from the group ting of GGSGGS, 116., (GGS)2 (SEQ ID NO: 10); GGSGGSGGS, 1'. e., (GGS)3 (SEQ ID NO: 11); GGSGGSGGSGGS, 1'. e., (GGS)4 (SEQ ID NO: 12); and GGSGGSGGS, i.e., (GGS)5 (SEQ ID NO: 13).

In some embodiments, the cleavable linker is a polypeptide. In some embodiments, the cleavable linker is a polypeptide that is a substrate for a protease. In some embodiments, the protease is produced by a tumor that is in proximity to cells that express CD38 and/or is ed by a tumor that is co-localized with cells that express CD38 in a tissue, and wherein the protease cleaves the cleavable linker in the multispeci?c polypeptide construct when the multispeci?c ptide construct is exposed to the protease. In some embodiments, the protease is produced by a tumor that is in ity to cells that express one or more tumor associated antigens (TAA) and/or is produced by a tumor that is co- localized with cells that express the target TAA(s) in a tissue, and wherein the protease s the cleavable linker in the multispeci?c polypeptide construct when the multispeci?c polypeptide construct is exposed to the protease.

In some embodiments, the cleavable linker is a polypeptide of up to 50 amino acids in length. In some embodiments, the cleavable linker is a polypeptide of up to 25 amino acids in length. In some embodiments, the cleavable linker is a polypeptide of up to 15 amino acids in length. In some embodiments, the cleavable linker is a substrate for a protease selected from the proteases described herein. In some ments, the cleavable linker is a substrate for a protease selected from the group ting of uPA, legumain, matriptase (also ed to herein as MT-SPlor MTSPl), ADAM17, BMP-l, TMPRSS3, TMPRSS4, MIVIP- 9, MMP-12, MMP-l3, MMP-14, and any combination thereof. In some embodiments, the ble linker is a substrate for a protease selected from the group consisting of uPA, legumain, and matriptase. In some embodiments, the cleavable linker is a substrate for a matrix metalloprotease (MMP).

In some embodiments, the multispeci?c construct also includes an agent conjugated to the multispeci?c construct. In some embodiments, the agent is a therapeutic agent. In some embodiments, the agent is a detectable moiety. In some ments, the detectable moiety is a diagnostic agent. In some embodiments, the agent is conjugated to the multispeci?c construct Via a linker. In some ments, the linker is a cleavable linker. In some embodiments, the linker is a non-cleavable linker.

In some embodiments, the anti multispecific construct bed herein is used in conjunction With one or more additional agents or a combination of additional agents. le onal agents include current pharmaceutical and/or surgical therapies for an intended application, such as, for example, cancer. For example, the pecific construct can be used in conjunction with an additional chemotherapeutic or anti-neoplastic agent.

In some embodiments, the multispecific construct and additional agent are formulated into a single therapeutic composition, and the multispecific construct and additional agent are administered aneously. In some embodiments, the multispecific construct and additional agent are separate from each other, e.g., each is formulated into a separate therapeutic composition, and the multispecific construct and the additional agent are administered simultaneously, or the multispecific construct and the additional agent are administered at different times during a ent regimen. For example, the multispecific construct is administered prior to the administration of the additional agent, the multispecific construct is administered subsequent to the administration of the additional agent, or the multispecific construct and the additional agent are administered in an alternating fashion. As described herein, the multispecific construct and additional agent are administered in single doses or in multiple doses.

In some embodiments, the multispecific construct naturally contains one or more disulfide bonds. In some embodiments, the multispecific construct can be engineered to include one or more disulfide bonds.

The disclosure also provides an isolated nucleic acid molecule or polynucleotide encoding at least a portion of a multispecific construct described herein and/or one or more nucleic acid molecules encoding a multispecific construct bed herein, such as for example, at least a first c acid ng at least a n of the first component of the multispeci?c construct and a second nucleic acid encoding at least a portion of the second component of the multispecific construct, as well as vectors that include these isolated nucleic acid sequences.

Among the provided ments is a polynucleotide(s) encoding any of the ed multispecific polypeptide constructs. Also provided is a polynucleotide encoding a polypeptide chain of any of the provided multispecific polypeptide constructs. Further provided is a polynucleotide, comprising a first nucleic acid ce encoding a first polypeptide of any of the provided multispecific constructs and a second nucleic acid ce encoding a second polypeptide of the multispecific construct, wherein the first and second nucleic acid sequence are separated by an internal me entry site (IRES), or a nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping. In some cases, the ?rst nucleic acid sequence and second c acid ce are operably linked to the same er. In some embodiments, the peci?c polypeptide construct comprises a third polypeptide chain, and the polynucleotide r comprises a third nucleic acid encoding the third polypeptide of the multispeci?c construct. In some embodiments, the third nucleic acid is separated from the ?rst and/or second polypeptide by an internal ribosome entry site (IRES), or a nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping and/or the third c acid sequence is operably linked to the same promoter as the ?rst and/or second c acid sequence. In some examples, the nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping is selected from a T2A, a P2A, a E2A or a F2A (SEQ ID NOS: 159—164, or encoded by the ce set forth in SEQ ID NO: 165).

Provided herein is a vector comprising any of the provided polynucleotides. In some embodiments, the vector is an expression vector. In some examples, the vector is a viral vector or a eukaryotic vector, optionally wherein the eukaryotic vector is a mammalian vector.

Provided is a cell, comprising any of the ed polynucleotides or vectors. In some cases, the cell is recombinant or ed. In some examples, the cell is a mammalian cell. In some examples, the cell is a HEK293 or CHO cell.

The sure provides methods of producing a multispeci?c construct by ing a cell under conditions that lead to expression of the multispeci?c construct, wherein the cell comprises such a nucleic acid le(s). In some embodiments, the cell comprises such a vector.

Provided herein is a method of producing a multispeci?c polypeptide construct, the method comprising introducing into a cell any of the provided polynucleotides or vectors and culturing the cell under conditions to that lead to expression of the multispeci?c construct to produce the multispeci?c polypeptide uct. Also provided is a method of producing a multispeci?c polypeptide construct, the method comprising culturing any of the provided cells under conditions in which the multispeci?c polypeptide is expressed or produced by the cell. In some cases, the cell is a mammalian cell. In some examples, the cell is a HEK293 or CHO cell. In some embodiments, the method further includes isolating or purifying the multispeci?c polypeptide uct from the cell. In some cases, the multispeci?c polypeptide construct is a heterodimer.

Provided herein is a multispecific polypeptide construct produced by any of the provided methods.

Provided herein is a method of stimulating or inducing an immune response, the method comprising contacting a target cell and a T cell with the any of the ed multispecific polypeptide constructs or pharmaceutical compositions, said target cell expressing a tumor associated antigen ized by the multispecific polypeptide construct.

In some embodiments, the target cell is a tumor cell expressing the tumor ated n (TAA).

In some embodiments, the multispecific polypeptide construct comprises a cleavable linker that functions as a substrate for a protease and the inducing or stimulating the immune response is increased in the presence of the protease. In some cases, the protease is produced by an immune effector cell, by a tumor, or by cells present in the tumor microenvironment.

In some embodiments, the protease is produced by an immune effector cell and the immune or cell is an activated T cell, a natural killer (NK) cell, or an NK T cell. In some instances, the immune effector cell is in proximity to cells that s the antigen. In some embodiments, the protease is produced by a tumor that is in proximity to cells that express the TAA in a tissue and/or produced by a tumor that is co-localized with TAA in a tissue, and wherein the protease cleaves the cleavable linker in the multispecific polypeptide construct when the multispecific polypeptide construct is exposed to the se. In some examples, the se is selected from among tase, a matrix metalloprotease (MIVIP), granzyme B, and combinations thereof. In some instances, the protease is granzyme B.

In some embodiments, the contacting is carried out ex vivo or in vitro. In some embodiments, the contacting is carried out in vivo in a subject.

Provided is a method of stimulating or inducing an immune response in a subject, the method comprising administering, to a t in need thereof, a therapeutically effective amount of any of the provided multispecific conjugates or pharmaceutical compositions. In some cases, the method increases cell-mediated immunity. In some embodiments, the method increases T-cell activity. In some embodiments, the method ses cytolytic T- cell (CTL) ty. In some examples, the immune response is increased against a tumor or cancer. In some embodiments, the method treats a disease or condition in the t.

The present disclosure also es methods of treating, preventing, delaying the progression of or otherwise ameliorating a symptom of one or more pathologies or alleviating a symptom associated with such pathologies, by administering a multispeci?c polypeptide construct of the disclosure to a subject in which such treatment or prevention is desired.

Provided herein is a method of treating a disease or condition in a subject, the method comprising administering, to a subject in need thereof, a therapeutically effective amount of any of the provided multispecific conjugates or pharmaceutical compositions. In some embodiments, the disease or ion is a tumor or a .

In some embodiments of any of the provided , the subject, such as the subject to be treated is, e. g., human or other mammal. In some ments of any of the provided method, the subject is a human. In some embodiments, the subject is a non-human mammal, such as a man primate, companion animal (e.g., cat, dog, horse), farm animal, work animal, or zoo animal. In some embodiments, the subject is a rodent.

A multispecific polypeptide uct of the disclosure used in any of the embodiments of these methods and uses can be administered at any stage of the disease. For example, such a multispecific polypeptide construct can be administered to a patient suffering cancer of any stage, from early to metastatic. The terms t and t are used interchangeably herein.

A multispecific polypeptide uct of the disclosure used in any of the embodiments of these methods and uses can be used in a treatment regimen comprising neoadjuvant therapy.

A multispecific polypeptide construct of the disclosure used in any of the embodiments of these methods and uses can be administered either alone or in ation with one or more onal agents, including small le inhibitors, other antibody-based therapies, polypeptide or peptide-based therapies, nucleic ased therapies and/or other biologics. In some embodiments, a multispecific polypeptide construct is administered in combination with one or more additional agents such as, by way of non-limiting example, a chemotherapeutic agent, such as an alkylating agent, an anti-metabolite, an anti-microtubule agent, a topoisomerase inhibitor, a cytotoxic antibiotic, and any other nucleic acid damaging agent. In some embodiments, the additional agent is a taxane, such as paclitaxel (e.g., ne®). In some embodiments, the additional agent is an anti-metabolite, such as gemcitabine. In some embodiments, the additional agent is an alkylating agent, such as platinum-based chemotherapy, such as carboplatin or cisplatin. In some embodiments, the onal agent is a targeted agent, such as a kinase inhibitor, e.g., sorafenib or erlotinib. In some embodiments, the additional agent is a targeted agent, such as another antibody, e.g., a monoclonal dy (e.g., bevacizumab), a bispecific antibody, or a multispecific antibody.

In some embodiments, the additional agent is a proteasome inhibitor, such as bortezomib or car?lzomib. In some ments, the additional agent is an immune modulating agent, such as lenolidominde or IL-2. In some embodiments, the additional agent is radiation. In some embodiments, the additional agent is an agent considered standard of care by those skilled in the art. In some embodiments, the additional agent is a chemotherapeutic agent well known to those skilled in the art. In some embodiments, the multispeci?c polypeptide construct and the additional agent(s) are formulated in a single composition. In some embodiments, the multispeci?c polypeptide construct and the additional agent(s) are administered as two or more separate compositions. In some embodiments, the multispeci?c polypeptide construct and the additional agent(s) are stered simultaneously. In some embodiments, the multispeci?c polypeptide construct and the additional agent(s) are administered sequentially.

In some embodiments, the additional agent(s) is a chemotherapeutic agent, such as a chemotherapeutic agent selected from the group consisting of docetaxel, paclitaxel, abraxane (11a, albumin-conjugated paclitaxel), doxorubicin, oxaliplatin, carboplatin, cisplatin, irinotecan, and abine.

In some embodiments, the additional agent(s) is a checkpoint inhibitor, a kinase inhibitor, an agent targeting inhibitors in the tumor microenvironment, and/or a T cell or NK agonist. In some embodiments, the additional agent(s) is radiation therapy, alone or in combination with another additional s) such as a chemotherapeutic or anti-neoplastic agent. In some embodiments, the additional agent(s) is a vaccine, an oncovirus, and/or a DC- activating agent such as, by way of non—limiting example, a toll—like receptor (TLR) agonist and/or d-CD40. In some ments, the additional s) is a targeted dy designed to kill the tumor Via ADCC or Via direct conjugation to a toxin (e.g., an dy drug conjugate (ADC).

In some embodiments, the checkpoint inhibitor is an inhibitor of a target selected from the group consisting of CTLA-4, LAG-3, PD-l, PDLl, TIGIT, TIM-3, B7H3, B7H4, and Vista. In some embodiments, the kinase inhibitor is selected from the group consisting of , MEKi, and Btk inhibitors, such as ibrutinib. In some embodiments, the kinase inhibitor is crizotinib. In some embodiments, the tumor microenVironment inhibitor is selected from the group consisting of an IDO inhibitor, an R inhibitor, an a—CCR4 inhibitor, a TGF-beta, a myeloid-derived suppressor cell, or a T-regulatory cell. In some embodiments, the agonist is selected from the group consisting of 0X40, GITR, CD137, CD28, ICOS, CD27, and HVEM. In some embodiments, the checkpoint inhibitor is an antibody that binds a target selected from CTLA-4, PD-l, and/or PD-Ll. In some embodiments, the checkpoint tor is an TLA4 dy, an anti-PD-l antibody, and an anti-PD-Ll antibody, and/or combinations thereof. In some embodiments, the checkpoint inhibitor is an anti-CTLA4 antibody such as, e.g., YervoyTM. In some embodiments, the checkpoint inhibitor is an anti-PD-l antibody such as, e.g., OpdivoTM and/or KeytrudaTM.

In some embodiments, the inhibitor is a CTLA-4 inhibitor. In some ments, the inhibitor is a LAG-3 inhibitor. In some embodiments, the inhibitor is a PD-l inhibitor. In some ments, the inhibitor is a PDL1 tor. In some embodiments, the inhibitor is a TIGIT inhibitor. In some embodiments, the inhibitor is a TIM-3 tor. In some embodiments, the inhibitor is a B7H3 inhibitor. In some embodiments, the inhibitor is a B7H4 inhibitor. In some ments, the inhibitor is a Vista inhibitor. In some embodiments, the inhibitor is a B-RAFi inhibitor. In some embodiments, the inhibitor is a MEKi inhibitor. In some embodiments, the inhibitor is a Btk inhibitor. In some embodiments, the inhibitor is ibrutinib. In some embodiments, the inhibitor is crizotinib. In some embodiments, the tor is an IDO inhibitor. In some embodiments, the inhibitor is an 0t- CSFlR inhibitor. In some embodiments, the inhibitor is an d-CCR4 inhibitor. In some embodiments, the inhibitor is a TGF-beta. In some embodiments, the inhibitor is a myeloid- derived suppressor cell. In some ments, the inhibitor is a T—regulatory cell.

In some embodiments, the agonist is 0X40. In some embodiments, the agonist is GITR. In some embodiments, the agonist is CD137. In some embodiments, the agonist is CD28. In some embodiments, the agonist is ICOS. In some embodiments, the agonist is CD27. In some embodiments, the agonist is HVEM.

In some embodiments, the multispeci?c polypeptide construct is administered during and/or after treatment in combination with one or more additional agents such as, for example, a chemotherapeutic agent, an anti-in?ammatory agent, and/or an immunosuppressive agent. In some embodiments, the multispecific polypeptide construct and the additional agent are formulated into a single therapeutic composition, and the multispecific polypeptide construct and additional agent are administered simultaneously.

Alternatively, the multispecific polypeptide construct and onal agent are separate from each other, e. g., each is ated into a te therapeutic composition, and the multispeci?c polypeptide construct and the additional agent are administered simultaneously, or the multispecific polypeptide construct and the onal agent are administered at different times during a treatment regimen. For example, the multispecific ptide construct is stered prior to the stration of the additional agent, the multispecific polypeptide construct is administered subsequent to the administration of the additional agent, or the multispecific polypeptide construct and the additional agent are administered in an alternating fashion. As described herein, the multispecific polypeptide construct and additional agent are administered in single doses or in multiple doses.

In some embodiments, the multispecific polypeptide construct and the additional agent(s) are administered simultaneously. For example, the multispecific polypeptide construct and the additional agent(s) can be formulated in a single composition or administered as two or more separate compositions. In some embodiments, the multispecific polypeptide construct and the additional s) are administered sequentially, or the multi speci?c polypeptide construct and the additional agent are administered at different times during a treatment regimen.

In addition to the elements described above, the multispecific ptide uct can contain onal elements such as, for example, amino acid sequence N- or C- terminal of the pecific polypeptide construct. For example, a multispecific polypeptide construct can include a targeting moiety to facilitate delivery to a cell or tissue of st.

Multispecific polypeptide construct can be conjugated to an agent, such as a therapeutic agent, a detectable moiety or a diagnostic agent. Examples of agents are sed herein.

The multispecific polypeptide construct can also include any of the conjugated agents, linkers and other components described herein in conjunction with a multispecific polypeptide construct of the disclosure.

The disclosure also pertains to immunoconjugates comprising a multispecific ptide construct conjugated to a cytotoxic agent such as a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (1'.e., a onjugate). Suitable cytotoxic agents for use in targeting diseased T cells such as in a T erived lymphoma include, for example, dolastatins and derivatives f (8.g. auristatin E, AFP, MMAD, MMAF, MMAE). In some embodiments, the agent is a dolastatin. In some embodiments, the agent is an auristatin or derivative thereof.

In some embodiments, the agent is a maytansinoid or maytansinoid tive. In some embodiments, the agent is DMl or DM4. In some embodiments, the agent is a duocarmycin or tive thereof. In some embodiments, the agent is a calicheamicin or derivative thereof. In some embodiments, the agent is a pyrrolobenzodiazepine.

In some embodiments, the linker between the multispecific polypeptide construct and the cytotoxic agent is cleavable. In some embodiments, the linker is non-cleavable. In some ments, two or more linkers are present. The two or more linkers are all the same, e.g., ble or non-cleavable, or the two or more linkers are different, e.g., at least one cleavable and at least one non-cleavable.

The multispeci?c polypeptide constructs and conjugates thereof are useful in methods for treating a variety of disorders and/or diseases. Non-liming examples of disease include: all types of s (breast, lung, colorectal, prostate, melanomas, head and neck, pancreatic, etc), rheumatoid arthritis, Crohn’s disuse, SLE, cardiovascular damage, ischemia, etc. For example, indications would include leukemias, including T-cell acute lymphoblastic leukemia (T-ALL), lymphoblastic diseases including le myeloma, and solid tumors, ing lung, colorectal, prostate, pancreatic, and breast, including triple negative breast cancer. For example, indications include bone disease or metastasis in cancer, regardless of primary tumor origin, breast cancer, including by way of miting example, ER/PR+ breast cancer, Her2+ breast cancer, triple-negative breast cancer; colorectal cancer; endometrial cancer, gastric cancer, glioblastoma, head and neck cancer, such as esophageal ; lung , such as by way of non—limiting example, non—small cell lung cancer, multiple myeloma ovarian cancer; pancreatic cancer; prostate cancer; sarcoma, such as osteosarcoma; renal cancer, such as by way of nonlimiting example, renal cell carcinoma, and/or skin cancer, such as by way of nonlimiting example, us cell cancer, basal cell carcinoma, or ma. In some ments, the cancer is a squamous cell cancer. In some embodiments, the cancer is a skin squamous cell carcinoma. In some embodiments, the cancer is an esophageal squamous cell carcinoma. In some embodiments, the cancer is a head and neck squamous cell carcinoma. In some embodiments, the cancer is a lung squamous cell carcinoma.

Also ed is a pharmaceutical composition comprising any of the multispeciflc polypeptide ucts provided herein and a pharmaceutically acceptable carrier. In some cases, the pharmaceutical composition is sterile. Pharmaceutical compositions according to the sure can include a multispeciflc polypeptide construct of the disclosure and a carrier. These pharmaceutical compositions can be included in kits, such as, for e, diagnostic kits.

One skilled in the art will appreciate that the antibodies of the disclosure have a variety of uses. For example, the proteins of the sure are used as therapeutic agents for a variety of ers. The antibodies of the sure are also used as reagents in diagnostic kits or as diagnostic tools, or these antibodies can be used in competition assays to generate therapeutic reagents.

BRIEF DESCRIPTION OF DRAWINGS is a schematic of the basic components of the multispeciflc polypeptide constructs of the present disclosure having constrained CD3 g. The antigen binding domain(s) are positioned at the amino and/or carboxy termini. The Fc region, such as a heterodimeric Fc region, is positioned N—terminal to the CD3 binding region. This positioning of the Fc in close proximity to the CD3 binding region obstructs CD3 g. is an illustration depicting an exemplary structure of a multispeci?c molecule of the disclosure ning a cleavable linker and having dual effector functions, wherein proteolytic cleavage of the cleavable linker results in activation of the multispeci?c ptide construct to produce two components that each have biological activity. is a schematic of various FROt-targeting constrained CD3 construct composed of two polypeptides, Chain 1 and Chain 2. The top panel provides an exemplary depiction of a cleavable multispeci?c polypeptide construct having a cleavable linker containing a protease ate recognition site or sites, e. g. for one or more of MTSPl, MTVIP and/or granzyme B. Chain 1 contains a FRd sdAb (antigen binding domain), linked to a heterodimeric Fc "hole", linked via the protease cleavable linker (cx1547: granzyme B only, cx309: MTSPl, MMP and granzyme B) to anti-CD3 VL , linked to a second FROL sdAb Chain 2 contains a FRa sdAb, linked to a complementary heterodimeric Fc "knob", linked via the same protease linker as above to anti—CD3 VH domain, linked to second FROL sdAb. The bottom panel of depicts a r configuration as the top panel, except that the linker is a non-cleavable linker (ranging from 3 amino acids in cxl356 to 18 amino acids in cx681). When ressed the CD3 binding domain is properly assembled via the association of the VLzVH on the hole and knob, respectively. -4C depicts constructs that were generated to compare the effect of the linker to constrain CD3 binding in the generated ucts. s an example of a multispeci?c polypeptide construct containing the same cleavable linker in each polypeptide chain to couple each PC polypeptide of the heterodimeric Fc to a domain of the CD3 binding region (exemplary construct cx1762 is shown). In the format shown in , the construct is depicted in its uncleaved state. An alternative version of a construct is shown in in which only a single cleavable linker is employed to link the Fc region to the CD3 binding domain, designated half cleaved (exemplary construct cx3238 is shown). s a structure that represents the C-terminal portion of the format of the ucts in and 4B when fully cleaved (exemplary construct cx2190 is shown). Constructs representing the proteolytic cleavage product can be produced recombinantly by co- expressing the various chains depicted. FROt-targeting sdAb are positioned at the C-terminal position in each construct. -5E depicts representative EGFR-targeted and EGFR/cMET-dual targeted constrained CD3 engagers. In , cx2513 has an EGFR—targeting sdAb positioned at the C-termini of each chain of the heterodimer and thereby displays bivalent g to EGFR. In , cx3 030 has EGFR-targeting sdAbs positioned at both the N and C-termini of each chain of the heterodimer and thereby displays tetravalent binding to EGFR. , cx2973 has a cMET-targeting sdAb positioned at the N—termini and an EGFR-targeting sdAb oned at the C-termini of each chain of the heterodimer and thereby displays nt binding to each cMET and EGFR. In , cx2979 has a cMET-targeting sdAb positioned at the N—terrnini of one chain of the heterodimer and an EGFR-targeting sdAb positioned at the C-termini of each chain of the heterodimer and thereby displays monovalent binding cMET and nt binding to EGFR. In , cx2977 has a cMET-targeting sdAb positioned at the ini and an EGFR-targeting sdAb positioned at the C-termini of one or the other chain of the heterodimer and thereby displays lent binding to each cMET and EGFR. and 6B are schematics of the component chains to assemble exemplary B7H3-targeted constrained CD3 engagers. B7H3-binding domains utilized in these representative constructs included sdAb, scFv or FAB. Generally, sdAb and scFv containing ucts were composed as two heterodimeric chains, whereas FAB containing constructs included a third chain for the cognate light chain (VL-CL). depicts 5T4—targeting constrained CD3 engagers. The core of the molecule was ted to contain a heterodimeric Fc followed by cleavable linkers and a disulfide stabilized anti-CD3 Fv. The TAA g portion of these molecules was placed on the N— or C—termini of either dimeric Fc chain. In the top row, the TAA binding unit is a Fab, being composed of a Fd (VH-CHl) on N—terminus of the knob polypeptide, and C- terminus of the hole polypeptide. In the case of a Fab being the binding unit, a third chain (the light chain - VL-CL) was expressed to ate with the Fd. In the middle and bottom row, the TAA binding units are single domain antibodies that were both positioned on the knob polypeptide at the N— and C-terminus. In the middle row, the TAA binding sdAbs of the ted construct are the same, and in the bottom row, the TAA g sdAbs of the generated construct are different sequences with different epitopes. is a schematic of a representative CD20-targeted constrained CD3 engaging construct, cx3309, wherein the CD20 binding domains are scFvs derived from the CD20 antibody GAlOl. is schematic of a representative DLL3-targeted constrained CD3 engaging construct, cx3308, wherein the DLL3 g s are scFvs. This exemplary construct is comprised of two chains each with a complementary component of a heterodimeric Fc linked to one component of the CD3 binding domain and a DLL3 binding scFv. In the assembled form the construct is nt to DLL3 and has the CD3 binding domain positioned C- terminal to the Fc heterodimer.

A is an image of a SDS-PAGE of a representative FROt-targeted ained CD3 engaging construct, cx1547, reducing (R) and ducing (NR) conditions. Expected molecular weight l35kDa. B and 10C are graphs of chromatogram from size-exclusion analysis of , demonstrating that it is single s with a determined molecular weight of 137.9kDa. C is a zoomed in view around the main peak shown in B.

A and 11B are a pair of graphs demonstrating the binding capacity of an exemplary multispeci?c ptide construct of the disclosure, referred to herein as cx309, to bind human T-cell in the uncleaved or proteolytically cleaved state. Matriptase and MM?- 2 were used to cleave cx3 O9 in A and B, respectively.

A-12D depicts cellular binding by representative FROt—targeting constrained CD3 engaging constructs, cxl356, cx681 and cx1547. A and C shows g to Ovcar5 cells (a FROt positive ovarian cancer cell line). B and D depicts the lack binding to T—cells. A and B display histograms of the normalized cell counts vs ?uorescence at the lOOnM of each construct. The full titration of each construct on the various cell types are shown in C and D. The secondary anti—human APC antibody only control is shown in the ?lled black trace, while the positive control anti-CD3 binding is shown in the open trance, and cxl356, cx681 and cx1547 are shown in the gray shaded traces in A and B.

A-13B depicts cellular binding by a representative EFGR-targeting constrained CD3 engaging construct, cx3030. A shows binding to an EGFR positive cell line, Colo-205 at 100nM. B demonstrates the lack of g to s at 100nM. Binding is displayed as histograms of the normalized cell counts vs ?uorescence.

The secondary anti-human APC antibody only control is shown in the ?lled black trace, while the positive control anti-CD3 binding is shown in the open trance, and cx3 030 is shown in the gray shaded trace.

A-14D depicts binding to B7H3 positive A375 (A and 14B) and the lack of binding to CD3 on T-cells (C and 14D) by the B7H3 -targeted constrained CD3 engagers. The alternative format DART-Fc targeting B7H3 and CD3 displayed strong binding to both B7H3 and CD3 on T-cells. s B7H3 antigen binding domains were used herein including cx3095 sdAb, cx33 l3 FAB, and cx33 l4 scFv. The scFv and FAB contain the same anti-B7H3 VH and VL sequences used in the DART-Fc format. A and 14C show the comparative histograms of the lOOnM concentration for each construct. The secondary anti-human APC antibody only l is shown in the ?lled black trace and various B7H3—targeted CD3 engaging constructs are shown in the white non—shared .

B and 14D show titrations of binding by various constructs to BH73 and CD3, respectively.

FIG. ISA-15B depicts cellular binding by representative rgeting constrained CD3 engaging constructs, cx3262 and cx3315. A shows g to a 5T4 positive cell line, Ovcar-5 at 400nM. B demonstrates the lack binding to T-cells at 400nM. Binding is displayed as histograms of the normalized cell counts vs ?uorescence.

The secondary uman APC antibody only control is shown in the ?lled black trace, the while the ve control anti-CD3 binding is shown in the open trance, and cx3262 and cx3315 are shown in the gray shaded .

A-16D depicts cellular binding by a representative CD20-targeting constrained CD3 engaging construct, cx3309. A and C shows binding to Ramos cells (a CD20 ve cell line). B and D demonstrates the lack binding to T-cells. A-16B display histograms of the normalized cell counts vs ?uorescence at lOOnM of each construct. The full titration of each construct on the s cell types are shown in C-16D. The secondary anti—human APC antibody only control is shown in the ?lled black trace, while the positive control anti-CD3 binding is shown in the open trance, and cx3309 is shown in the gray shaded traces. is a graph demonstrating the ability of cleaved or uncleaved cx3 09 to activate a CD3 NFAT er Jurkat cell line (Promega, USA) in the presence or absence of FRoc sing cells, Ovcar5. depicts antigen dependent T-cell activation by cX1547. Various cell lines being either FROL positive (T47D, IGROVl, NCI—H2342, Ovcar-5, Skov-3, and A2780) or negative (NCI-H460), were co-incubated in with a Jurkat CD3 NFAT-GFP reporter cell line and cence was measured at 6 hours. This demonstrates the capacity of the constrained CD3 constructs to activate s in an antigen manner.

A-19D depicts the enhancement of T-cell activating capacity of the ained CD3 engagers if proteolysis were to occur within the linker between the Fc domain and the CD3 binding domain. Shown here are the kinetics of T-cell activation mediated by 20nM of cx1762, cx3238 or cx2190 in the presence of FROt positive Ovcar-S cells (A) or FROt negative CCRF-CEM cells (B). Also shown here is the potency of T-cell activation mediated by cxl762, cx3238 or cx2190 in the presence of FROt positive Ovcar-S cells (C) or FROL negative EM cells (D). A Jurkat CD3 NFAT—GFP er was used to monitor CD3 signaling over a 24 hour period using an Incucyte ZOOM imager. Notably T-cell activation is dependent on n expression on the target cell line and is y enhanced by l of the Fc domain N-terminal to the CD3 g domain on one or both sides of the CD3 binding VHzVL domains.

A-20D is a series of graphs demonstrating the antigen-dependent T-cell activating capacity of various EGFR and EGFR/cMET-targeted constrained CD3 engagers. Notably, the T—cell activating capacity is enhanced with increased valencey or an additional target antigen binding speci?city. T-cell tion kinetics mediated by the various constructs on antigen positive A431 cells is depicted in A or antigen negative CCRF-CEM cells C. The potency of T—cell activation by the various constructs on antigen positive A431 cells is depicted in B or antigen negative CCRF-CEM cells in D. Herein the Jurkat CD3 NFAT-GFP reporter cell line was used.

A-21B depicts the capacity to mediate target antigen speci?c T—cell activation by a representative B7H3-targeted constrained CD3 engaging construct, cx3 095 and an alternative DART-Fc format targeting B7H3 and CD3. Jurkat CD3 NFAT-GFP reporter cells were used to assess T—cell activation in the presence of a B7H3 positive cell line, A375 (A) and B7H3 negative cell line, Raji (B).

A-22F depicts the ty to mediate target antigen c T-cell activation by representative B7H3 ted constrained CD3 engaging constructs, and an alternative DART-Fc format targeting B7H3 and CD3. Notably the constrained CD3 engaging constructs utilize either a B7H3 ted sdAb, scFv, or FAB. Jurkat CD3 NFAT- GFP reporter cells were used to assess T-cell activation in the presence of a B7H3 positive cell line, A3 75 (A, 22C, 22E) and B7H3 negative cell line, CCRF (B, 22D, 22F). The cs of T-cell activation mediated by SOnM (A and 22B) or 2nM (C or 22D) of each construct is shown. Also shown is the potency of T-cell activation ed by each construct on the antigen ve (E) and ve (F) cell lines.

A-23B is a series of graphs g the T cell activating capacity of 5T4- targeted constrained CD3 engaging constructs. This example shows how bivalent biepitopic TAA targeting can increase the activity of ained CD3 engager over a bivalent monoepitopic protein on TAA positive cells (OVCARS). Neither construct induced T cell activation in the presence of TAA negative cells . is a graph showing the ability to induce antigen dependent T-cell activation by a representative 5T4-targeted constrained CD3 engaging construct, cx3315. A Jurkat CD3 NFAT—GFP reporter cell line was used to monitor T—cell activation by cx3315 in the presence of a 5T4 positive cell line (OVCARS), and a 5T4 negative cell line (CCRF- CEM). s the ability to induce antigen dependent T—cell activation by a representative CD20-targeted constrained CD3 engaging construct, 06309. A Jurkat CD3 NFAT-GFP reporter cell line was used to monitor T-cell activation by cx3309 in the presence of a CD20 positive cell line: Ramos and a cell CD20 negative cell line: CCRF—CEM. is a graph showing the ability to induce T-cell activation by a representative DLL3 -targeted constrained CD3 engaging construct, cx3308. A Jurkat CD3 NFAT—GFP reporter cell line was used to monitor T—cell activation by cx3309 in the presence of SHP-77 cells, which are DLL3 positive. This demonstrates that scFv moieties can be used to target TAAs in the constrained CD3 format and effectively activate T-cells when bound to a cognate TAA positive cell line.

A-27F depicts the impact of linker length on the capacity to activate T- cells in the presence of FRa positive cells - IGROVl (A, 27C, 27E), or FRa negative NCI—H460 (B, 27D, 27F). A-27B show the kinetics of T—cell tion by 2nM of various constructs on n positive and negative cells, respectively. C- 27D show the magnitude of T-cell activating ty by 2nM of various constructs on n positive and negative cells, respectively. E-27F show the potency of T-cell ting capacity various constructs with differing linker lengths on antigen positive and negative cells, respectively. A Jurkat CD3 NFAT-GFP reporter cell line was used to assess T-cell activation. Constrained CD3 proteins only ively engage and cluster CD3 on T cells when bound to a second antigen on target cells.

A-28C depicts FROL-dependent T-cell mediated cytotoxicity by cx1547. A trates that cx1547 does not induce T-cell mediated cytotoxicity of an antigen-negative cell line (NCI-H460). B demonstrates that cxlS47 induces T-cell mediated cytotoxicity of an antigen-positive cell line (Ovcar5). C shows the cs of T-cell mediated cytotoxicity towards OVCARS cells induced by cx1547 at 3nM. cx1547 induced T-cell mediated cytotoxicity only in antigen positive cell lines. Cytotoxicity was monitored using a caspase-3/7 ?uorogenic substrate of differentially labeled target cells on an Incucyte ZOOM imager. Effector to target cell ratio (ET) was assessed at 20:1 and 10:1 in this assay.

A-29F depicts the kinetics of T-cell-mediated cytotoxicity driven by representative B7H3 —targeted constrained CD3 engaging constructs and an alternative DART-Fc format targeting B7H3 and CD3. A titration range of 50nM to 80pM of the CD3 engaging ucts on the B7H3 positive A375 cell line are shown in A-29E. F s the ement at 50nM of each construct on A549 cell in which B7H3 expression has been knocked down. Notably all constructs display B7H3 -dependent T-cell mediated cytotoxicity. depicts the magnitude of induced T—cell ed cytotoxicity by 2.5nM of B7H3 ted constrained CD3 engaging constructs and the DART-Fc B7H3 x CD3 format on antigen ve (A375) and negative (A549-B7H3 knock-down) cell lines.

FIG. F depicts the comparative potency of two formats FRa—targeted CD3 engagers at inducing mediated T-cell cytotoxicity toward FROL positive Ovcar-5 cells (FIG.

E) and FROL negative NCI-H60 cells (F). cx2190 is a entative C- terminal product that would be derived from granzyme B proteolytic processing of cx1762.

Notably cx2190 displays superior potency ed to cxl792, demonstrating the substantial enhancement in CD3 binding mediated by proteolysis within the linker region between the Fc and CD3 binding domain. The kinetics of T—cell mediated cytotoxicity on FRd positive cells at ZOnM, 32pM and 6pM are depicted in A, 31B, and 31C, respectively. D and E show the potency of the two formats of FRa CD3 engager at 24 and 40 hours, respectively. Graph F. demonstrates that no substantial cytotoxicity is ed by any uct in the absence of FROL expression on the target cell. depicts T-cell-mediated cytotoxicity mediated by a representative 5T4- targeted constrained CD3 engaging construct, cx3315. cx3315 induced speci?c T-cell cytotoxicity toward a 5t4 expressing cell line, Ovcar-5, but not toward a 5T4 negative cell line, CCRF-CEM. ZOnM cx3315 was used in this assay. is a graph demonstrating the tion of T-cells following a 20hr co- culture of T-cells and Ovcar5 cell in the presence of cleaved or uncleaved cx309. Only cleaved CX3O9 was capable of ing FROt-dependent T-cell tion via CD3 binding.

T—cell activation was monitored by flow cytometric is of the CD25% of CD4 and CD8 populations.

A-34H depicts the capacity to active CD4 (A and 34E) and CD8 (C and 34G) T—cells in a target—dependent manner by representative B7H3 —targeted constrained CD3 engaging constructs and an ative DART-Fe format targeting B7H3 and CD3. T-cells were incubated with the B7H3 positive cell line A3 75 (A, 34C, 34E, 34G) or the B7H3 knock-down A549 cell line (B, 34D, 34F, 34H) and activation markers CD25 and CD71 were assessed by ?ow cytometry. These data demonstrate B7H3-dependent T-cell activation capacities of the constructs used. depicts the ability of a B7H3 —targeted constrained CD3 engaging construct, cx3095, to mediate antigen-dependent INFy production. Cytokine production was quantitated using an INFy ELISA. A375 was used as B7H3 ve cell line, whereas a B7H3 knock—down A549 cell line was used as negative cell line.

A-36B depicts the ability of a representative FRd-targeted constrained CD3 engaging construct, cx1547, to induce pendent IFNy (A) and lL-Z (B) from human PBMCs. Cytokine production was measured using a FluoroSpot cytokine capture assay. The l and NCI—H46O were used as the FRd ve and ve cell lines, respectively. depicts the ability of a B7H3 -targeted constrained CD3 engaging construct, cx3095, to mediate antigen-dependent INFy production. Cytokine production was monitored using a Spot assay. A375 and CCRF-CEM cell line were used as B7H3 positive and negative cell lines, tively.

A-38D depicts the ability of the FROt-targeting constrained CD3 construct, CX1547, to activate T-cells present in a dissociated primary human ovarian tumor sample and elicit cytotoxicity. A depicts the ?ow plot of the ve prevalence of the tumor cells (EpCAM+) and in?ltrating lymphocytes (CD45+) in the dissociated ovarian tumor sample. B shows the viability (CellTiterGlo) 0f the adherent tumor cells following treatment with a conventional FROL antibody or CX1547 after a 6 day incubation. C shows the INFy production ing treatment with an FROt antibody or CX1547 after a 6 day incubation. D shows representative images of the remaining adherent tumor cells following the 6 day treatment with no antibody , a conventional FROL antibody (middle) or cx1547 (right).

DETAILED DESCRIPTION The present disclosure provides constrained T-cell engaging fusion proteins in the form of multispeci?c polypeptide constructs that bind at least CD3 and a second antigen. The multispeci?c polypeptide ucts provided herein e at least a ?rst component that es one or more copies of an antigen-binding domain that bind an antigen operably linked to an immunoglobulin Fc region, a second component that includes one or more copies of at least a binding domain that binds CD3 (referred to herein as an anti—CD3 binding domain or a CD3 binding region, which are terms that are used interchangeably ), and a linker, such as a polypeptide linker, that joins the ?rst component and the second component.

In some embodiments, the antigen is a tumor associated antigen (TAA). In some embodiments, the linker is a cleavable linker.

The provided multispeci?c polypeptide constructs e a con?guration in which the ?rst ent containing the Fc region is N—terminal to the second component containing the CD3 binding region. In such an embodiment, the ?rst and second components are joined via a linker that is C-terminal to the end of the Fc region. In some embodiments the antigen g domain(s) are positioned on the amino-terminal (N-term) region of the multispeci?c polypeptide construct. In some embodiments, the antigen binding domain(s) are positioned on the carboxy-terminal (C-term) region of the multispeci?c polypeptide construct. In some ments, the antigen g domain(s) are positioned on both the N— and C-terminal regions of the multispeci?c polypeptide construct. Various rations of a multispeci?c polypeptide construct as provided herein are shown in The provided multispeci?c polypeptide constructs exhibit constrained T-cell engaging activity because such constructs only substantially bind to CD3 once an n is bound via the antigen-bind domain. This is exempli?ed in the es and Figures provided herein, which demonstrate the ability of constrained CD3 engaging proteins to ef?ciently bind TAA positive cells, while having little to no binding of T cells. This unique property allows constrained CD3 engaging proteins to distribute to sites where TAA is present without binding to peripheral T cells. This format is distinct from other CD3 engaging peci?c constructs, in that constituitiveconstitutive CD3 binding is disallowed or eliminated, providing a signi?cant bene?t by avoiding peripheral T-cell binding and permitting superior distribution to the site(s) where antigen is t as recognized by the antigen binding domain. For example, as shown in the Examples, the constrained CD3 engaging format enables similar potency to the DART-Fc format (e.g. published PCT Appl.

No. W02017/030926), however, binding to eral T-cell is signi?cantly attenuated.

Furthermore, other CD3 engaging constructs mediate antigen-dependent T-cell activation, however, the multispecific polypeptide ucts provided herein mediate both n dependent T-cell binding and activation.

The constrained T-cell engaging activity of the provided multispeci?c ptide ucts is due, in some aspects, to the positioning of the Fc region N—terminal to the nding region. In some embodiments, such positioning reduces, attenuates, dampens and/or prevents CD3 binding by the CD3 binding region. In the absence of antigen g by the antigen binding , the multispeci?c polypeptide constructs provided herein demonstrate reduced or ated CD3 binding and T-cell activating capacity. In some embodiments, in the presence of an antigen binding event mediated by the antigen binding domain(s) of the pecific polypeptide constructions, the capacity to bind CD3 by the CD3 g region is y enhanced. In some embodiments, in the presence of an antigen binding event mediated by the antigen binding s(s) of the peciflc polypeptide constructs the capacity to activate T—cells is greatly enhanced. Engagement of its cognate antigen by the antigen binding domain(s) within the multispeciflc polypeptide construct leads to subsequent T-cell engagement and mediates antigen-dependent T-cell activation, such as cytotoxicity, cytokine release, degranulation and proliferation. In some embodiments, the provided multispeciflc ptide constructs can be used to increase an immune response, such as to enhance T-cell activity, including cytolytic (or cytotoxic) T-cell activity. The modulation of the immune response can, in some aspects, treat a e or condition in a subject.

In some ments, the one or more antigen binding domains bind an antigen on a tumor cell or a cell of the tumor microenvironment. In some aspects, the provided multispeciflc polypeptide constructs can be used to increase immune responses, such as T- cell activity, e.g. cytotoxicity activity, against a tumor or cancer. In some embodiments, the provided multispecific polypeptide constructs can be used to treat a tumor or cancer in the subject.

The multispeciflc polypeptide constructs of the disclosure ensure that there will be no binding of T-cells via CD3 in peripheral blood, as the CD3 binding region of these constructs is constrained or otherwise blocked and/or inhibited by the presence of the Fc region. Thus, the multispeci?c polypeptide constructs of the disclosure provide a number of advantages. In some aspects, these ucts limit the sink effect caused by binding all T- cells. In some aspects, these constructs reduce systemic toxicity.

In some embodiments, the provided multispeci?c polypeptide constructs of the disclosure allow for controlled biodistribution to a desired site in a t, such as, for example, a site of tumor-associated antigen (TAA) expression. Sites of TAA expression e, for example, tumor and the surrounding tumor microenvironment.

In some embodiments, the multispeci?c polypeptide constructs of the sure exhibit city for CD3 and one or more other antigen. In some embodiments, the peci?c ptide constructs can contain more than one antigen binding domain able to bind one or more TAA, such as 2, 3 or 4 antigen binding domains, see e.g. In some embodiments, the one or more antigen g domains bind the same antigen. In some embodiments, the multispeci?c polypeptide constructs include more than one antigen binding domains that bind distinct epitopes on the same antigen. In some embodiments, the multispeci?c ptide constructs include more than one antigen binding domain that bind one or more distinct antigens. In some embodiments, the multispeci?c polypeptide constructs include more than one antigen g s that bind distinct epitopes on the same antigens as well as include additional antigen binding domains that bind to one or more distinct antigens. In some aspects, the provided multispeci?c polypeptide constructs are bispeci?c polypeptide ucts, such that they are able to bind to CD3 and to another antigen, such as a TAA, via binding of the antigen—binding domain of the multispeci?c polypeptide construct. In some examples, the provided multispeci?c polypeptide constructs are bispeci?c polypeptide constructs that provide tetravalent engagement of one or more TAA through the use of a ?rst antigen—binding domain and a second antigen—binding domain.

For example, in some embodiments, the bispeci?c polypeptide constructions include a ?rst antigen-binding single domain antibody (sdAb) and a second antigen-binding sdAb as shown in FIGS. 1 and 2.

In some embodiments, the multispeci?c polypeptide constructs provided herein exist in two states in terms of capacity to bind CD3 and subsequently activate T-cells: (l) the ive" state, i.e. uncleaved state, occurs when there is no binding of any or all of the antigen binding domain(s), such that the CD3 binding is constrained and T-cell interaction is obviated, and (2) the "active" state occurs upon antigen binding by any or all of the antigen binding (s), such that the CD3 binding region is able to bind CD3 and the T-cell interaction is allowed.

In some embodiments, the Fc region is linked to the CD3 binding domain via a linker or linkers. In some embodiments, the Fc region is linked to the CD3 binding region via a non-cleavable inker or linkers In some embodiments, the Fc region is linked to the CD3 binding region via a cleavable linker or an otherwise labile linker or linkers.

In some embodiments, the Fc region and the CD3 binding region are linked by a cleavable linker. In some aspects, enhanced CD3 binding occurs following cleavage of the cleavable linker. In some such aspects, the "active" state can be further ampli?ed via several isms, including via ge of the linker joining the CD3 binding region and the Fc region. In some embodiments, the ble linker is a linker that contains a substrate recognition site for a protease. In some embodiments, wherein the Fc region and the CD3 binding region are linked by a cleavable , enhanced CD3 binding may occur ing cleavage within the linker(s).

In some aspects, the multispecific polypeptide constructs of the disclosure allow for therapeutic efficacy in the absence of proteolysis.

In some embodiments, the Fc region is a homodimeric Fc region. In some embodiments, the Fc region is a dimeric Fc . In some embodiments, the Fc region is a ric Fc region. In some embodiments, the Fc region of the multispeci?c polypeptide constructs are capable of interacting with FcyRs and mediating innate immune effector functions, for example, antibody dependent cellular toxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). In some embodiments, the Fc region of the multispeci?c polypeptide constructs are capable of interacting with complement proteins, namely Clq, and mediating complement ent xicity. Thus, in some aspects, the multispeci?c polypeptide constructs of the disclosure allow for multiple immune effector mechanisms, including innate immune effectors and s.

In some embodiments, wherein the Fc region and the CD3 binding region are operably linked by a cleavable linker, cleavage of the (s) n the Fc region and the CD3 g region may separate the multispeci?c polypeptide constructs into a ?rst and second component. Depending on the ition of the multispeci?c polypeptide construct, the first and second component may have distinct functionalities. In some embodiments, the Fc region is a region that exhibits one or more effector functions, such as ADCC, CDC or ADCP functions. In such examples, the multispecific polypeptide ucts of the disclosure can be used to produce a self-amplifying system. For example, the multispeci?c constructs can be used as follows: ADCC mediated by NK cell following TAA targeting and CD16 binding of Fc region results in the release granzyme B that is capable of extracellular proteolysis and ge of linkers between the first and second ents of the multispecific polypeptide constructs.

In some ments, the linker is a cleavable linker. The multispecific polypeptide constructs provide a two-in-one therapeutic moiety having dual effector functions, n proteolytic activation of the multispecific polypeptide ucts produces two components that each have biological activity. The multispecific polypeptide constructs of the disclosure are capable of providing Fc-mediated effector functions, such as for example, ADCC (e.g, release of Granzyme B by NK cells), ADCP, and/or CDC.

It is plated that the constrained CD3 engaging constructs are amenable for use with any TAA-binding domain, allowing better therapeutic exposure within the tumor or tumor—microenvironment by avoiding interactions with peripheral T—cells and ing potent TAA-dependent T-cell cytotoxicity The incorporation of a protease cleavable linker between the Fc and the components of the CD3 binding domain s for amplification of the T—cell activating capacity by allowing full exposure of the CD3 binding .

Depending on the specific linker included, the amplification step can be mediated by tumor associated proteases or by granzymes released following antigen dependent-T-cell activation. If a tumor protease cleavable linker is included the amplification is mediated by the tumor or tumor-microenvironment. Whereas, if a granzyme B cleavable linker is included the amplification may be self-mediated by T-cells following antigen-dependent activation. rmore, in cases wherein an effector enabled Fc is included in the construct, ication may be ed by granzymes ed from NK cell that occurs through an ADCC mechanism.

In some embodiments, the protease is a protease that is ed in the tumor microenvironment and/or upon T cell activation induced by initial binding of the CD3 binding region to CD3 in the tumor microenvironment via g of the antigen binding domain(s) to a TAA. In some embodiments, the protease is granzyme B. In some aspects, the multispecific polypeptide constructs of the disclosure leverage the ability of a protease within the tumor microenvironment and/or granzyme B to cleave the linker within the multispecific polypeptide construct at a position below the Fc immunoglobulin ptide, thereby generating two therapeutically active proteins with, in some cases, distinct effector cell engagement. In some aspects, upon cleavage of the cleavable linker, the cleaved first portion or component retains Fc-effector functions and bivalent targeting of a first antigen, such as, e.g, a TAA, via a ?rst antigen-binding domain, and the second portion or component retains the ability for T-cell engagement, as separation of the CD3 binding region from the Fc region allows for CD3 binding. The cleaved second portion or ent also, in some cases, retains the ability for binding to a TAA, which can be a bivalent binding via a second antigen-binding domain.

In some embodiments, the second portion or component contains a CD3 binding region that is monovalent to CD3, such that there will be no activation of T-cell unless there is TAA present. In some aspects, where the alent polypeptide construct contains a cleavable linker, the cleaved second portion or component allows for TAA-dependent, - mediated cytotoxicity. In some cases, the cleaved second portion or component ensures there will be no FcRn interaction. rmore, the d second portion or component will be suf?ciently small in size, for example, only ~50kDa, which will ensure rapid clearance if, for any reason, the cleaved second n or component distributes outside tumor site after cleavage and/or if it is aberrantly cleaved outside of the tumor site.

In some embodiments, the multispeci?c polypeptide constructs of the disclosure allow for T—cell and NK cell mediated cytotoxicity to occur simultaneously. In some cases, such activity can occur in a multispeci?c polypeptide construct in which is contained a ?rst antigen binding , e.g., a ?rst anti-TAA antigen binding , and a second antigen binding domain, e.g, a second anti—TAA antigen binding domain, that can target distinct and/or non-competing es on a given TAA.

In some aspects, the multispeci?c polypeptide constructs of the disclosure provide a number of advantages over current bispeci?c therapeutics. The multispeci?c polypeptide constructs of the disclosure are smaller than a conventional therapeutic antibody, e. g., lSOkDa vs. 125kDa, which will allow for better target, e.g. tumor, penetration. First, the size of the entire multispeci?c polypeptide construct provides long half—life for the uncleaved construct, and upon cleavage of the construct, the cleaved second portion or component will be suf?ciently small to ensure a short half-life. In some aspects, the peci?c polypeptide constructs of the disclosure t reduced ic toxicity or toxicity of any area outside the tumor and/or tumor nvironment, since CD3 binding by the CD3 binding region depends on TAA engagement before CD3 engagement will occur. In some cases, the inclusion of a cleavable linker speci?c to a se of the tumor environments reduces CD3 binding by the multispeci?c constructs until proteolytic activation and TAA engagement, thereby ying or enhancing the CD3 engagement.

The multispeci?c polypeptide constructs of the disclosure are designed to ensure that the protease that cleaves the cleavable linker does not need to be tumor-biased (e.g, does not need to be differently expressed only at a tumor site and/or in the tumor environment).

Rather, these multispecific polypeptide constructs only require that the protease is present in the same location as the TAA. The valency of these constructs will drive biodistribution and retention within the tumor and/or tumor microenvironment.

All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was speci?cally and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an admission that any is pertinent prior art, nor does it constitute any admission as to the contents or date of the same. The ion having now been described by way of written description, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments and that the foregoing description and examples below are for es of ration and not limitation of the claims that . 1. Definitions Unless otherwise de?ned, scientific and technical terms used in connection with the t disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. The term L: 33 a entity or "an" entity refers to one or more of that entity.

For example, a compound refers to one or more compounds. As such, the terms c: 77 (r. 77 a an , , "one or more" and "at least one" can be used interchangeably. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. lly, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or cleotide chemistry and hybridization described herein are those well-known and commonly used in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as bed herein. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as bed in various general and more ic nces that are cited and discussed throughout the present specification. See e.g, Sambrook et a]. Molecular g: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. (1989)). The nomenclatures ed in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry bed herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, al analyses, ceutical preparation, formulation, and delivery, and treatment of patients.

As utilized in accordance with the t disclosure, the following terms, unless otherwise indicated, shall be tood to have the following meanings: As used herein, the term "antibody" refers to immunoglobulin molecules and antigen-binding portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. By "specifically bind" or "immunoreacts wit " or "immunospeciflcally bind" is meant that the antibody reacts with one or more antigenic determinants of the desired antigen and does not react with other polypeptides or binds at much lower af?nity (Kd > 106). Antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, fully human, domain antibody, single chain, Fab, and F(ab')2 nts, Fvs, scFvs, and a Fab expression y.

The basic antibody structural unit is known to se a tetramer. Each tetramer is composed of two cal pairs of polypeptide chains, each pair having one " (about kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to l 10 or more amino acids primarily responsible for antigen recognition. The carboxy—terminal portion of each chain de?nes a constant region primarily responsible for effector function. In general, antibody molecules obtained from humans relate to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain s have sses as well, such as IgGl, Ing, IgG3, IgG4, and others. rmore, in humans, the light chain may be a kappa chain or a lambda chain.

The term "monoclonal antibody" (mAb) or "monoclonal dy composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of dy molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding af?nity for it.

The term "antigen-binding site" or "binding portion" refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen g site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains, referred to as "hypervariable regions," are osed between more conserved ?anking stretches known as "framework regions," or "FRs". Thus, the term "FR" refers to amino acid sequences that are naturally found n, and nt to, hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervaIiable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding e. The antigen-binding surface is mentary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as ementarity-determining regions," or "CDRs." The assignment of amino acids to each domain is in accordance with the de?nitions of Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 1961901—917 (1987), Chothia er al. Nature 342:878—883 (1989).

As used herein, the term "epitope" includes any speci?c portion of an antigen targeted by an antibody, antibody fragment or other binding domain. The term "epitope" includes any protein region to which speci?c g is directed. The term "epitope" includes any protein determinant capable of speci?c g to an immunoglobulin or T-cell receptor.

Epitopic determinants usually consist of chemically active surface groupings of les such as amino acids or sugar side chains and usually have c three dimensional structural characteristics, as well as speci?c charge characteristics. For example, antibodies may be raised against N—terminal, central, or C-terminal peptides of a polypeptide. In on, antibodies may be raised against linear or discontinuous epitopes of a polypeptide.

An antibody is said to speci?cally bind an n when the dissociation nt is S 1 uM; for example, in some embodiments S 100 nM and in some embodiments, S 10 nM and does not display binding to other proteins either closely d or distinct.

As used herein, the terms "speci?c binding," "immunological binding," and "immunological binding properties" refer to the non-covalent interactions of the type that occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is c. The strength, or af?nity of immunological binding interactions can be expressed in terms of the dissociation constant (Kd) of the interaction, wherein a smaller Kd represents a greater af?nity. Immunological binding properties of ed polypeptides can be quanti?ed using methods well known in the art. One such method entails measuring the rates of antigen- binding site/antigen x formation and dissociation, wherein those rates depend on the concentrations of the complex rs, the af?nity of the interaction, and geometric parameters that equally in?uence the rate in both ions. Thus, both the "on rate constant" (K011) and the "off rate constant" (K03) can be determined by calculation of the concentrations and the actual rates of association and dissociation. (See Nature 361: 186-87 (1993)). The ratio of Koff /Kon enables the cancellation of all ters not related to affinity and is equal to the dissociation constant Kd. (See, generally, Davies et al, (1990) Annual Rev Biochem 59:43 9-473). An dy of the present disclosure is said to speci?cally bind to EGFR, when the binding nt (Kd) is $1 uM, for example, in some embodiments S 100 nM, in some embodiments S 10 nM, and in some embodiments S 100 pM to about 1 pM, as ed by assays such as radioligand binding assays or similar assays known to those skilled in the art.

The term "isolated polynucleotide" as used herein shall mean a polynucleotide of genomic, cDNA, or tic origin or some combination thereof, which by virtue of its origin the "isolated polynucleotide" (1) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (2) is operably linked to a polynucleotide that it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence. Polynucleotides in accordance with the disclosure e the nucleic acid molecules encoding the heavy chain immunoglobulin molecules shown , and nucleic acid molecules encoding the light chain immunoglobulin molecules shown herein.

The term "isolated protein" referred to herein means a protein of cDNA, recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein" (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g, free of murine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.

The term "polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein fragments, and analogs are species of the polypeptide genus. Polypeptides in accordance with the sure se the heavy chain immunoglobulin molecules shown herein, and the light chain immunoglobulin molecules shown herein, as well as antibody molecules formed by combinations comprising the heavy chain immunoglobulin molecules with light chain immunoglobulin molecules, such as kappa light chain immunoglobulin molecules, and vice versa, as well as fragments and analogs f.

The term "naturally-occurring" as used herein as d to an object refers to the fact that an object can be found in nature. For example, a ptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and that has not been intentionally d by man in the laboratory or ise is lly-occurring.

The term "operably linked" as used herein refers to positions of components so described are in a onship permitting them to function in their intended manner. A control sequence "operably " to a coding sequence is ligated in such a way that expression of the coding sequence is ed under conditions compatible with the control sequences.

The term "control sequence" as used herein refers to polynucleotide sequences that are necessary to effect the expression and processing of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence in eukaryotes, generally, such control sequences include promoters and transcription ation sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is ageous, for example, leader sequences and fusion partner sequences. The term "polynucleotide" as referred to herein means nucleotides of at least 10 bases in , either ribonucleotides or deoxynucleotides or a modi?ed form of either type of nucleotide. The term includes single and double stranded forms of DNA.

The term oligonucleotide referred to herein includes naturally occurring, and modi?ed nucleotides linked together by naturally ing, and non-naturally occurring oligonucleotide es. Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. In some embodiments, Oligonucleotides are 10 to 60 bases in length, for example, in some embodiments, 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single ed, e.g., for probes, although Oligonucleotides may be double ed, e. g., for use in the construction of a gene mutant.

Oligonucleotides of the disclosure are either sense or antisense Oligonucleotides.

The term "naturally occurring nucleotides" referred to herein includes deoxyribonucleotides and ribonucleotides. The term "modi?ed nucleotides" referred to herein includes nucleotides with modi?ed or substituted sugar groups and the like. The term "oligonucleotide linkages" referred to herein includes ucleotide linkages such as phosphorothioate, orodithioate, phosphoroselerloate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate, phosphoronmidate, and the like. See e.g., LaPlanche et al. Nucl. Acids Res. 14:9081 (1986), Stec er a]. J. Am. Chem. Soc. 106:6077 (1984), Stein er al. Nucl. Acids Res. 16:3209 (1988), Zon el al. Anti Cancer Drug Design 6:539 (1991); Zon et al. ucleotides and Analogues: A Practical ch, pp. 87-108 (F. in, Ed., Oxford University Press, Oxford England (1991)); Stec et a]. US. Patent No. 5,151,510; Uhlmann and Peyman Chemical s 90:543 (1990). An oligonucleotide can include a label for detection, if desired.

As used , the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology - A Synthesis (2nd Edition, ES. Golub and DR.

Gren, Eds, Sinauer Associates, land7 Mass. (1991)). Stereoisomers (e.g, D- amino acids) of the twenty conventional amino acids, unnatural amino acids such as 01-, Ot- disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present sure. Examples of unconventional amino acids include: 4 hydroxyproline, y-carboxyglutamate, a-N,N,N- trimethyllysine, s -N-acetyllysine, O-phosphoserine, N- acetylserine, ylmethionine, 3- methylhistidine, 5-hydroxylysine, o-N-methylarginine, and other similar amino acids and imino acids (e.g, 4- hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right—hand direction is the carboxy—terminal direction, in accordance with standard usage and convention.

Similarly, unless speci?ed otherwise, the left-hand end of single- stranded polynucleotide sequences is the 5' end the left—hand direction of double—stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction sequence regions on the DNA strand having the same ce as the RNA and that are 5' to the 5‘ end of the RNA ript are referred to as "upstream sequences", sequence regions on the DNA strand having the same sequence as the RNA and that are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".

As applied to polypeptides, the term antial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, for example, in some embodiments, at least 90 percent sequence identity, in some embodiments, at least 95 percent sequence identity, and in some embodiments, at least 99 percent sequence identity.

In some embodiments, residue positions that are not cal differ by vative amino acid substitutions.

As discussed herein, minor variations in the amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the present disclosure, providing that the variations in the amino acid sequence maintain at least 75%, for example, in some ments, at least 80%, 90%, 95%, and in some embodiments 99%. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side . Genetically encoded amino acids are generally divided into families: (1) acidic amino acids are aspartate, glutamate, (2) basic amino acids are lysine, arginine, histidine, (3) non-polar amino acids are alanine, valine, e, isoleucine, proline, alanine, methionine, tryptophan, and (4) uncharged polar amino acids are glycine, asparagine, ine, cysteine, serine, threonine, tyrosine. The hydrophilic amino acids include arginine, asparagine, aspartate, glutamine, glutamate, histidine, lysine, serine, and threonine. The hobic amino acids e alanine, cysteine, isoleucine, leucine, methionine, alanine, proline, tryptophan, tyrosine and valine. Other families of amino acids include (i) serine and threonine, which are the aliphatic-hydroxy family, (ii) asparagine and ine, which are the amide containing family; (iii) alanine, valine, leucine and cine, which are the aliphatic family; and (iv) phenylalanine, tryptophan, and tyrosine, which are the aromatic family. For example, it is reasonable to expect that an isolated replacement of a e with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a urally related amino acid will not have a major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site.

Whether an amino acid change results in a functional peptide can readily be determined by assaying the speci?c activity of the polypeptide derivative. Assays are described in detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be readily ed by those of ordinary skill in the art. In some ments, amino— and carboxy— termini of fragments or analogs occur near boundaries of functional domains. Structural and functional domains can be identi?ed by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence databases. Computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or on. s to identify protein sequences that fold into a known three-dimensional structure are known. Bowie et a]. Science 253: 164 (1991). Thus, the foregoing examples demonstrate that those of skill in the art can recognize sequence motifs and structural conformations that may be used to de?ne structural and functional domains in accordance with the disclosure.

In some embodiments, amino acid tutions are those that: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to ion, (3) alter binding af?nity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogs can include s muteins of a sequence other than the naturally-occurring e sequence. For example, single or multiple amino acid substitutions (for example, conservative amino acid substitutions) may be made in the naturally- occurring sequence (for example, in the portion of the polypeptide outside the domain(s) g intermolecular contacts. A conservative amino acid substitution should not substantially change the ural characteristics of the parent ce (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of cognized polypeptide secondary and tertiary structures are described in ns, ures and Molecular Principles (Creighton, Ed, W. H.

Freeman and Company, New York (1984)), Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, NY. (1991)); and Thornton et at. Nature 354: 105 (1991).

The term "polypeptide fragment" as used herein refers to a polypeptide that has an amino terminal and/or y—terminal deletion and/or one or more internal deletion(s), but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full length cDNA sequence.

Fragments typically are at least 5, 6, 8 or 10 amino acids long, for example, in some embodiments, at least 14 amino acids long, in some embodiments, at least 20 amino acids long, usually at least 50 amino acids long, and in some embodiments, at least 70 amino acids long. The term "analog" as used herein refers to polypeptides that are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and that has speci?c binding to EGFR, under suitable binding conditions.

Typically, polypeptide s comprise a conservative amino acid substitution (or addition or deletion) with respect to the lly- occurring sequence. Analogs typically are at least amino acids long, for example, in some embodiments, at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.

As used herein, the terms "label" or "labeled" refers to incorporation of a able marker, e.g, by incorporation of a radiolabeled amino acid or attachment to a polypeptide of yl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or calorimetric s). In certain situations, the label or marker can also be therapeutic.

Various methods of ng polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e. g., 3H, 14C, 15N, 358, 90Y, 99Tc, HlIn, 125I, 131I), cent labels (e.g., a ?uorophore, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish dase, p-galactosidase, luciferase, alkaline atase), chemiluminescent, biotinyl , predetermined polypeptide epitopes recognized by a secondary reporter (e.g., e zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance. The term "pharmaceutical agent or drug" as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when ly administered to a patient.

As used herein, "substantially pure" means an object species is the inant species present (126., on a molar basis it is more abundant than any other individual species in the composition), and a ntially puri?ed fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all olecular species present.

Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, for example, in some embodiments, more than about 85%, 90%, 95%, and 99%. In some embodiments, the object species is d to essential homogeneity (contaminant species cannot be detected in the composition by conventional ion methods) wherein the composition consists essentially of a single macromolecular species.

The term patient includes human and veterinary subjects.

Other chemistry terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (Parker, 8., Ed, McGraw—Hill, San Francisco (1985)). 11. Multispeci?c Polypeptide Constructs Provided herein is a multispeci?c polypeptide construct containing a ?rst component containing an immunoglobulin Fc region and a second component comprising a CD3-binding region, n the ?rst and second components are coupled by a linker, wherein the Fc region is positioned N—terminal to the CD3—binding region; and one or both of the ?rst and second components comprises an antigen binding domain that binds a tumor associated antigen (TAA).

In some embodiments, the multispeci?c polypeptide construct contains in order, from N-terminus to C-terminus: an globulin Fc region, a linker, a CD3 g region that binds CD3 (CD3 8), and an antigen binding domain that binds a tumor-associated antigen (TAA). In some embodiments, the multispeci?c polypeptide construct contains in order, from N—terminus to C-terminus: an antigen binding domain that binds to a tumor- associated antigen (TAA), an immunoglobulin Fc region, a linker, and a CD3 binding region that binds CD3 (CD38). In some embodiments, the multispeci?c polypeptide construct contains at least a ?rst antigen binding domain that binds a TAA and a second antigen binding domain that binds a TAA. In some embodiments, the multispeci?c polypeptide construct contains, in order, from N—terminus to inus: a ?rst antigen binding domain that binds to a tumor-associated antigen (TAA), an immunoglobulin Fc region, a linker, a CD3 binding region that binds CD3 (CD38); and a second antigen binding domain that binds a tumor-associated antigen (TAA).

Each of the components of the multispeci?c polypeptide constructs of the disclosure is described in more detail below. 1. Anti-CD3 Binding Domains: The multispeci?c polypeptide ucts of the sure include one or more copies of an D3 binding domain. The anti-CD3 binding domains of the disclosure activate T cells via engagement of CD38 on the T cells. The D3 g domains of the disclosure agonize, stimulate, activate, and/or otherwise augment CD3-mediated T cell activation. Biological activities of CD3 include, for example, T cell activation and other signaling through interaction n CD3 and the n-binding subunits of the T-Cell Receptor (TCR). For e, the anti-CD3 binding domains of the disclosure completely or partially activate T cells via engagement of CD38 on T cells by partially or completely modulating, e.g., agonizing, stimulating, activating or otherwise augmenting CD3-mediated T cell activation.

In preferred embodiments, the D3 binding domains of the disclosure speci?cally bind the epsilon chain of CD3, also known as CD38. The anti— CD38 binding domains of the disclosure activate T cells via engagement of CD38 on the T cells. The anti- CD38 binding domains of the disclosure include monoclonal antibodies, such as, for example, mammalian monoclonal antibodies, primate onal antibodies, fully human monoclonal antibodies, as well as humanized monoclonal antibodies and chimeric antibodies, as well as antigen-binding fragments thereof. In some embodiments, the D38 binding domain includes one or more copies of an antibody or an antigen-binding fragment thereof.

In some embodiments, the anti-CD38 binding domain includes one or more copies of an antibody or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, an Fv nt, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the D3 binding domain includes an Fv antibody fragment that binds CD38 (referred to herein as an anti-CD38 Fv fragment). In some embodiments, the anti-CD38 Fv antibody fragment is a disul?de stabilized anti-CD3 binding Fv fragment (dst). In some ments, the anti—CD3 binding domain is monovalent for binding CD3.

In some embodiments, the anti-CD38 binding domain thereof includes a variable heavy chain (Hv) comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, the anti-CD38 binding domain es a le light chain (Lv) comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-CD38 binding domain thereof includes a variable heavy chain (Hv) sing the amino acid sequence of SEQ ID NO: 14 and a variable light chain (Lv) comprising the amino acid ce of SEQ ID NO: 15. In some embodiments, the anti-CD38 binding domain thereof includes a variable heavy chain (Hv) comprising the amino acid sequence of SEQ ID NO: 44. In some embodiments, the D38 g domain includes a variable light chain (Lv) comprising the amino acid sequence of SEQ ID NO: 72. In some embodiments, the anti-CD38 binding domain f includes a variable heavy chain (Hv) comprising the amino acid sequence of SEQ ID NO: 44 and a variable light chain (Lv) comprising the amino acid sequence of SEQ ID NO: 72. In some embodiments, the anti-CD38 binding domain thereof includes a combination of a heavy chain variable region amino acid sequence and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group of SEQ ID NO: 32—81. In some embodiments, the anti—CD38 binding domain thereof includes a combination of a heavy chain variable region amino acid sequence selected from the group of SEQ ID NO: 32-62 and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group of SEQ ID NO: 63—81.

In some embodiments, the anti-CD38 binding domain f includes a variable heavy chain (Hv) sing an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more cal to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the anti-CD38 binding domain includes a variable light chain (Lv) comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-CD38 binding domain thereof includes a variable heavy chain (Hv) comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more cal to the amino acid sequence of SEQ ID NO: 14 and a variable light chain (Lv) comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid ce of SEQ ID NO: 15.

In some embodiments, the anti-CD38 binding domain thereof includes a le heavy chain (Hv) comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 44. In some ments, the anti-CD38 binding domain includes a variable light chain (Lv) comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 72. In some embodiments, the anti-CD38 binding domain thereof includes a variable heavy chain (Hv) sing an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 44 and a variable light chain (Lv) comprising an amino acid ce that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 72.

In some embodiments, the anti-CD38 Fv dy fragment includes an amino acid sequence selected from the group of SEQ ID NO: 32-81. In some embodiments, the anti- CD3e Fv antibody fragment includes an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 32—81. In some embodiments, the anti—CD38 Fv antibody fragment includes a combination of an amino acid sequence selected from the group of SEQ ID NO: 32-62 and an amino acid ce selected from the group consisting of SEQ ID NO: 63-81. In some embodiments, the anti-CD38 FV antibody fragment includes a combination of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 32-62 and an amino acid ce that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 63-81 an amino acid sequence.

In some embodiments, the anti-CD38 binding domain includes a combination of a VH CDRl sequence, a VH CDR2 sequence, and a VH CDR3 sequence, wherein at least one of the VH CDRl sequence, the VH CDR2 sequence, and the VH CDR3 sequence is selected from a VH CDRl sequence that includes at least the amino acid sequence TYAMN (SEQ ID NO: 16); a VH CD2 sequence that es at least the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17), and a VH CDR3 sequence that es at least the amino acid ce HGNFGNSYVSWFAY (SEQ ID NO: 18).

In some ments, the anti-CD38 binding domain includes a combination of a VL CDRl sequence, a VL CDR2 sequence, and a VL CDR3 sequence, wherein at least one of the VL CDRl sequence, the VL CDR2 sequence, and the VL CDR3 sequence is selected from a VL CDRl sequence that includes at least the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 19), a VL CDR2 sequence that includes at least the amino acid sequence GTNKRAP (SEQ ID NO: 20); and a VL CDR3 sequence that includes at least the amino acid sequence ALWYSNLWV (SEQ ID NO: 21).

In some embodiments, the anti—CD38 binding domain includes a VH CDRl sequence that includes at least the amino acid sequence TYAMN (SEQ ID NO: 16), a VH CD2 sequence that includes at least the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17), a VH CDR3 ce that includes at least the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDRl sequence that includes at least the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 19), a VL CDR2 sequence that includes at least the amino acid sequence GINKRAP (SEQ ID NO: 20), and a VL CDR3 sequence that includes at least the amino acid sequence ALWYSNLWV (SEQ ID NO: 21).

In some ments, the anti-CD38 binding domain includes a combination of a VH CDRl sequence, a VH CDR2 sequence, and a VH CDR3 sequence, n at least one of the VH CDRl sequence, the VH CDR2 sequence, and the VH CDR3 sequence is selected from a VH CDR1 sequence that includes a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence TYAMN (SEQ ID NO: 16), a VH CD2 sequence that includes a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17); and a VH CDR3 sequence that includes a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more cal to the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18).

In some embodiments, the anti-CD38 binding domain includes a combination of a VL CDR1 sequence, a VL CDR2 ce, and a VL CDR3 sequence, wherein at least one of the VL CDR1 sequence, the VL CDR2 sequence, and the VL CDR3 sequence is selected from a VL CDR1 sequence that includes a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more cal to the amino acid ce RSSTGAVTTSNYAN (SEQ ID NO: 19), a VL CDR2 sequence that includes a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence P (SEQ ID NO: 20); and a VL CDR3 sequence that includes a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence ALWYSNLWV (SEQ ID NO: 21).

In some embodiments, the anti-CD38 binding domain includes a VH CDR1 sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence TYAMN (SEQ ID NO: 16), a VH CD2 sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17); a VH CDR3 sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more cal to the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDR1 sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid ce RSSTGAVTTSNYAN (SEQ ID NO: 19), a VL CDR2 sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence GTNKRAP (SEQ ID NO: 20); and a VL CDR3 ce that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence ALWYSNLWV (SEQ ID NO: 21).

In some embodiments, the anti-CD38 binding domain thereof is an Fv fragment that includes a combination of heavy chain variable amino acid sequence and a light chain variable amino acid sequence. In some embodiments, the anti-CD38 binding domain thereof is an Fv fragment that includes a combination of heavy chain variable amino acid sequence and a light chain variable amino acid sequence comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 32-81. In some embodiments, the anti-CD38 binding domain f is an Fv fragment that includes a combination of heavy chain variable amino acid sequence and a light chain variable amino acid sequence comprising an amino acid sequence selected from the group ting of SEQ ID NOs: 32-81. In some embodiments, the anti-CD38 binding domain thereof is an Fv nt that includes a combination of heavy chain variable amino acid sequence selected from the group of SEQ ID NO: 32-62 and an amino acid ce ed from the group consisting of SEQ ID NO: 63-81. In some embodiments, the anti-CD38 binding domain thereof is an Fv fragment that includes a combination of heavy chain variable amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 32-62 and an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to an amino acid sequence ed from the group consisting of SEQ ID NO: 63-81 an amino acid sequence. 2. Immunoglabulin Fc polypeptides: The ?rst component of the multispeciflc polypeptide constructs of the disclosure includes an immunoglobulin Fc . In some embodiments, the immunoglobulin Fc region is an IgG isotype selected from the group consisting of IgGl isotype, IgG2 isotype, IgG3 isotype, and IgG4 subclass. In some embodiments, the Fc region is a human Fc. In some embodiments, the immunoglobulin Fc region is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6. In some embodiments, the immunoglobulin Fc region contains an Fc chain that is an immunologically active fragment of any of SEQ ID Nos: 1-6. In some embodiments, the immunoglobulin Fc region contains an Fc polypeptide chain that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any of SEQ ID NOs: 1—6 or an immunologically active fragment thereof.

In some embodiments, the multispeciflc ptide construct is a dimer formed by polypeptides, each containing an EC. In some speci?c embodiments, identical or substantially identical polypeptides will be dimerized to create a homodimer. In some embodiments, the dimer is a homodimer in which the two polypeptides of the multispeci?c polypeptide construct are the same. In other cases, the Fc region is formed by Fc domains that are mutated or modi?ed to promote dime?zation in which different polypeptides can be dimerized to yield a heterodimer. Thus, in some embodiments, the dimer is a heterodimer in which two polypeptide chains of the multispeci?c polypeptide construct are different.

Exemplary modi?cations to promote heterodime?zation are known, including any as described below.

In general, the Fc region is responsible for effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC), in addition to the antigen-binding capacity, which is the main function of immunoglobulins. Additionally, the FcRn ce present in the Fc region plays the role of regulating the IgG level in serum by increasing the in viva half-life by conjugation to an in viva FcRn receptor. In some embodiments, such functions can be d, such as reduced or enhanced, in an Fc for use with the provided multispeci?c polypeptide constructs.

In some embodiments, the Fc region of the provided multispeci?c polypeptide constructs t one or more effector functions. In some cases, the Fc region is capable of providing Fc—mediated effector functions, such as for example, ADCC (e.g., release of me B by NK cells), ADCP, and/or CDC. Thus, in some embodiments in which the peci?c polypeptide constructs contain a ble linker, cleavage of the linker can produce two components that each have biological activity: the nding region that is able to bind and engage CD3 on a T cell and the Fc region linked to the TAA-antigen binding domain that can exhibit -speci?c effector function.

In some embodiments, the Fc region includes an Fc polypeptide that is mutated or modi?ed to alter one or more or functions. Various examples of mutations to Fc polypeptides to alter, such as reduce, effector function are known, including any as described below. In some embodiments, reference to amino acid substitutions in an Fc region is by EU ing by Kabat (also called Kabat numbering) unless described with reference to a speci?c SEQ ID NO. EU numbering is known and is according to the most recently updated IMGT Scienti?c Chart (HVIGT®, the international ImMunoGeneTics information system®, http://www.imgt.org/IMGTScienti?cChart/Numbering/Hu_IGHaner.html (created: 17 May 2001, last updated: 10 Jan 2013) and the EU index as reported in Kabat, EA. et a1. ces of Proteins of Immunological st. 5th ed. US Department of Health and Human Services, NIH publication No. 91—3242 (1991).

In some embodiments, provided multispecific polypeptide constructs that contain an Fc region that ts reduced effector functions, may be a desirable candidate for applications in which constrained CD3 binding is desired yet certain effector functions (such as CDC and ADCC) are unnecessary or rious. In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.

For example, Fc receptor (FcR) binding assays can be conducted to ensure that the multispeci?c polypeptide constructs and/or cleaved components thereof lack FcyR binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, s chRIII only, whereas monocytes express FcyRI, FcyRII and FcyRIII. miting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in US. Pat. No. 5,500,362 (see, e.g., Hellstrom, I. et al. Proc. Nai'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, Iet 611., Proc. Nat’lAcad. Sci. USA 82:1499-1502 (1985), US. Pat. No. 337 (see Bruggemann, M. et 61]., J. Exp. Med. 166: 1351-1361 (1987)). Alternatively, dioactive assay methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for ?ow cytometry (CellTechnology, Inc. Mountain View, Calif, and CytoTox 96TM non-radioactive cytotoxicity assay (Promega, Madison, Wis). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and l Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes er al. Proc. Nai’l Acad Sci. USA 95:652-656 (1998). Clq binding assays may also be carried out to confirm that the pecific polypeptide construct or cleaved components f is unable to bind Clq and hence lacks CDC ty. See, e.g., Clq and C3c binding ELISA in 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro er al., J. Immunol. Methods 202: 163 (1996), Cragg, M. S. et al., Blood 101:1045—1052 (2003), and Cragg, M. S. and M. J. Glennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance/half—life determinations can also be performed using s known in the art (see, e.g, Petkova, S. B. et al., Ini’l. Immunol. 18(12):]759- 1769 (2006)).

In some embodiments, the immunoglobulin Fc region or immunologically active nt thereof is an IgG isotype. For example, the immunoglobulin Fc region of the fusion protein is of human IgG1 isotype, having an amino acid sequence: PAPE-IGPS VFLFPPKPKD TTIM SRTB*.V VSH*. DB*.VKJ:\TWYV DGVEVHNA AP *.KT SéA KGQPRIEPQVY TLPPSRDELFT KNQVSLTCLV KGFYPSDIAV 41W41$NGQPEN NYKTT’?PVLD SDGSFFLYSK RWQQ GNVFSCSVMH EAL-INHYTQK SLSLS’?GK (SiZQ 3 \TO: 1) In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof comprises a human IgG1 ptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid ce of SEQ ID NO: 1.

In some embodiments, the human IgG1 Fc region is modi?ed to alter antibody- dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC), e.g., the amino acid modi?cations described in Natsume et al., 2008 Cancer Res, 68(10): 3863-72, Idusogie et al., 2001 J Immunol, : 2571-5, Moore et al., 2010 mAbs, 2(2): 181-189; Lazar et al., 2006 PNAS, 103(11): 4005—4010, Shields et al., 2001 JBC, 276(9): 6591—6604, Stavenhagen et al., 2007 Cancer Res, : 8882-8890, Stavenhagen et al., 2008 Advan. Enzyme Regul, 48: 152-164, Alegre et al, 1992 J l, 148: 3461-3468, Reviewed in Kaneko and Niwa, 2011 Biodrugs, 25(1): l-1 1, the contents of each of which are hereby incorporated by reference in their entireties.

In some embodiments, the Fc region, such as the human IgG1 Fc region is modi?ed to enhance ADCC activity or CDC activity. Examples of mutations that enhance ADCC include modi?cation at Ser239 and Ile332, for example Ser239Asp and Ile332Glu (S23 9D, I332E). Examples of mutations that enhance CDC include modi?cations at Lys326 and Glu333. In some embodiments, the Fc region is modi?ed at one or both of these positions, for example Lys326Ala and/or Glu333Ala (K326A and E333A) using the Kabat ing .

In some embodiments, the human IgG1 Fc region fusion proteins of the present sure lack or have reduced Fucose attached to the N—linked -chain at N297. There are numerous ways to prevent fucosylation, including but not limited to production in a FUT8 de?cient cell line; addition inhibitors to the mammalian cell culture media, for example Castanospermine; and metabolic engineering of the production cell line. In some embodiments, the human IgG1 Fc region is modi?ed at amino acid Asn297 (Boxed, Kabat Numbering) to prevent glycosylation of the fusion protein, e.g., Asn297Ala ) or Asn297Asp (N297D).

In some embodiments, the Fc region of the fusion protein is altered at one or more of the following positions to reduce Fc receptor binding: Leu 234 (L234), Leu235 (L235), Asp265 (D265), Asp270 (D270), Ser298 (8298), Asn297 (N297), Asn325 (N325) orAla327 (A327). For example, Leu 234Ala (L234A), Leu235Ala (L235A), Asn (D265N), Asp27OAsn (D270N), Ser298Asn (8298N), Asn297Ala (N297A), Asn325Glu (N325E) orAla327Ser ). In some embodiments, the Fc region of the fusion protein is modi?ed at amino acid Leu235 (Boxed in SEQ ID NO:1 above, Kabat Numbering) to alter Fc receptor interactions, e.g, Leu235Glu (L23 5E) or Leu235Ala (L235A). In some embodiments, the Fc region of the fusion protein is modi?ed at amino acid Leu234 (Boxed in SEQ ID NO:1 above, Kabat Numbering) to alter Fc receptor interactions, e.g, Leu234Ala (L234A). In some embodiments, the Fc region of the fusion protein is altered at both amino acid 234 and 235, e.g., Leu234Ala and Leu23 5Ala (L234A/L235A) or Leu234Val and Leu235Ala (L234V/L235A). In red embodiments, modi?cations within the Fc region reduce binding to Fc—receptor—gamma ors while have minimal impact on binding to the neonatal Fc receptor (FcRn).

In some ments, the human IgG Fc region is modi?ed to e FcRn binding. Examples of PC ons that enhance binding to FcRn are Met252Tyr, Ser254Thr, Thr256Glu (M252Y, S254T, T256E, respectively) (Kabat numbering, Dall’Acqua et al 2006, J. Biol Chem Vol. 281(33) 23514—23524), Met428Leu and Asn434Ser (M428L, N434S) (Zalevsky et a] 2010 Nature Biotech, Vol. 28(2) 157-159) (EU index ofKabat et a] 1991 Sequences ofProteins nological Interest). In some embodiments, the mutated or modi?ed Fc polypeptide includes the following mutations: Tyr and Met428Leu or Met252Tyr and Met428Val (M252Y, M428L, or M252Y, M428V) using the Kabat numbering system.

In some embodiments, the Fc region of the fusion protein is lacking an amino acid at one or more of the ing positions to reduce Fc receptor g: Glu233 (E233), Leu234 (L234), or Leu235 (L235). In these embodiments, Fc deletion of these three amino acids reduces the ment protein Clq binding.

PAPGG'98VFL FPPKPKDTLM SRTB?VTCV VVDVSHiZDP? V EVHNA ".KT S SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVM-L ALL‘LJ {NHYTQKSLS LSPGK (SiZQ 3 \TO: 2) In some embodiments, the Fc region of the fusion protein is altered at Gly236 (boxed in SEQ ID NO:1 above) to reduce Fc receptor binding. For e, wherein Gly236 is deleted from the fusion protein. In some embodiments, the human IgG1 Fc region is modi?ed at amino acid Gly236 to enhance the interaction with CD32A, e.g., Gly236Ala (G236A).

In some ments, the human IgG1 Fc region lacks Lys447 (EU index of Kabat et a] 1991 Sequences ofProteins ofImmunological Interest).

In some embodiments, the fusion or immunologically active fragment thereof ses a human IgG2 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 2.

In some embodiments, the immunoglobulin Fc region or immunologically active fragment of the fusion protein is of human IgG2 isotype, having an amino acid sequence: PA?PVAGPSV PKDT PM SRTPOVT CVVVDVSH?D P?VQENWYVD GVEVHNA P ?KT S WESNGQPENN MLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALINHYTQKS LSLSPGK (S?Q 3 W0: 3) In some embodiments, the fusion or immunologically active fragment thereof comprises a human IgG2 ptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 3.

In some embodiments, the human IgG2 Fc region is modified at amino acid Asn297 (Boxed, to prevent to glycosylation of the antibody, e. g., Asn297Ala (N297A) or Asn297Asp (N297D). In some embodiments, the human IgG2 Fc region lacks Lys447 (EU index ofKabat et a] 1991 Sequences ofProteins ofImmunological Interest).

In some embodiments, the immunoglobulin Fc region or immunologically active fragment of the fusion protein is of human IgG3 e, having an amino acid sequence: ?APELLGGPS VFLTPPKPKD TKM SRTP?V TCVVVDVSl? DP?VQEKWYV DGVEVHNAKT KPR??QYuST ERVVSVHTVU HQDWLWGKEY AP ?KT SK? KGQ?REPQVY ??MT TCLV KGFYPSDIAV ?W?SSGQPEN NYNTTPPMLD SDGSFFLYSK LTVDKSRWQQ GNIFSCSVMH EALHNEFTQK SLSLSPGK (S?Q 3 NO: 4) In some embodiments, the antibody or immunologically active fragment thereof comprises a human IgG3 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 4.

In some embodiments, the human IgG3 Fc region is modi?ed at amino acid Asn297 , Kabat Numbering) to t to glycosylation of the antibody, e.g, Asn297Ala (N297A) or Asn297Asp (N297D). In some embodiments, the human IgG3 Fc region is modi?ed at amino acid 435 to extend the half-life, e.g., Arg43 5His (R43 5H). In some embodiments, the human IgG3 Fc region lacks Lys447 (EU index ofKabat et a] 1991 Sequences ofProteins ofImmunological Interest).

In some embodiments, the immunoglobulin Fc region or immunologically active fragment of the fusion protein is of human IgG4 isotype, having an amino acid sequence: PAPEEEGGPS VFLFPPKPKD TPM SRTB?V TCVVVDVSQ? DB?VQbWWYV DGVEVHNA SS ?KT S ?W?SNGQPEN NYKTT?PVLD SDGSFFLYSR LTVDKSRWQ:.L SVMH EALINHYTQK SLSLSLGK (S?Q 3 V0: 5) In some embodiments, the dy or immunologically active fragment thereof comprises a human IgG4 ptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 5.

In some ments, the immunoglobulin Fc region or immunologically active fragment of the fusion protein is of human IgG4 isotype, having an amino acid sequence: ?APELLGG?S VFLFPPKPKJ TPjV TCVVVDVSQj DPjVQENWYV DGVEVHNA SS ?KT 84A KGQ??3PQVY TKPPSQ??MT KNQVSLTCLV KGFYPSDIAV ?W?SNGQPEN NYKTTPPVLD SDGSFFLYSR RWQ:.L GNVFSCSVMH EALINHYTQK SLSLSLGK (S?Q 3 W0: 6) W0 91438 In some ments, the antibody or immunologically active fragment thereof comprises a human IgG4 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 6.

In other embodiments, the human IgG4 Fc region is modi?ed at amino acid 235 to alter Fc receptor interactions, e.g., Leu235Glu (L23 5E). In some embodiments, the human IgG4 Fc region is modi?ed at amino acid Asn297 (Boxed, Kabat Numbering) to prevent to glycosylation of the antibody, e.g., Asn297Ala (N297A) or Asn297Asp (N297D). In some embodiments, the human IgG4 Fc region lacks Lys447 (EU index ofKabat er a! 1991 Sequences ofProteins oflmmunological Interest).

In some ments, the human IgG Fc region is modi?ed to stabilize the homodimerization at the CH3 :CH3 ace by introducing two disulfide bonds by changing Ser354 to Cys (83 54C) and Tyr349 to Cys (Y349C) (S354C/Y349C).

In some embodiments, the human IgG Fc region is modified to induce heterodimerization. s methods are known for promoting heterodimerization of complementary Fc polypeptides, see e.g. Ridgway et al, Protein Eng. 9:617—621 (1996), Merchant et al, Nat. Biotechnol. 16(7): 677-81 (1998); Moore et al. (2011) MAbs, 3:546-57; Von Kreudenstein et al. MAbs, (2013) 5646-54, Gunasekaran et al. (2010) J. Biol. Chem, 285: 1963 7-46, Leaver-Fay et al. (2016) Structure, 24:641-51, Ha et al. (2016) Frontiers in Immunology, 7:1, Davis et al. (2010) Protein Eng Des Sel, 23: 195-202, hed international PCT Appl. No. 2014/067011, wo 2012/058768, W02018027025, published US. patent Appl. No.

US201403 63426, US20150307628, US201800163 54, US20150239991; and U. S. patent Nos.

US5731168, US7183076, US970l759, US9605084, and US9650446. Methods to promote heterodimerization of Fc chains include nesis of the Fc , such as by ing a set of "knob-into—hole" mutations or including mutations to effect electrostatic steering of the Fc to favor attractive interactions among ent polypeptide chains. For example, in some embodiments, the Fc polypeptides of a heterodimer includes a mutation to alter charge polarity across the Fc dimer interface such that coexpression of electrostatically matched Fc chains support favorable attractive ctions thereby promoting desired Fc heterodimer formation, s unfavorable repulsive charge ctions suppress unwanted Fc homodimer formation (Guneskaran et al. (2010) JBC, 285: 1963 7-19646). When co- expressed in a cell, association between the chains is possible but the chains do not substantially self-associate due to charge ion. Other strategies for generating a heterodimeric Fc include mixing human IgG and IgA CH3 domain segments to create a complementary CH3 heterodimer, which is referred to as a SEED Fc.

In some embodiments, to promote heterodimerization both polypeptides of the Fc heterodimer contain paired or complementary amino acid ations. Exemplary paired amino acid modi?cation of polypeptides of an Fc fusion are set forth in Table 1.

Table 1: Paired amino acids of Heterodimeric Fc First Fe 01 nuetide Second Fc Pol Hetide T366W T366S/L368W/Y407V T366W/S354C L368A/Y407V/Y349C S3 64H/F405A Y349T/Y349F T3 50V/L351Y/F405A/Y407V T350V/T366L/K392L/T394W K360D/D399M/Y407A E345R/Q347R/T366V/K409V K409D/K392D D399K/E356K K360E/K409W Q347R/D399V/F405T L360E/K409W/Y349C Q347R/399V/F405T/S3 54C K370E/K409W E357N/D399V/F405T In some embodiments, modi?cations e introduction of a protuberance (knob) into a ?rst Fc polypeptide and a cavity (hole) into a second Fc ptide such that the protuberance is positionable in the cavity to promote complexing of the first and second Fc-containing polypeptides. Amino acids targeted for ement and/or modification to create protuberances or cavities in a polypeptide are typically interface amino acids that interact or contact with one or more amino acids in the interface of a second polypeptide.

In some ments, a first PC polypeptide that is modified to contain protuberance (hole) amino acids include replacement of a native or original amino acid with an amino acid that has at least one side chain which projects from the ace of the first Fc polypeptide and is ore positionable in a compensatory cavity (hole) in an nt interface of a second polypeptide. Most often, the replacement amino acid is one which has a larger side chain volume than the original amino acid e. One of skill in the art knows how to determine and/or assess the properties of amino acid residues to identify those that are ideal replacement amino acids to create a protuberance. In some embodiments, the replacement residues for the formation of a protuberance are naturally occurring amino acid residues and include, for example, arginine (R), phenylalanine (F), tyrosine (Y), or tryptophan (W). In some examples, the original residue identi?ed for replacement is an amino acid residue that has a small side chain such as, for example, alanine, asparagine, aspartic acid, glycine, serine, threonine, or valine.

In some embodiments, a second Fc polypeptide that is modi?ed to contain a cavity (hole) is one that includes replacement of a native or original amino acid with an amino acid that has at least one side chain that is ed from the interface of the second polypeptide and thus is able to accommodate a ponding protuberance from the interface of a ?rst polypeptide. Most often, the replacement amino acid is one which has a smaller side chain volume than the original amino acid residue. One of skill in the art knows how to determine and/or assess the properties of amino acid residues to fy those that are ideal replacement residues for the formation of a cavity. Generally, the replacement residues for the formation of a cavity are naturally occurring amino acids and include, for example, e (A), serine (S), threonine (T) and valine (V). In some es, the original amino acid identi?ed for replacement is an amino acid that has a large side chain such as, for example, tyrosine, arginine, phenylalanine, or tryptophan.

The CH3 interface of human IgG1, for example, involves sixteen residues on each domain located on four anti-parallel nds which buries 1090 A2 from each e (see e,g., Deisenhofer et a1, (1981) Biochemistry, 20:2361-2370, Miller et al., (1990) J Mol.

Biol, 216, 965-973, y et al., (1996) Prot. Engin, 9: 617-621, US. Pat. No. ,731,168). Modi?cations of a CH3 domain to create protuberances or cavities are described, for example, in US. Pat. No. 5,731,168; International Patent Applications WO98/50431 and WO 63816, and Ridgway et al., (1996) Prot. Engin, 9: 617-621. In some examples, ations of a CH3 domain to create protuberances or cavities are typically targeted to residues located on the two central anti-parallel B-strands. The aim is to ze the risk that the protuberances which are created can be accommodated by protruding into the surrounding solvent rather than being accommodated by a compensatory cavity in the partner CH3 domain.

For example, in some embodiments the heterodimeric Fc includes a polypeptide having an amino acid modi?cation within the CH3 domain at Thr366, which when replaced with a more bulky amino acid, e.g., Try (T3 66W), is able to preferentially pair with a second CH3 domain having amino acid modi?cations to less bulky amino acids at ons Thr3 66, Leu368, and Tyr407, e.g, Ser, Ala and Val, respectively (T366S/L368A/Y407V).

Heterodimerization via CH3 modi?cations can be further stabilized by the introduction of a de bond, for example by changing Ser3 54 to Cys (S3 54C) and Tyr349 to Cys (Y349C) on opposite CH3 domains (Reviewed in Carter, 2001 Journal of Immunological Methods, 248:7—15) The resulting multispeci?c polypeptide constructs can be puri?ed by any suitable method such as, for example, by y tography over Protein A or n G columns. Where two nucleic acid molecules encoding different polypeptides are transformed into cells, formation of homo- and heterodimers will occur. Conditions for expression can be adjusted so that heterodimer formation is favored over homodimer formation.

Techniques for recovery of heterodimers from homodimers based on a differential af?nity of the heterodimers for an af?nity reagent are known. In some aspects, such techniques include designing a heterodimer so that one of the Fc polypeptide chains does not bind to the af?nity t n A. In some cases, one of the polypeptide chain can contain one or more amino acid substitution to abrogate or reduce y for the protein A reagent in one of the polypeptides of the Fc heterodimer, see e. g. W02017l34440, WO2010151792, Jendeberg et al. (Jendeberg et al., (1997) J. l. Methods, 201(1): 25- 34. In some of these embodiments, the Fc region may be modi?ed at the protein-A binding site on one member of the heterodimer so as to prevent n—A binding and thereby enable more ef?cient puri?cation of the dimeric fusion protein. An exemplary modi?cation within this binding site is Ile253, for example Ile253Arg (I253R). In some embodiments, the ation may be H43 SR or H435R/Y436F. In some embodiments, an Fc polypeptide of an Fc heterodimer can contain a modi?cation so that it is capable of binding protein A but not protein G (pA+/pG-). Exemplary pA+/pG- amino acid modi?cations include an Fc containing serine at position 428, serine at on 434 and optionally ine at position 436, with reference to human IgG1 or comprising these residues at the corresponding ons in human IgG 2, 3, or 4. In some aspects, such amino acid modi?cations in one IgG Fc polypeptide at positions 428, 434 and optionally 436 reduces or prevents the binding of protein G, enhancing the puri?cation of the protein.

In some embodiments, any of such ations to confer differential af?nity to an af?nity reagent can be combined with any one or more other amino acid modi?cations described above. For example, the I253R modi?cation maybe combined with either the T366S/L368A/Y407V modi?cations or with the T366W modi?cations. The T366S/L368A/Y407V modi?ed Fc is capable of forming homodimers as there is no steric occlusion of the dimerization interface as there is in the case of the T336W modi?ed Fc.

Therefore, in some ments, the I253R modi?cation is combined with the T366S/L368A/Y407V modi?ed Fc to disallow puri?cation any homodimeric Fc that may have formed. Similar modi?cations can be employed by ing T366S/L368A/Y407V and H453R.

In some embodiments, the Fc regions of the heterodimeric molecule additionally can contain one or more other Fc mutation, such as any described above. In some embodiments, the heterodimer molecule contains an Fc region with a mutation that reduces or function.

In some embodiments, one Fc polypeptide of a heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS:82, 86, 94 or 96, and the other PC ptide of the heterodimeric Fc contains the sequence of amino acids set forth in any of SEQ ID , 87, 90, 92, 98 or 100. In some embodiments, one Fc polypeptide ofa dimeiic Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS: 84, 88, 95 or 97 and the other Fc polypeptide of the dimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS: 85, 89, 91, 93, 99 or 101.

In some embodiments, the human IgG Fc region is modi?ed to prevent dimerization. In these embodiments, the fusion proteins of the present disclosure are monomeric. For example modi?cation at residue Thr3 66 to a charged residue, 6. g.

Thr366Lys, Thr366Arg, Thr366Asp, or Thr366Glu (T366K, T366R, T366D, or T366E, respectively), prevents CH3 -CH3 dimerization.

In some embodiments, the Fc region of the fusion protein is altered at one or more of the following positions to reduce Fc receptor binding: Leu 234 (L234), Leu235 (L235), Asp265 (D265), Asp270 (D270), Ser298 (S298), Asn297 (N297), Asn325 (N325) orAla327 (A327). For example, Leu 234Ala (L234A), Leu235Ala (L23 5A), Asn (D265N), Asp27OAsn (D270N), Asn (S298N), Asn297Ala (N297A), Asn325Glu ) orAla327Ser (A327 S). In preferred embodiments, modi?cations within the Fc region reduce binding to Fc—receptor—gamma receptors while have minimal impact on binding to the neonatal Fc or (FcRn).

In some embodiments, the fusion protein contains a polypeptide derived from an immunoglobulin hinge region. The hinge region can be selected from any of the human IgG subclasses. For example, the fusion protein may contain a modi?ed IgGl hinge having the sequence of EPKSSDKTHTCPPC (SEQ ID NO: 7), where in the Cys220 that forms a disulfide with the C-terminal ne of the light chain is mutated to , e.g., CysZZOSer (C220S). In other embodiments, the fusion protein contains a truncated hinge having a sequence DKTHTCPPC (SEQ ID NO: 8).

In some embodiments, the fusion protein has a modified hinge from IgG4, which is modi?ed to prevent or reduce strand ge, e.g, Ser228Pro (S228P), having the ce ESKYGPPCPPC (SEQ ID NO: 9). In some embodiments, the fusion protein contains linker polypeptides. In other embodiments, the fusion protein contains linker and hinge polypeptides. 3. Linkers The provided peci?c polypeptide constructs contain a linker that joins or couples the ?rst component ning the immunoglobulin Fc region and the second component containing the CD3 binding region. In some embodiments, the linker is positioned at the end of the C-terminal region of the Fc region, such that the Fc region is N- al to the CD3 binding region. Because the ed multispeci?c polypeptide constructs are multimers, such as dimers, the provided constructs include a linker joining the ?rst Fc polypeptide and a ?rst domain (e. g. VH) of the CD3 binding region of the ?rst polypeptide and the second Fc polypeptide and second domain (e.g. VL) of the CD3 binding region of the second polypeptide. Typically, the linkers present in the ?rst and second polypeptides of the peci?c polypeptide construct are the same. Thus, in some embodiments, each domain of the CD3 binding domain is linked via a linker, such as the same linker, to opposite polypeptides of the Fc, such as dimeric Fc.

Various polypeptide linkers for use in fusion proteins are known (see e. g. Chen et al. (2013) Adv. Drug. Deliv. 65: 369, and International PCT publication No. WO 2014/099997, W02000/24884; US. Pat. No. 5,258,498, US. Pat. No. 5,525,491; US. Pat.

No. 5,525,491, US. Pat. No. 6,132,992).

In some embodiments, the linker is chosen so that, when the CD3 binding region is joined to the Fc region of the multispeci?c polypeptide conjugate, the CD3 binding region is constrained and not able to, or not substantially able to, bind or engage CD3 on the surface of a cell, e. g. T cell, upon contact of the multispeci?c polypeptide construct with the cell.

Various assays can be employed to assess g or ment of CD3 by the multispeci?c polypeptide construct, including assays to assess T cell binding, NFAT activation using a reporter system, cytolytic T cell activity, cytokine production and/or expression of T cell activation markers. Exemplary assays are shown in the provided Examples. lly, the linker also is one that ensures t folding of the polypeptide construct, does not exhibit a charge that would be inconsistent with the activity or on of the linked polypeptides or form bonds or other interactions with amino acid residues in one or more of the domains that would impede or alter activity of the linked polypeptides. In some embodiment, the linker is a polypeptide linker. The polypeptide linker can be a ?exible linker or a rigid linker or a combination of both. In some aspects, the linker is a short, medium or long linker. In some embodiments, the linker is up to 40 amino acids in length. In some embodiments, the linker is up to 25 amino acids in length. In some embodiments, the linker is at least or is at least about 2 amino acids in length. In some aspects, a suitable length is, e.g., a length of at least one and lly fewer than about 40 amino acid residues, such as 2-25 amino acid residues, -20 amino acid residues, 5-15 amino acid residues, 8-l2 amino acid . In some embodiments, the linker is from or from about 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 24 amino acids, 6 to 20 amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 24 amino acids, 8 to amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, 10 to 14 amino acids, 10 to 12 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 24 amino acids, 18 to 20 amino acids or 20 to 24 amino acids. In some embodiments, the linker is 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, 12, l3, 14, 15, 16, l7, l8, 19 or 20 amino acids in length.

In certain aspects, the longer the linker length, the greater the CD3 binding when the multispeci?c polypeptide conjugate is bounds to its antigen, e.g. TAA. Thus, in some aspects, the linker is r than 12 amino acids in length, such as greater than 13, 14, 15, 16, 17 or 18 amino acids in length. In some ments, the linker is 12 to 40 amino acids in length, 12 to 30 amino acids, 12 to 24 amino acids, 12 to 18 acids, 12 to 15 amino acids, 15 to 40 amino acids, 15 to 30 amino acids, 15 to 24 amino acids, 15 to 18 amino acids, 18 to 40 amino acids, 18 to 30 amino acids, 18 to 24 amino acids, 24 to 40 amino acids, 24 to 30 amino acids or 30 to 40 amino acids.

The linkers can be naturally—occurring, synthetic or a combination of both.

Particularly suitable linker polypeptides predominantly include amino acid residues selected from Glycine (Gly), Serine (Ser), Alanine (Ala), and Threonine (Thr). For e, the linker may contain at least 75% (calculated on the basis of the total number of residues present in the peptide linker), such as at least 80%, at least 85%, or at least 90% of amino acid residues selected from Gly, Ser, Ala, and Thr. The linker may also consist of Gly, Ser, Ala and/or Thr residues only. In some embodiments, the linker ns 1-25 glycine residues, 5-20 glycine residues, 5-15 glycine residues, or 8-12 glycine residues. In some s, suitable peptide linkers typically contain at least 50% glycine es, such as at least 75% glycine residues.

In some embodiments, a peptide linker comprises glycine es only. In some embodiments, a peptide linker comprises glycine and serine es only.

In some ments, these linkers are composed predominately of the amino acids Glycine and Serine, denoted as GS-linkers herein. In some embodiments, the linker contains (GGS)n, wherein n is 1 to 10, such as 1 to 5, for example 1 to 3, such as GGS(GGS)n (SEQ ID NO: 171), wherein n is O to 10. In particular embodiments, the linker contains the sequence )n (SEQ ID NO: 173), wherein n is 1 to 10 or n is 1 to 5, such as 1 to 3. In further embodiments, the linker contains (GGGGGS)n (SEQ ID NO: 172), wherein n is 1 to 4, such as 1 to 3. The linker can include combinations of any of the above, such as repeats of 2, 3, 4, or 5 GS, GGS, GGGGS, and/or GGGGGS linkers may be combined. In some embodiments, such a linker is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 amino acids in length.

In some embodiments, the linker is (in one-letter amino acid code): GGS, GGGGS (SEQ ID NO: 149), or GGGGGS (SEQ ID NO: 135). In some embodiments, the GS-linker comprises an amino acid sequence of GGSGGS, i.e., (GGS)2 (SEQ ID NO: 10); GGSGGSGGS, i.e., (GGS)3 (SEQ ID NO: 11), GGSGGSGGSGGS, i.e., (GGS)4 (SEQ ID NO: 12), GGSGGSGGSGGSGGS, i.e., (GGS)5 (SEQ ID NO: 13), GGGGGSGGGGGSGGGGGS, 1'.e., (G5 S)3 (SEQ ID NO: 119), GGSGGGGSGGGGSGGGGS (SEQ ID NO: 147) and GGGGSGGGGSGGGGS (SEQ ID NO: 170). In some embodiments, the linker is GGGG (SEQ ID NO: 103). In some of any of the above examples, serine can be replaced with alanine (e. g., (Gly4Ala) or (Gly3Ala)).

In some ments, the linker includes a e linker having the amino acid sequence GlyXXaa—Glyy—Xaa—GlyZ (SEQ ID NO: 174), wherein each Xaa is independently selected from Alanine (Ala), Valine (Val), e (Leu), cine (Ile), Methionine (Met), Phenylalanine (Phe), Tryptophan (Trp), Proline (Pro), Glycine (Gly), Serine (Ser), Threonine (Thr), ne (Cys), Tyrosine (Tyr), Asparagine (Asn), Glutamine (Gln), Lysine (Lys), Arginine (Arg), Histidine (His), Aspartate (Asp), and Glutamate (Glu), and wherein X, y, and z are each integers in the range from 1-5. In some embodiments, each Xaa is independently selected from the group consisting of Ser, Ala, and Thr. In a speci?c variation, each of x, y, and z is equal to 3 (thereby yielding a peptide linker having the amino acid sequence Gly- y-Xaa-Gly-Gly-Gly-Xaa-Gly-Gly-Gly (SEQ ID NO: 175), wherein each Xaa is selected as above.

In some embodiments, the linker is serine-rich linkers based on the repetition of a (SSSSG)y (SEQ ID NO: 185) motifwhere y is at least 1, though y can be 2, 3, 4, 5, 6, 7, 8 and In some cases, it may be desirable to e some rigidity into the peptide linker.

This may be accomplished by including proline residues in the amino acid ce of the peptide linker. Thus, in some embodiments, a linker comprises at least one proline residue in the amino acid sequence of the peptide . For example, a peptide linker can have an amino acid sequence wherein at least 25% (e.g., at least 50% or at least 75%) of the amino acid residues are proline residues. In one particular ment, the peptide linker comprises proline residues only.

In some aspects, a peptide linker comprises at least one cysteine residue, such as one cysteine residue. For e, in some embodiments, a linker comprises at least one cysteine residue and amino acid residues selected from the group consisting of Gly, Ser, Ala, and Thr. In some such embodiments, a linker comprises glycine residues and cysteine residues, such as e residues and cysteine residues only. Typically, only one cysteine residue will be ed per peptide linker. One example of a speci?c linker comprising a cysteine residue includes a peptide linker having the amino acid sequence Glym—Cys—Glyn , wherein n and m are each integers from 1-12, e.g., from 3-9, from 4-8, or from 4-7. In a speci?c ion, such a peptide linker has the amino acid sequence GGGGG—C-GGGGG (SEQ ID NO:l77).

In some embodiments, the linker of the fusion protein is a structured or constrained linker. In particular ments, the structured linker contains the sequence (AP)n or (EAAAK)n (SEQ ID NO: 178), wherein n is 2 to 20, preferably 4 to 10, including but not limited to, AS-(AP)n-GT (SEQ ID NO: 179) or AS-(EAAAK)n-GT (SEQ ID NO:l80), wherein n is 2 to 20, such as 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14 or 15. In other embodiments, the linker ses the sequences )n (SEQ ID NO: 181), (PGGGS)n (SEQ ID NO: 182), (AGGGS)n (SEQ ID NO: 183) or GGS-(EGKSSGSGSESKST)n-GGS (SEQ ID NO: 184, wherein n is 2 to 20. In some embodiments, the linker is SSSASASSA (SEQ ID NO: 186), GSPGSPG (SEQ ID NO: 187), or ATTTGSSPGPT (SEQ ID NO: 176). In some embodiments, such linkers, by virtue of their structure, may be more resistant to proteolytic degradation, thereby offering an advantage when injected in vivo.

In some embodiments, the linker is not a cleavable , also called non- ble linker. In some embodiments, the linker is not a cleavable by a protease. In some embodiments, a linker that is not a cleavable linker or that is not cleavable by a protease is one that is generally stable for in vivo ry or inant production. In some aspects, a linker that is not cleavable by a protease includes those that do not contain at least one peptide bond which preferably lies within a cleavable peptide ce or recognition site of a protease. In particular embodiments, a non-cleavable linker is not a target ate for a protease, such that it is not preferentially or speci?cally cleaved by a protease compared to a linker that contains a substrate recognition site for the same protease.

In some embodiments, the linker is a cleavable linker. In some aspects, a cleavable linker is a linker that includes a sequence that is a substrate for a protease due to the presence of at least one bond that can be broken under physiological conditions. In some cases, a cleavable linker is susceptible to or sensitive to cleavage under speci?c conditions that exist in vivo, such as ing exposure to an extracellular protease, including those present in cellular environments in vivo. In some cases, the protease may be present in a particular physiological microenvironment, such as the tumor microenvironment, thereby restricting the sites at which cleavage may occur.

A se typically exhibits speci?city or preference for cleavage of a particular target substrate compared to r non-target substrate. Such a degree of speci?city can be determined based on the rate constant of ge of a sequence, eg. linker, which is a measure of preference of a protease for its substrate and the ef?ciency of the enzyme. Any method to determine the rate of increase of cleavage over time in the presence of various concentrations of substrate can be used to calculate the speci?city constant. For example, a ate is linked to a ?uorogenic moiety, which is ed upon cleavage by a protease. By determining the rate of cleavage at different protease concentrations the speci?city constant for cleavage (km/Km) can be determined for a particular protease towards a particular linker.

In some embodiments, a cleavable linker is a linker that is capable of being speci?cally cleaved by a protease at a rate of about at least l>< 104 M_IS_1, or at least 5>< 104 M_IS, at least 10x104 M‘ls. at least 10x105 M‘ls or more.

Cleavable Linker In some embodiments, the multispeci?c polypeptide constructs of the disclosure include a cleavable linker that joins the ?rst and second components. In some embodiments, the cleavable linker includes an amino acid sequence that can serve as a substrate for a se, usually an extracellular protease. For example, the ble linker may include a cleavage sequence containing at least one e bond which preferably lies within a cleavable peptide sequence of a protease. Suitable proteases e, for example, matrix metalloproteases (MMP), cysteine proteases, serine proteases and n activators, which are formed or activated in i?ed manner in diseases such as rheumatoid arthritis or cancer, g to excessive tissue degradation, inflammations and metastasis. In particular embodiments, the protease is a protease that is produced by a tumor, an activated immune effector cell (e. g. a T cell or a NK cell), or a cell in a tumor microenvironment. In some ments, the protease is a granzyme B, a matriptase or an MMP, such as MMP-Z.

The cleavable linker may be selected based on a protease that is produced by a tumor that is in proximity to cells that express the target and/or produced by a tumor that is co-localized in tissue with the desired target of the multispeci?c ptide constructs.

There are reports in the literature of increased levels of proteases having known substrates in a number of cancers, e.g., solid tumors. See, e. g., La Rocca et al, (2004) British J. of Cancer 90(7): 1414—1421.

In some embodiments, the cleavable linker that joins the first and second component multispecific polypeptide construct is cleaved by a protease produced by an immune or cell that is activated by one of the components. For example, multispecific polypeptide constructs that encompass an effector enabled or enhanced IgG Fc region are capable of eliciting ADCC when engaged with the target antigen. Central to ADCC is the release of granzyme B and perforin from the effector cells, namely NK cells and cytotoxic T— cells. Upon release granzyme B enters the target cell in a in dependent manner wherein it es apoptosis. Importantly, granzyme B is active within the extracellular synapse between the effector cell and the target cell. In some embodiments, the cleavable linker that joins the first and second component multispecific polypeptide construct is cleaved by granzyme B. Granzyme B is released during effector cell activation mediated by one of the ents of the multispecific polypeptide construct. In some embodiments, granzyme B and other ses can be produced by immune effector cells, including activated T cells or NK cells. In some embodiments, activation of T cells by CD3 engagement upon binding of a TAA by a multispeci?c polypeptide construct may release such proteases, which then can cleave a specific cleavable linker thereby potentiating or increasing activity of the CD3 binding molecule to engage CD3. In some embodiments, the cleavage can amplify or increase the activity achieved by the multispecific construct when bound to TAA in an uncleaved state. ary substrates include but are not limited to substrates cleavable by one or more of the following enzymes or proteases: ADAMS, , e.g. ADAMS, ADAM9; ADAM10;ADAM12; ; ADAMl7/TACE;ADAMDEC1;ADAMTS1; ADAMTS4; ADAMTSS; ate proteases, e.g, BACE or Renin; aspartic cathepsins, e.g, Cathepsin D or Cathepsin E, Caspases, e.g., e 1, Caspase 2, Caspase 3, Caspase 4, Caspase 5, Caspase 6, Caspase 7, Caspase 8, Caspase 9, Caspase 10, or Caspase 14; cysteine cathepsins, e.g., sin B, sin C, sin K, Cathepsin L, Cathepsin S, Cathepsin V/L2, Cathepsin X/Z/P; Cysteine proteinases, e.g, ain, Legumain, Otubain-2, KLKs, e.g., KLK4, KLKS, KLK6, KLK7, KLKS, KLKIO, KLK] 1, KLK13, or KLK14; Metallo proteinases, e.g., , Neprilysin, PSMA, BMP-l; MMPS, e.g., MlVIPl, MMPZ, MMP3, IVJMP7,IVIIVIP8,MMP9,MMP10,MMP11,IV?VIPlZ,l\/?\/JP13,IVIIVIP14, MMP15,MMP16, lV?VIPl7, MMPl9, MlV[P20, MIVIP23, MlVIP24, Ml\/[P26, or Ml\/[P27, serine proteases, e.g., activated protein C, Cathepsin A, Cathepsin G, Chymase, coagulation factor proteases (e.g., FVIIa, FIXa, FXa, FXIa, FXIIa), Elastase, granzyme B, Guanidinobenzoatase, HtrAl, Human Neutrophil Elastase, Lactoferrin, Marapsin, NS3/4A, PACE4, Plasmin, PSA, tPA, Thrombin, Tryptase, uPA, Type II Transmembrane Serine Proteases (TTSPs), e.g., DESCl, DPP-4, FAP, Hepsin, Matriptase-Z, Matriptase, TMPRSSZ, TMPRSS3, or TMPRSS4, and any combination thereof.

In some embodiments, the ble linker is cleaved by multiple proteases, e.g., 2 or more proteases, 3 or more ses, 4 or more proteases, and so on.

In some embodiments, the cleavable linker is selected for use with a speci?c protease, for example a protease that is known to be produced by a tumor that is in ity to cells that express the target and/or produced by a tumor that is co-localized with the target of the multispeci?c polypeptide construct.

In some embodiments, the cleavable linker contains a substrate recognition site or cleavage site for a particular protease, which is the sequence recognized by the active site of a protease that is cleaved by a protease. lly, for example, for a serine protease, a cleavage sequence is made up of the Pl-P4 and P1 ’-P4’ amino acids in a substrate, where cleavage occurs after the P1 position. Typically, a cleavage ce for a serine protease is six residues in length to match the extended substrate speci?city of many proteases, but can be longer or shorter depending upon the protease. Typically, the cleavable linker includes a Pl-Pl' scissile bond sequence that is recognized by a protease. In some s, the cleavable linker is engineered to introduce a e bond able to be cleaved by a speci?c protease, for example by introducing a substrate recognition site sequence or cleavage sequence of the protease.

In some embodiments, the ble linker includes a combination of two or more ate sequences. In some embodiments, each substrate sequence is cleaved by the same protease. In some embodiments, at least two of the substrate sequences are cleaved by different proteases. In some embodiments, the cleavable linker comprises an amino acid that is a substrate for granzyme B. In some embodiments, a granzyme B cleavable linker contains an amino acid sequence having the l formula P4 P3 P2 Pl 1 Pl’ (SEQ ID NO: 150), wherein P4 is amino acid I, L, Y, M, F, V, or A, P3 is amino acid A, G, S, V, E, D, Q, N, or Y; P2 is amino acid H, P, A, V, G, S, or T, P1 is amino acid D or E, and P1’ is amino acid I, L, Y, M, F, V, T, S, G or A. In some embodiments, a granzyme B cleavable linker contains an amino acid sequence having the general a P4 P3 P2 P1 1 P1’ (SEQ ID NO: 151), wherein P4 is amino acid I or L; P3 is amino acid E, P2 is amino acid P or A, P1 is amino acid D, and P1’ is amino acid I, V, T, S, or G.

In some embodiments, the substrate for granzyme B comprises the amino acid sequence LEAD (SEQ ID NO: 22), LEPG (SEQ ID NO: 142), or LEAE (SEQ ID NO: 143).

In some embodiments, the cleavable linker contains the amino acid sequence the cleavable linker comprises the amino acid sequence IEPDI (SEQ ID NO: 136), LEPDG (SEQ ID NO: 152, LEADT (SEQ ID NO:137), IEPDG (SEQ ID NO: 138), IEPDV (SEQ ID NO:139), IEPDS (SEQ ID NO: 140), IEPDT (SEQ ID NO: 141), IEPDP (SEQ ID NO:144), LEPDG (SEQ ID NO:152) or LEADG (SEQ ID NO: 153).

In some embodiments, the cleavable linker ses an amino acid that is a substrate for tase. In some ments, the cleavable linker comprises the sequence P4QAR[(A/V) (SEQ ID NO: 154), wherein P4 is any amino acid. In some embodiments, the cleavable linker comprises the sequence /V) (SEQ ID NO: 155). In some embodiments, the substrate for matriptase comprises the amino acid sequence RQAR (SEQ ID NO: 23). In some embodiments, the cleavable linker comprises the amino acid sequence RQARV (SEQ ID NO: 156).

In some embodiments, the cleavable linker comprises an amino acid that is a substrate for one or more matrix metalloproteases (MMPs). In some embodiments, the MMP is MMP—2. In some embodiments, the cleavable linker contains. the general formula P3 P2 P1 [P1’ (SEQ ID NO: 157), wherein P3 is P, V or A, P2 is Q or D, P1 is A or N, and P1’ is L, I or M. In some embodiments, the cleavable linker contains the general formula P3 P2 P1 [P1’ (SEQ ID NO: 158), wherein P3 is P, P2 is Q or D; P1 is A or N, and P1’ is L or I. In some embodiments, the substrate for MMP comprises the amino acid sequence PAGL (SEQ ID NO: 24).

In some embodiments, the cleavable linker comprises a ation of an amino acid sequence that is a substrate for granzyme B and an amino acid ce that is a substrate for matriptase. In some embodiments, the cleavable linker comprises a combination of the amino acid ce LEAD (SEQ ID NO: 22) and the amino acid sequence RQAR (SEQ ID NO: 23).

In some embodiments, the cleavable linker comprises a combination of an amino acid sequence that is a substrate for granzyme B and an amino acid sequence that is a substrate for MMP. In some ments, the cleavable linker comprises a combination of the amino acid sequence LEAD (SEQ ID NO: 22) and the amino acid sequence PAGL (SEQ ID NO: 24).

In some embodiments, the cleavable linker comprises a combination of an amino acid sequence that is a substrate for matriptase and an amino acid sequence that is a substrate for MMP. In some embodiments, the cleavable linker comprises a combination of the amino acid sequence RQAR (SEQ ID NO: 23) and the amino acid sequence PAGL (SEQ ID NO: In some embodiments, the cleavable linker comprises a combination of an amino acid sequence that is a substrate for granzyme B, an amino acid sequence that is a substrate for matriptase, and an amino acid sequence that is a substrate for MMP. In some embodiments, the cleavable linker comprises a combination of an amino acid sequence that is a substrate for granzyme B and an amino acid sequence that is a substrate for MMP. In some embodiments, the cleavable linker comprises a combination of the amino acid sequence LEAD (SEQ ID NO: 22), the amino acid sequence RQAR (SEQ ID NO: 23), and the amino acid sequence PAGL (SEQ ID NO: 24).

The cleavable linker can include any known s. Examples of cleavable linkers are bed in Be’liveau et al. (2009) FEBS Journal, 276, US. published ation Nos. US20160194399, US20150079088, US20170204139; USZOl60289324, US20160122425; US20150087810; US20170081397, US. Patent No. US9644016.

In some embodiments, the cleavable linker comprises an amino acid sequence selected from the group consisting of TGLEADGSPAGLGRQARVG (SEQ ID NO: 25), TGLEADGSRQARVGPAGLG (SEQ ID NO: 26); TGSPAGLEADGSRQARVGS (SEQ ID NO: 27), TGPAGLGLEADGSRQARVG (SEQ ID NO: 28), TGRQARVGLEADGSPAGLG (SEQ ID NO: 29), TGSRQARVGPAGLEADGS (SEQ ID NO: 30), and TGPAGLGSRQARVGLEADGS (SEQ ID NO: 31); GPAGLGLEPDGSRQARVG (SEQ ID NO: 104), GGSGGGGIEPDIGGSGGS (SEQ ID NO: 105), GGSGGGGLEADTGGSGGS (SEQ ID NO: 106), IGS (SEQ ID NO: 107); TGS (SEQ ID NO: 108), GGSGGGGIEPDGGGSGGS (SEQ ID NO: 109); GGSGGGGIEPDVGGSGGS (SEQ ID NO: 110), GGSGGGGIEPDSGGSGGS (SEQ ID NO: 111), GGSGGGGIEPDTGGSGGS (SEQ ID NO: 112); GGGSLEPDGSGS (SEQ ID NO: 113); and GPAGLGLEADGSRQARVG (SEQ ID NO: 114), GGEGGGGSGGSGGGS (SEQ ID NO: 115); GSSAGSEAGGSGQAGVGS (SEQ ID NO: 116); GGSGGGGLEAEGSGGGGS (SEQ ID NO: 117); GGSGGGGIEPDPGGSGGS(SEQ ID NO: 118); TGGSGGGGIEPDIGGSGGS (SEQ ID NO: 148). 4. Antigen Binding Domains: The multispeci?c polypeptide constructs of the present sure include at least one antigen binding domain; such as at least a first antigen binding domain and a second antigen binding . In some aspects; the antigen binding domain; or independently each of the antigen binding domains; is selected from an antibody or n binding fragment; a natural cognate binding partner; an Anticalin (engineered lipocalin); a Darpin; a Fynomer; a Centyrin (engineered fibroneticin III ); a cystine-knot domain; an Affilin; an dy; or an engineered CH3 domain. In some embodiments; the natural cognate binding partner ses an extracellular domain or binding fragment thereof of the native cognate g partner of the TAA; or a variant f that exhibits binding activity to the In some embodiments; the antigen binding domain; or independently each of the antigen binding domains, such as the first antigen-binding domain and the second antigen binding domains; includes one or more copies of an antibody or an antigen-binding nt thereof. In some embodiments; the n binding domain or independently each of the antigen binding domains, such as the first antigen-binding domain and the second antigen binding domains; includes one or more copies of an antibody or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment; a F(ab')2 fragment, an Fv fragment; a scFv; a scAb; a dAb; a single domain heavy chain antibody; and a single domain light chain antibody. In some embodiments; the antigen binding domain or independently each of the antigen binding domains; such as the first antigen-binding domain and the second antigen binding domains; includes one or more single domain antibody (sdAb) fragments; for example VHH; VNAR; engineered VH or VK domains. VHHs can be generated from natural camelid heavy chain only antibodies; cally modified rodents that produce heavy chain only antibodies; or naive/synthetic camelid or humanized camelid single domain antibody libraries. VNARS can be generated from cartilaginous fish heavy chain only dies.

Various methods have been implemented to generate monomeric sdAbs from conventionally heterodimeric VH and VK domains, including interface engineering and selection of speci?c ne es. In some embodiments, the antigen binding domain or independently each of the antigen binding domains, such as the ?rst antigen-binding domain and/or the second antigen g domains, of the multispeci?c polypeptide constructs contains VH and VL sequences led as FABs or scFvs. In some embodiments, the antigen binding domain or independently each of the antigen binding domains, such as the ?rst antigen-binding domain and/or the second antigen binding domains, of the multispeci?c polypeptide constructs contains binding domains as single domain antibodies ).

In some embodiments, the n binding domain, or independently each of the antigen g domains, is or includes an extracellular domain or binding fragment thereof of the native cognate binding partner of the TAA, or a variant thereof that exhibits binding activity to the TAA.

In some ments, the antigen binding domain or independently each of the antigen binding domains, such as the ?rst antigen—binding domain and the second antigen binding s, bind the same antigen. In some embodiments, the antigen binding domain or independently each of the antigen binding domains, such as the ?rst antigen-binding domain and the second antigen binding domains, bind a ent antigen. In some embodiments, the antigen binding domain or independently each of the antigen binding domains, such as the ?rst antigen-binding domain and the second antigen binding domains, bind the same tumor associated antigen (TAA). In some embodiments, the antigen binding domain or independently each of the antigen binding domains, such as the ?rst n- binding domain and the second antigen binding domains bind a different TAA. In some embodiments, the antigen binding domain or ndently each of the antigen g domains, such as the ?rst antigen-binding domain and the second n binding domains bind a different epitope on the same TAA. In some embodiments, the antigen binding domain or independently each of the antigen binding domains, such as the ?rst antigen—binding domain and the second antigen binding domains, bind the same epitope on the same TAA.

In some embodiments, the antigen binding domain, or independently each of the antigen binding domains that binds TAA results in monovalent, bivalent, trivalent, or tetravalent binding to the TAA.

In some embodiments, the TAA is ed from the group consisting of 1 LFA-3, 5T4, 4 integrin, Alpha-V integrin, alpha4betal integrin, alpha4beta7 integrin, AGRZ, Anti-Lewis-Y, Apelin I receptor, APRIL, B7-H3, B7—H4, BAFF, BTLA, C5 complement, C-242, CA9, CAl9-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CD11a, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD4OL, CD41, CD44, CD44V6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD137, CD138, CD166, CD172A, CD248, CDH6, S (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, en, Cripto, CSFR, CSFR-l, CTLA-4, CTGF, CXCL10, CXCL13, CXCRl, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL3, DLL4, DPP- 4, DSGl, EDA, EDB, EGFR, EGFRViii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1,FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FROL), GAL3ST1, G—CSF, , GD2, GITR, GLUTl, GLUT4, GM-CSF, GM—CSFR, GP IIb/IIIa receptors, Gpl30, GPIIB/IIIA, GPNMB, GRP78, HER2/neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICO S, IFNalpha, IFNbeta, IFNgamma, IgE, IgE or (FceRI), IGF, IGFlR, ILlB, IL1R, 1L2, ILl 1, IL12, IL12p40, IL—12R, IL—12Rbeta1, 1L13, IL13R, 1L15, 1Ll7, 1L18, IL21, IL23, IL23R, IL27/IL27R (wsxl), IL29, IL-31R, IL31/IL31R, IL2R, 1L4, 1L4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISSl-R, LAG-3, LIE-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, elin, MRP4, MUC1, Mucin—l6 (MUC16, CA-125), Na/K ATPase, NGF, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, ox—40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD—L1, PD—L2, Phosphatidyl—serine, P1GF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine l Phosphate, STEAPl, STEAP2, TAG-72, TAPAl, TEM-8, TGFbeta, TIGIT, THVI-3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, , TNFalpha, TNFR, 2A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAPl, VCAM-l, VEGF, VEGF-A, VEGF-B, , VEGF-D, VEGFRl, VEGFRZ, VEGFR3, VISTA, , WISP-2, and WISP-3.

In some embodiments, at least one antigen binding domain, or independently each antigen g domain, binds the tumor associated antigen (TAA) folate receptor alpha (FRoc). For example, the antigen binding domain contains the binding domain as an sdAb that binds FRoc. Exemplary FRoc-binding sdAbs are set forth in SEQ ID NOS: 120, 121, and In some embodiments, at least one n binding domain, or independently each antigen binding domain, binds the tumor ated antigen (TAA) cMET. For example, the antigen binding domain contains the binding domain as a sdAb that binds cMET. An exemplary cMET-binding sdAb is set forth in SEQ ID NO: 123 (US. Pat. No. 9,346,884).

In some ments, at least one antigen binding domain, or independently each antigen binding domain, binds the tumor associated antigen (TAA) B7H3. For example, the n binding domain contains the binding domain as an scFV that binds B7H3. An exemplary inding scFV is set forth in SEQ ID NO: 124. In some embodiments, the n binding domain is or contains a Fab antibody fragment comprising a VH—CHl (Pd) and LC. An exemplary B7H3 Fd is set forth in SEQ ID NO: 127 and an exemplary B7H3 LC is set forth in SEQ ID NO: 128 (PCT Publication No, WO2017/030926).

In some embodiments, at least one antigen binding , or independently each antigen g domain, binds the tumor associated antigen (TAA) CD20. For example, the antigen binding domain contains the binding domain as an scFV that binds CD20. Exemplary CD20-binding scFvs are set forth in SEQ ID NO: 125, 189, and 190 (US.

Pub. No. US 123546).

In some embodiments, at least one antigen binding domain, or independently each antigen binding domain, binds the tumor associated antigen (TAA) DLL3. For example, the antigen binding domain contains the binding domain as an scFV that binds DLL3. ary DLL3-binding scFV is set forth in SEQ ID NO: 126 and 189 (US. Pub.

No. US 2017/0037130). In some embodiments, the antigen binding domain is or contains a Fab antibody fragment comprising a Pd and LC that binds DLL3. An exemplary DLL3 Ed is set forth in SEQ ID NO: 133 and an exemplary DLL3 LC is set forth in SEQ ID NO: 134 (US. Pat. No. US 8,044,178).

In some embodiments, at least one antigen binding domain, or independently each antigen binding domain, binds the tumor associated antigen (TAA) 5T4. An exemplary 514 Ed is set forth in SEQ ID NO: 129 and an exemplary 5T4 LC is set forth in SEQ ID NO: 130. In some ments, the antibody binding domain comprises a VH-CHl (Fd) or VL- CL as set forth in SEQ ID NOS: 167 and 168 (US. Pat. No. US 8,044,178).

In some embodiments, at least one antigen binding domain, or independently each antigen binding domain, binds the tumor associated antigen (TAA) gpNMB. In some embodiments, the n g domain is or contains a Fab fragment comprising a Fd and LC chain. An exemplary gpNMB Fd is set forth in SEQ ID NO: 131 and an exemplary gpNMB LC is set forth in SEQ ID NO: 132.

In some embodiments, the antigen binding domain is linked, directly or indirectly via a linker, to the Fc region and/or to the CD3 binding region. In some ments, e is via a linker. In some embodiments, the linker is a linking peptide (LP), which can include any ?exible or rigid linker as described in Section 113, although generally es linking the antigen binding domain or domains is not a cleavable liker.

In some embodiments, the multispeci?c polypeptide construct comprises a ?rst linking peptide (LPl) between the ?rst antigen binding domain and the Fc region. In some ments, the peci?c polypeptide construct comprises a second linking peptide (LP2) between the CD3 binding region and the second antigen binding domain. In some embodiments, the multispeci?c polypeptide construct comprises a ?rst linking peptide (LP1) between the ?rst antigen binding domain and the Fc region and a second linking peptide (LP2) between the CD3 binding region and the second antigen binding domain. In some aspects, the multi speci?c polypeptide construct has the structural arrangement from N- terminus to C—terminus as follows: ?rst antigen binding domain , LP1— Fc region flinker , CD3 binding region — LP2 — second antigen binding domain. In some embodiments, the two g peptides are not cal to each other.

In some embodiments, the LP1 or LP2 is independently a e of about 1 to 20 amino acids in length. In some embodiments, the LPl or LP2 is independently a peptide that is or comprises any Gly-Ser linker as set forth in SEQ ID NOS: 10-13, 119, 135, 147, 149 or III. PharmaceuticalComposition Provided herein are compositions of any of the ed multispeci?c polypeptide constructs. It will be appreciated that administration of therapeutic entities in accordance with the disclosure will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of riate formulations can be found in the formulary known to all pharmaceutical chemists: Remington’s Pharmaceutical Sciences (15th ed., Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) ning vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil ons, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi- solid mixtures containing carbowax. Any of the foregoing es may be appropriate in treatments and therapies in accordance with the present sure, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See also Baldrick P. aceutical excipient development: the need for preclinical guidance." Regul. Toxicol Pharmacol. 32(2):210-8 (2000), Wang W. "Lyophilization and development of solid protein pharmaceuticals." Int. J. Pharm. 203(1-2):l-60 (2000), Channan WN "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts." J Pharm Sci.89(8):967-78 (2000), Powell et a]. "Compendium of excipients for parenteral formulations" PDA J Pharm Sci Technol. 52:23 8-3 11 (1998) and the ons therein for additional information related to formulations, excipients and rs well known to pharmaceutical chemists.

In some embodiments, the multispecific polypeptide constructs, conjugated multispeci?c polypeptide constructs, and compositions thereof — referred to collectively herein as the Therapeutic(s) and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of ents are provided, for example, in ton’s Pharmaceutical Sciences: The Science And Practice Of Pharmacy 19th ed. so R. Gennaro, et al., editors) Mack Pub.

Co, Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And , Harwood Academic Publishers, Langhome, Pa, 1994, and Peptide And Protein Drug Delivery (Advances In eral Sciences, Vol. 4), 1991, M. Dekker, New York.

Such compositions typically comprise the multispecific polypeptide construct or a conjugated thereof and a pharmaceutically acceptable carrier. Where a multispecific polypeptide construct includes a fragment of an dy, the smallest fragment of the antibody that specifically binds to the target protein can be used. For e, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability of the antibody to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by inant DNA technology. (See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993)).

As used , the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal , isotonic and absorption delaying , and the like, compatible with pharmaceutical stration. Suitable carriers are described in the most recent edition of Remington’s Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. le examples of such carriers or diluents include, but are not limited to, water, saline, ringer’s solutions, dextrose solution, and 5% human serum albumin. mes and non-aqueous vehicles such as ?xed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is plated.

The formulations to be used for in viva stration must be sterile. This is readily accomplished by filtration through sterile tion membranes.

A pharmaceutical composition of the disclosure is ated to be compatible with its intended route of administration. Examples of routes of administration include eral, e. g., intravenous, intradermal, subcutaneous, oral (e. g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for eral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, f1xed oils, polyethylene glycols, ine, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA), buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.

The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.

The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile s for the extemporaneous ation of sterile inj ectable ons or dispersion. For intravenous administration, suitable carriers include physiological saline, iostatic water, Cremophor ELTM (BASF, Parsippany, NJ.) or phosphate buffered saline (PBS). In all cases, the ition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper ?uidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be le to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for e, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active nd in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by ?ltered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that ns a basic dispersion medium and the required other ingredients from those ated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile—filtered on thereof. Where the composition is lyophilized, sterilization using this method may be conducted either prior to or following lyophilization and reconstitution. The composition for parenteral administration may be stored in lized form or in solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

In some embodiments, the pharmaceutical composition is administered to a t through any route, including orally, transdermally, by inhalation, intravenously, intra- ally, intramuscularly, direct application to a wound site, application to a surgical site, intraperitoneally, by suppository, subcutaneously, ermally, utaneously, by nebulization, intrapleurally, intraventricularly, intra-articularly, intraocularly, or pinally.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the e of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a ?uid carrier for use as a mouthwash, wherein the compound in the ?uid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be ed as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as rystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a ant such as magnesium stearate or Sterotes; a glidant such as dal silicon dioxide; a sweetening agent such as sucrose or sacchai‘in; or a ?avoring agent such as mint, methyl salicylate, or orange ?avoring.

For administration by inhalation, the multispecific polypeptide construct are delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by ucosal or transdermal means.

For transmucosal or transdermal administration, penetrants appropriate to the banier to be permeated are used in the formulation. Such penetrants are lly known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and c acid derivatives. Transmucosal stration can be lished through the use of nasal sprays or itories. For transdermal administration, the active compounds are formulated into ointments, , gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the Therapeutics are prepared with carriers that will protect the compound t rapid elimination from the body, such as sustained/controlled release formulations, including implants and microencapsulated delivery systems.

Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be nt to those skilled in the art.

For example, the Therapeutics can be entrapped in microcapsules prepared, for example, by coacervation techniques or by acial polymerization, for example, hydroxymethylcellulose or gelatin—microcapsules and poly—(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin pheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

In some embodiments, the pharmaceutical composition comprises a pharmaceutically-acceptable excipient, for example a filler, binder, coating, preservative, lubricant, ?avoring agent, sweetening agent, coloring agent, a solvent, a buffering agent, a chelating agent, or stabilizer. Examples of pharmaceutically-acceptable fillers include cellulose, dibasic calcium phosphate, calcium carbonate, microcrystalline cellulose, sucrose, lactose, glucose, mannitol, sorbitol, maltol, pregelatinized starch, corn starch, or potato starch. Examples of ceutically-acceptable binders e polyvinylpyrrolidone, starch, lactose, xylitol, sorbitol, maltitol, gelatin, sucrose, polyethylene glycol, methyl cellulose, or cellulose. Examples of pharmaceutically-acceptable gs include hydroxypropyl methylcellulose (HPMC), shellac, corn protein zein, or gelatin. es of pharmaceutically-acceptable disintegrants include polyvinylpyrrolidone, carboxymethyl cellulose, or sodium starch glycolate. Examples of pharmaceutically-acceptable lubricants include polyethylene glycol, magnesium stearate, or stearic acid. es of pharmaceutically-acceptable preservatives include methyl parabens, ethyl ns, propyl paraben, benzoic acid, or sorbic acid. Examples of pharmaceutically-acceptable sweetening agents include sucrose, saccharine, aspartame, or ol. Examples of ceutically— acceptable buffering agents include carbonates, citrates, ates, acetates, phosphates, or tartrates. ned—release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the dy, which es are in the form of shaped articles, e.g., ?lms, or microcapsules. In some embodiments, the pharmaceutical composition further comprises an agent for the controlled or ned release of the product, such as injectable microspheres, bio-erodible particles, polymeric compounds (polylactic acid, polyglycolic acid), beads, or liposomes. Examples of sustained—release matrices include polyesters, hydrogels (for example, poly(2—hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (US. Pat. No. 3,773,919), copolymers of L-glutamic acid and y ethyl-L- ate, non—degradable ethylene—vinyl acetate, able lactic acid—glycolic acid copolymers such as the LUPRON DEPOT TM (injectable microspheres composed of lactic acid-glycolic acid mer and leuprolide acetate), and poly-D-(-)hydroxybutyric acid.

While polymers such as ethylene—vinyl acetate and lactic acid—glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) and can also be used as pharmaceutically acceptable carriers. These can be prepared according to s known to those skilled in the art, for e, as described in US. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be d; each unit containing a ermined quantity of active nd calculated to produce the desired therapeutic effect in association with the ed pharmaceutical carrier, The specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Further provided are kits comprising the pharmaceutical compositions (or articles of manufacture) described herein. The pharmaceutical compositions can be ed in a container, pack, or dispenser together with instructions for stration. The kits described herein may also include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, s, syringes, and package inserts with instructions for performing any methods described herein.

The formulation can also contain more than one multispecific polypeptide construct as ary for the particular indication being treated, for example, those with complementary activities that do not adversely affect each other. In some embodiments, or in on, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.

Such molecules are ly present in combination in amounts that are effective for the purpose intended.

In some embodiments, the dosage of the pharmaceutical composition is a single dose or a repeated dose. In some embodiments, the doses are given to a subject once per day, twice per day, three times per day, or four or more times per day. In some embodiments, about 1 or more (such as about 2 or more, about 3 or more, about 4 or more, about 5 or more, about 6 or more, or about 7 or more) doses are given in a week. In some embodiments, le doses are given over the course of days, weeks, months, or years. In some embodiments, a course of treatment is about 1 or more doses (such as about 2 or more does, about 3 or more doses, about 4 or more doses, about 5 or more doses, about 7 or more doses, about 10 or more doses, about 15 or more doses, about 25 or more doses, about 40 or more doses, about 50 or more doses, or about 100 or more doses).

In some embodiments, the pharmaceutical composition is administered to a subject. lly, dosages and routes of administration of the pharmaceutical composition are determined according to the size and condition of the subject, according to standard pharmaceutical practice. For example, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, pigs, or monkeys. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. The exact dosage will be determined in light of factors related to the subject requiring ent. Dosage and administration are adjusted to provide sufficient levels of the active compound or to maintain the d effect. Factors that may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. The optimal dosage and ent regime for a particular patient can readily be determined by one skilled in the art of medicine by monitoring the patient for signs of disease and adjusting the treatment accordingly.

IV. s of Use and eutic Administration Also provided are s for using and uses of the multispecific polypeptide constructs. Such methods and uses include eutic methods and uses, for e, involving administration of the molecules or compositions containing the same, to a subject having a disease, condition, or disorder, such as a tumor or cancer. In some embodiments, the molecule and/or composition is administered in an effective amount to effect treatment of the disease or disorder. Uses include uses of the multispeci?c polypeptide constructs in such methods and treatments, and in the preparation of a medicament in order to carry out such therapeutic methods. In some embodiments, the methods are carried out by administering the multispeciflc polypeptide constructs, or itions comprising the same, to the subject having or suspected of having the disease or condition. In some embodiments, the methods thereby treat the disease or condition or disorder in the subject.

In one embodiment, a multispecific polypeptide construct of the disclosure may be used as therapeutic agents. Such agents will generally be employed to diagnose, prognose, r, treat, alleviate, and/or prevent a disease or pathology in a subject. A eutic regimen is carried out by identifying a subject, e.g, a human patient or other mammal ing from (or at risk of developing) a disorder using standard s. A multispeci?c polypeptide construct is administered to the subject. A pecific ptide construct is administered to the subject and will generally have an effect due to its binding with the target(s).

In some embodiments, provided herein is a method of modulating an immune response in a subject by administering a eutically effective amount of any of the provided multispecific conjugates or pharmaceutical compositions. In some embodiments, the method of modulating an immune response increases or enhances an immune se in a t. For example, the increase or enhanced response may be an increase in cell- mediated immunity. In some examples, the method increases T-cell activity, such as cytolytic T-cell (CTL) activity. In some embodiments, the modulated (e.g., increased) immune response is against a tumor or cancer.

Administration of the multispecific polypeptide construct may activate innate immune cells via engagement of FcyRs through the Fc—region of the multispeci?c polypeptide construct. Administration of the multispecifrc polypeptide construct may agonize, stimulate, activate, and/or augment innate immune cell effector functions, including ADCC, ne release, degranulation and/or ADCP. Administration of the multispeci?c ptide construct may activate T-cell once the linker(s) joining the first and second component is cleaved by a se thereby allowing the anti-CD3 binding portion to bind CD33 on the T cells. Administration of the multispecifrc polypeptide construct may agonize, stimulate, activate, and/or augment CD3-mediated T cell activation, cytotoxicity, ne release and/or proliferation.

In some embodiments, the provided methods are for treating a disease or ion in a subject by administering a therapeutically effective amount of any of the provided multispecifrc conjugates or pharmaceutical compositions. In some ments, the disease or condition is a tumor or a cancer. Generally, alleviation or treatment of a disease or disorder involves the ing of one or more symptoms or medical problems associated with the disease or disorder. For example, in the case of cancer, the therapeutically ive amount of the drug can accomplish one or a combination of the following: reduce the number of cancer cells, reduce the tumor size, inhibit (1.8., to decrease to some extent and/or stop) cancer cell in?ltration into peripheral organs, inhibit tumor asis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. In some embodiments, a composition of this disclosure can be used to prevent the onset or reoccurrence of the disease or disorder in a t, e. g., a human or other mammal, such as a non-human primate, companion animal (e.g., cat, dog, horse), farm animal, work , or zoo animal. The terms subject and patient are used hangeably herein.

In some embodiments, the pharmaceutical composition can be used to inhibit growth of mammalian cancer cells (such as human cancer cells). A method of ng cancer can include administering an effective amount of any of the pharmaceutical compositions described herein to a subject with cancer. The effective amount of the pharmaceutical composition can be administered to inhibit, halt, or e progression of cancers. Human cancer cells can be treated in viva, or ex viva. In ex viva treatment of a human patient, tissue or fluids containing cancer cells are d outside the body and then the tissue or fluids are reintroduced back into the patient. In some embodiments, the cancer is d in a human patient in vivo by administration of the therapeutic ition into the patient.

Non-liming examples of disease include: all types of cancers (breast, lung, colorectal, prostate, melanomas, head and neck, pancreatic, etc), rheumatoid tis, Crohn’s disuse, SLE, cardiovascular damage, ischemia, etc. For example, indications would include leukemias, including T-cell acute lymphoblastic leukemia (T-ALL), lymphoblastic diseases including multiple myeloma, and solid tumors, including lung, colorectal, prostate, pancreatic, and breast, including triple negative breast cancer. For example, tions e bone e or metastasis in cancer, regardless of primary tumor origin, breast cancer, including by way of non—limiting e, ER/PR+ breast cancer, Her2+ breast cancer, triple-negative breast ; colorectal cancer; endometrial cancer; gastric cancer; glioblastoma, head and neck cancer, such as geal cancer, lung cancer, such as by way of non—limiting example, non—small cell lung , multiple myeloma ovarian cancer, pancreatic cancer; prostate cancer; sarcoma, such as osteosarcoma; renal cancer, such as by way of nonlimiting e, renal cell oma; and/or skin cancer, such as by way of nonlimiting example, squamous cell cancer, basal cell carcinoma, or melanoma. In some embodiments, the cancer is a squamous cell cancer. In some embodiments, the cancer is a skin squamous cell carcinoma. In some embodiments, the cancer is an esophageal squamous cell carcinoma. In some embodiments, the cancer is a head and neck squamous cell carcinoma. In some embodiments, the cancer is a lung squamous cell carcinoma.

A therapeutically effective amount of a multispeci?c polypeptide construct of the disclosure relates generally to the amount needed to achieve a eutic objective. As noted above, this may be a binding interaction between the multispecific polypeptide construct and its target antigen(s) that, in certain cases, agonize, stimulate, activate, and/or augment FcyR-mediated innate immune cell activation or CD3-mediated T cell activation.

The amount required to be administered will rmore depend on the binding affinity of the multispecific polypeptide uct for its speci?c antigen(s), and will also depend on the rate at which an administered multispecific polypeptide construct is depleted from the free volume other subject to which it is stered. Common ranges for therapeutically effective dosing of a multispecific polypeptide construct may be, by way of nonlimiting e, from about 0.01 ug/kg body weight to about 10 mg/kg body weight. In some embodiments, the therapeutically effective dosing of a multispecific polypeptide construct of the disclosure may be, by way of nonlimiting e, from about 0.01 mg/kg body weight to about 5-10 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

Efficaciousness of treatment is ined in association with any known method for diagnosing or treating the particular disorder. s for the screening of multispeci?c polypeptide construct that possess the desired speci?city include, but are not limited to, enzyme linked immunosorbent assay (ELISA) and other immunologically mediated techniques known within the art. A variety of means are known for determining if administration of the provided pecific polypeptide constructs sufficiently modulates immunological activity by eliminating, sequestering, or inactivating immune cells mediating or capable of mediating an undesired immune response; inducing, generating, or turning on immune cells that mediate or are capable of mediating a protective immune response; changing the physical or functional properties of immune cells; or a combination of these effects. Examples of measurements of the modulation of immunological activity include, but are not limited to, examination of the presence or absence of immune cell populations (using ?ow cytometry, histochemistry, histology, electron microscopy, rase chain on (PCR)), measurement of the functional capacity of immune cells including y or resistance to proliferate or divide in response to a signal (such as using T-cell proliferation assays and n analysis based on 3H-thymidine incorporation following ation with anti—CD3 antibody, anti—T—cell receptor antibody, anti—CD28 antibody, calcium ionophores, PMA (phorbol lZ-myristate l3-acetate) antigen ting cells loaded with a peptide or protein antigen, B cell proliferation assays), ement of the ability to kill or lyse other cells (such as cytotoxic T cell ), measurements of the cytokines, chemokines, cell surface molecules, antibodies and other products of the cells (e.g., by flow cytometry, enzyme-linked immunosorbent assays, Western blot analysis, protein microarray analysis, immunoprecipitation analysis), measurement of biochemical markers of activation of immune cells or signaling pathways within immune cells (e.g, n blot and immunoprecipitation analysis of tyrosine, serine or threonine phosphorylation, polypeptide cleavage, and formation or dissociation of protein complexes; protein array analysis; DNA transcriptional, pro?ling using DNA arrays or subtractive hybridization); measurements of cell death by apoptosis, necrosis, or other mechanisms (e.g., annexin V staining, TUNEL assays, gel electrophoresis to measure DNA laddering, histology; ?uorogenic caspase assays, n blot analysis of caspase ates); measurement of the genes, proteins, and other molecules produced by immune cells (e.g, Northern blot is, polymerase chain reaction, DNA microarrays, protein microarrays, 2- dimensional gel electrophoresis, Western blot is, enzyme linked immunosorbent assays, flow try); and measurement of clinical ms or outcomes such as improvement of autoimmune, neurodegenerative, and other diseases involving self-proteins or self-polypeptides (clinical scores, requirements for use of additional therapies, functional status, imaging studies) for e, by measuring relapse rate or disease ty.

The multispecific ptide construct are also useful in a variety of diagnostic and prophylactic formulations. In one embodiment, a pecific polypeptide construct is administered to patients that are at risk of developing one or more of the aforementioned disorders. A patient’s or organ’s predisposition to one or more of the disorders can be determined using genotypic, serological or biochemical markers.

In another embodiment of the disclosure, a multispecific polypeptide construct is administered to human individuals diagnosed with a clinical indication associated with one or more of the aforementioned disorders. Upon diagnosis, a multispecific polypeptide construct is administered to mitigate or reverse the effects of the clinical indication.

Combination Therapies In some embodiments, the multispecific polypeptide constructs, conjugated multispeci?c polypeptide constructs, and itions thereof — referred to collectively herein as the Therapeutic(s) — are administered in conjunction with one or more additional agents, or a combination of additional agents. le onal agents include current pharmaceutical and/or surgical therapies for an intended application. For example, the Therapeutic(s) can be used in conjunction with an additional chemotherapeutic or anti- neoplastic agent. For example, the Therapeutic(s) and additional agent are formulated into a single therapeutic composition, and the Therapeutic(s) and additional agent are administered aneously. In some embodiments, the Therapeutic(s) and additional agent are separate from each other, e.g, each is formulated into a separate therapeutic composition, and the eutic(s) and the additional agent are administered simultaneously, or the Therapeutic(s) and the additional agent are stered at different times during a treatment n. For example, the Therapeutic(s) is administered prior to the administration of the additional agent, the Therapeutic(s) is stered subsequent to the administration of the additional agent, or the Therapeutic(s) and the additional agent are administered in an alternating fashion. As described herein, the Therapeutic(s) and additional agent are stered in single doses or in multiple doses. In some embodiments, the additional agent is coupled or otherwise attached to the Therapeutic(s), Suitable additional agents are selected according to the purpose of the ed application (1'.e., killing, tion of cell proliferation, hormone therapy or gene therapy). Such agents may include but is not d to, for example, pharmaceutical agents, toxins, fragments of toxins, alkylating agents, enzymes, antibiotics, antimetabolites, antiproliferative agents, hormones, neurotransmitters, DNA, RNA, siRNA, oligonucleotides, antisense RNA, aptamers, diagnostics, radiopaque dyes, ctive isotopes, ?uorogenic compounds, magnetic labels, nanoparticles, marker compounds, lectins, compounds that alter cell membrane bility, hemical compounds, small molecules, liposomes, micelles, gene therapy vectors, viral vectors, and the like. Finally, combinations of agents or ations of different classes of agents may be used.

In one embodiment, the multispecific polypeptide constructs are administered in combination therapy, z'.e., combined with other agents, e.g., therapeutic agents, that are useful for treating pathological conditions or disorders, such as autoimmune disorders and in?ammatory diseases. The term "in ation" in this context means that the agents are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of stration of the second compound, the first of the two compounds is still detectable at effective concentrations at the site of treatment.

For example, the combination therapy can include one or more multispecific polypeptide constructs of the disclosure co-formulated with, and/or co-administered with, one or more additional eutic agents, e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, nflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described in more detail below. Furthermore, one or more multispecific polypeptide constructs described herein may be used in combination with two or more of the therapeutic agents described herein. Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible ties or complications associated with the various monotherapies.

In other embodiments, one or more peciflc polypeptide constructs of the disclosure can be co-formulated with, and/or co-administered with, one or more anti- in?ammatory drugs, immunosuppressants, or metabolic or enzymatic tors. Nonlimiting examples of the drugs or inhibitors that can be used in combination with the antibodies described herein, include, but are not limited to, one or more of: nonsteroidal anti- in?ammatory drug(s) (NSAIDs), e. g., ibuprofen, tenidap, naproxen, meloxicam, piroxicam, diclofenac, and indomethacin; sulfasalazine; corticosteroids such as prednisolone; cytokine suppressive anti-inflammatory drug(s) (CSAIDS), inhibitors of nucleotide biosynthesis, e.g., inhibitors of purine thesis, folate antagonists (e.g., rexate (N-[4-[[(2,4-diamino- 6-pteridinyl)methyl] methylamino] benzoyl]—L-glutamic acid), and inhibitors of pyrimidine biosynthesis, e. g., dihydroorotate dehydrogenase (DHODH) inhibitors. Suitable eutic agents for use in combination with the antibodies of the disclosure include NSAIDs, CSAIDs, (DHODH) inhibitors (e.g., le?unomide), and folate antagonists (e.g., methotrexate).

Examples of additional tors include one or more of: corticosteroids (oral, inhaled and local injection), immunosuppressants, e.g., porin, tacrolimus (PK-506), and mTOR inhibitors, e.g., sirolimus (rapamycin - RAPAMUNETM or rapamycin derivatives, e.g., soluble rapamycin tives (e.g., ester rapamycin derivatives, e.g., 9); agents that interfere With signaling by proin?ammatory cytokines such as TNFOL or IL-1 (e.g. IRAK, NIK, lKK, p38 or MAP kinase inhibitors), COX2 inhibitors, e.g., celecoxib, rofecoxib, and variants thereof; phosphodiesterase inhibitors, e.g., R973401 (phosphodiesterase Type IV inhibitor), phospholipase inhibitors, e.g., inhibitors of cytosolic phospholipase 2 (cPLAZ) (e.g., trifluoromethyl ketone analogs), tors of vascular endothelial cell growth factor or growth factor receptor, e.g., VEGF inhibitor and/or VEGF-R inhibitor, and inhibitors of angiogenesis. Suitable therapeutic agents for use in combination with the antibodies of the disclosure are immunosuppressants, e. g., cyclosporin, tacrolimus (FK—506), mTOR tors, e.g., sirolimus (rapamycin) or cin derivatives, e.g., e rapamycin derivatives (e.g., ester rapamycin derivatives, e.g, CCI-779), COX2 inhibitors, e.g., celecoxib and variants thereof, and phospholipase inhibitors, e.g., inhibitors of lic phospholipase 2 (cPLAZ), e.g, trifluoromethyl ketone analogsAdditional examples of therapeutic agents that can be combined with a multispecifrc polypeptide uct include one or more of: aptopurines (6-MP), azathioprine sulphasalazine, mesalazine, olsalazine, chloroquine/ hydroxychloroquine (PLAQUENIL®), pencillamine, aurothiornalate (intramuscular and oral), azathioprine, coichicine, beta-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines hylline, arninophylline); cromoglycate, nedocromil; fen; opium and oxitropium; mycophenolate mofetil; ine agonists, antithrombotic agents, complement inhibitors, and adrenergic agents.

V. Exemplary Embodiments Among the provided embodiments are: 1. A multispeci?c polypeptide construct, the multispeci?c polypeptide construct comprising a ?rst component comprising an immunoglobulin Fc region and a second component sing a CD3—binding , wherein: the ?rst and second ents are coupled by a linker, wherein the Fc region is positioned N-terminal to the CD3-binding , and one or both of the ?rst and second components comprises an antigen binding domain that binds a tumor associated n (TAA). 2. The multispeci?c polypeptide construct of embodiment 1, wherein the CD3- binding region binds CD3 (CD38). 3. The multispeci?c construct of embodiment 1 or embodiment 2, n the antigen g domain is positioned amino-terminally relative to the Fc region and/or carboxy-terminally relative to the CD3 binding region of the multispeci?c polypeptide construct. 4. The peci?c polypeptide construct of any of embodiments 1-3, wherein the ?rst component ses a ?rst antigen binding domain and the second component comprises a second antigen binding domain, wherein each of the antigen binding domains bind a tumor associated antigen (TAA).

. The multispeci?c polypeptide construct of embodiment 4, n the ?rst antigen binding domain is positioned amino-terminally relative to the Fc region of the multispeci?c construct and the second antigen binding domain is positioned carboxy- terminally relative to the CD3 binding region of the multispeci?c construct. 6. A peci?c polypeptide construct, wherein the multispeci?c construct comprises in order, from N—terminus to C-terminus: a ?rst antigen binding domain that binds to a associated antigen (TAA); an immunoglobulin Fc region; a linker, a CD3 binding region that binds CD3 (CD38); and a second antigen binding domain that binds a tumor-associated antigen (TAA). 7. A multispeci?c polypeptide construct, wherein the multispeci?c construct comprises in order, from N—terminus to C-terminus: an immunoglobulin Fc region, a linker; a CD3 binding region that binds CD3 (CD38); and an antigen binding domain that binds a tumor-associated antigen (TAA). 8. A multispecific polypeptide construct, wherein the multispecific construct comprises in order, from N—terminus to C-terminus: an antigen binding domain that binds to a associated antigen (TAA); an immunoglobulin Fc region; a linker; and a CD3 g region that binds CD3 (CD38). 9. The multispecific polypeptide uct of any of embodiments 1-8, wherein the Fc region is a homodimeric Fc region.

. The multispecific polypeptide construct of any of embodiments 1—9, wherein the Fc region is an Fc region of a human IgG1, a human IgG2, a human IgG3, or a human IgG4, or is an immunologically active fragment thereof. 11. The multispecific polypeptide construct of any of embodiments 1—10, wherein the Fc region comprises a polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or a ce of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID N02]. 12. The multispecific polypeptide construct of any of ments l-lO, wherein the Fc region comprises a polypeptide ses the amino acid sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID N022; the Fc region comprises a polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID N04; or the Fc region comprises a polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 5 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID N05. 13. The multispecific ptide construct of any of embodiments 1-6, 9 and 12, wherein the Fc region is a dimeric Fc region. 14. The multispecific polypeptide construct of embodiment 13, n one or both Fc polypeptides of the heterodimeric Fc region comprises at least one modi?cation to induce heterodimerization compared to a polypeptide of a homodimeric Fc region, optionally compared to the Fc polypeptide set forth in SEQ ID N01 or an immunologically active fragment thereof.

. The multispeci?c polypeptide construct of embodiment 14, wherein each of the Fc polypeptides of the heterodimeric Fc ndently comprise at least one amino acid modi?cation. 16. The multispeci?c polypeptide construct of embodiment 15, wherein each of the Fc ptides of the heterodimeric Fc comprise a knob-into-hole modi?cation or se a charge mutation to increase electrostatic complementarity of the polypeptides. 17. The multispeci?c polypeptide construct of embodiment 16, wherein the amino acid modi?cation is a knob-into-hole modi?cation. 18. The multispeci?c fusion polypeptide of any of ments 13-17, wherein the ?rst Fc polypeptide of the heterodimeric Fc comprises the modi?cation selected from among Thr366$er, Leu368Ala, Tyr407Val, and combinations thereof and the second Fc polypeptide of the dimeric Fc comprises the ation T366W. 19. The multispeci?c fusion polypeptide of embodiment 18, wherein the ?rst and second Fc polypeptides further comprises a modi?cation of a non-cysteine residue to a cysteine e, wherein the ation of the ?rst polypeptide is at one of the on Ser354 and Y349 and the modi?cation of the second Fc polypeptide is at the other of the position Ser354 and Y349.

. The multispeci?c polypeptide construct of embodiment 16, wherein the amino acid modi?cation is a charge mutation to increase ostatic complementarity of the polypeptides. 21. The multispeci?c polypeptide construct of any of embodiments 13—16 and 20, wherein the ?rst and/or second Fc polypeptides or each of the ?rst and second Fc polypeptide se a modi?cation in mentary positions, wherein the modi?cation is replacement with an amino acid having an opposite charge to the complementary amino acid of the other polypeptide. 22. The multispeci?c polypeptide construct of any of embodiments 14-21, wherein one of the ?rst or second Fc polypeptide of the heterodimeric Fc further comprises a modi?cation at residue Ile253. 23. The multispeci?c polypeptide construct of embodiment 22, wherein the modi?cation is Ile253Arg. 24. The multispeci?c polypeptide construct of any of embodiments 14-23, wherein one of the ?rst or second Fc polypeptide of the dimeric Fc further comprises a modi?cation at residue His435.

. The multispeci?c polypeptide construct of ment 24, wherein the modi?cation is His435Arg. 26. The multispeci?c polypeptide construct of any of embodiments l-25, n the Fc region comprises a polypeptide that lacks Lys447. 27. The multispeci?c polypeptide construct of any of embodiments 1-26, wherein the Fc region comprises a polypeptide comprising at least one modi?cation to enhance FcRn binding. 28. The multispeci?c fusion polypeptide of embodiment 27, wherein the modi?cation is at a position selected from the group consisting of Met252, Ser254, Thr256, Met428, Asn434, and combinations thereof. 29. The multispeci?c fusion polypeptide of embodiment 28, wherein the modi?cation is at a position selected from the group consisting of Met252Y, Ser254T, Thr256E, Met428L, Met428V, S, and combinations f.

. The multispeci?c fusion polypeptide of embodiment 28, n the modi?cation is at position Met252 and at position Met428. 31. The multispeci?c fusion polypeptide of embodiment 30, wherein the modi?cation is Met252Y and Met428L. 32. The multispeci?c fusion polypeptide of embodiment 30, wherein the modi?cation is Met252Y and Met428V. 33. The multispeci?c polypeptide construct of any of embodiments 13—32, wherein the ?rst polypeptide of the dimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS:82, 86, 94 or 96, and the second polypeptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS:83, 87, 90, 92, 98 or 100. 34. The peci?c polypeptide construct of any of embodiments 1-33, wherein the Fc region comprises a polypeptide comprising at least one amino acid modi?cation that s effector on and/or reduces g to an effector molecule selected from an Fc gamma receptor or Clq.

. The multispeci?c ptide uct of embodiment 34, wherein the one or more amino acid modi?cation is deletion of one or more of Glu233, Leu234 or Leu235. 36. The multispeci?c ptide construct of any of embodiments 13-32, 34 and , wherein the ?rst polypeptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS: 84, 88, 95 or 97 and the second polypeptide of the dimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS: 85, 89, 91, 93, 99 or 101. 37. The multispeci?c ptide construct of any of embodiments 1-32, wherein the Fc region comprises a polypeptide comprising at least one modi?cation to enhance FcyR binding. 38. The multispeci?c polypeptide construct of embodiment 37 wherein the modi?cation is modi?cation at Ser239 or Ile332. 39. The multispeci?c polypeptide construct of any of embodiments 1-32 and 37, wherein the glycosylation of the Fc region is modi?ed to enhance FcyR binding as compared to an unmodi?ed Fc region. 40. The multispeci?c polypeptide construct of embodiment 39, wherein the Fc region lacks or has reduced fucose content. 41. The multispeci?c polypeptide construct of any of embodiments 1-40, n the CD3 binding region is an anti-CD3 antibody or antigen-binding nt. 42. The multispeci?c polypeptide construct of embodiment 41, wherein the anti- CD3 antibody or antigen binding fragment ses a variable heavy chain region (VH) and a variable light chain region (VL). 43. The multispeci?c polypeptide construct of any of ments 1-42, wherein the CD3 binding region is monovalent. 44. The multispeci?c polypeptide uct of any of embodiments 41-43, wherein the D3 antibody or antigen binding nt is not a single chain antibody, optionally is not a single chain variable fragment (scFv). 45. The multispeci?c polypeptide construct of embodiment 42 or embodiment 44, wherein the Fc is a heterodimeric PC and the VH and VL that comprise the anti-CD3 antibody or antigen binding fragment are linked to opposite polypeptides of the heterodimeric PC. 46. The multispeci?c polypeptide construct of any of embodiments 1-45, wherein the CD3 g region is not able to, or is not substantially able to, bind or engage CD3 unless at least one of the antigen binding domain is bound to its TAA. 47. The multispeci?c polypeptide construct of any of embodiments 1-46, wherein the CD3 g region is not able to, or is not substantially able, to bind or engage CD3 unless at least two of the antigen binding domain is bound to its TAA. 48. The multispeci?c polypeptide construct of any of ments 1-47, wherein the linker is a polypeptide linker. 49. The multispeci?c polypeptide construct of embodiment 48, wherein the linker is a polypeptide of up to 25 amino acids in length. 50. The multispeci?c polypeptide construct of embodiment 48 or embodiment 49, wherein the linker is a polypeptide of from or from about 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 24 amino acids, 6 to 20 amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 24 amino acids, 8 to 20 amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, to 14 amino acids, 10 to 12 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 24 amino acids, 18 to 20 amino acids or 20 to 24 amino acids. 51. The multispeci?c polypeptide construct of any of embodiments 48-50, wherein the linker is a polypeptide that is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length. 52. The multispeci?c polypeptide construct of any of embodiments 1-51, wherein the linker is a cleavable . 53. A multispeci?c ptide construct, the multispeci?c polypeptide construct sing a ?rst component comprising a heterodimeric Fc region and a second component comprising an anti-CD3 antibody or antigen-binding nt comprising a variable heavy chain region (VH) and a variable light chain region (VL), wherein: the VH and VL that comprise the anti-CD3 dy or antigen binding fragment are linked to opposite polypeptides of the heterodimeric PC, the ?rst and second ents are coupled by a cleavable linker, wherein the heterodimeric Fc region is oned N—terminal to the anti-CD3 antibody; and one or both of the ?rst and second components comprises an antigen binding domain that binds a tumor associated antigen (TAA). 54. The multispecif1c polypeptide construct of embodiment 52 or embodiment 53, wherein binding of the CD3-binding region to CD3 is ntially reduced when the multispeci?c ptide construct is in an ved state compared to a d state. 55. The multispeciflc polypeptide of any of embodiments 52-54, wherein in a cleaved state the first and second ents are not linked. 56. The multispeci?c polypeptide construct of any of embodiments 52-5 5, wherein the cleavable linker is a polypeptide that functions as a substrate for a protease. 57. The multispeciflc polypeptide construct of embodiment 56, wherein the protease is produced by an immune effector cell, by a tumor, or by cells present in the tumor microenvironment. 58. The multispeciflc polypeptide construct of embodiment 57, wherein the protease is produced by an immune effector cell and the immune effector cell is an activated T cell, a natural killer (NK) cell, or an NK T cell. 59. The multispeciflc ptide construct of any of embodiments 56—5 8, wherein the protease is selected from among matriptase, a matrix metalloprotease (MMP), me B, and combinations thereof. 60. The multispeciflc polypeptide construct of embodiment 59, wherein the protease is granzyme B. 61. The multispeciflc polypeptide construct of any of embodiments 52-60, wherein the cleavable linker comprises an amino acid sequence of the general formula P4 P3 P2 P1 iPl’ (SEQ ID NO: 150), wherein P4 is amino acid I, L, Y, M, F, V, or A, P3 is amino acid A, G, S, V, E, D, Q, N, or Y, P2 is amino acid H, P, A, V, G, S, or T, P1 is amino acid D or E, and P1’ is amino acid I, L, Y, M, F, V, T, S, G or A. 62. The multispeciflc ptide construct of any of embodiments 52-61, n the cleavable linker comprises an amino acid sequence of the general formula P4 P3 P2 P1 iPl’ (SEQ ID NO: 151), wherein P4 is amino acid I or L, P3 is amino acid E, P2 is amino acid P or A, P1 is amino acid D; and P1’ is amino acid I, V, T, S, or G. 63. The multispeciflc polypeptide construct of any of embodiments 52-62, wherein the cleavable linker ses the amino acid sequence IEPDI (SEQ ID NO: 136), LEPDG (SEQ ID NO: 152, LEADT (SEQ ID NO: 137), IEPDG (SEQ ID NO: 138), IEPDV (SEQ ID NO: 139), IEPDS (SEQ ID NO: 140), IEPDT (SEQ ID NO: 141) or LEADG (SEQ ID NO: 153). 64. The multispeci?c polypeptide construct of any of embodiments 52-63, wherein the cleavable linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:22, 105-112, 136-141, 148,150-153. 65. The multispeci?c polypeptide construct of embodiment 59, n the protease is matiiptase. 66. The multispeci?c polypeptide construct of any of embodiments 52-65, wherein: the cleavable linker comprises the sequence P1QARL(A/V) (SEQ ID NO: 154), wherein P1 is any amino acid; or the cleavable linker comprises the sequence RQAR(A/V) (SEQ ID NO: 155). 67. The peci?c polypeptide construction of any of embodiments 52—66, wherein the cleayable linker comprises the ce RQARV (SEQ ID NO: 156). 68. The multispeci?c polypeptide construct of any of embodiments 52-67, wherein the cleavable linker comprises an amino acid sequence ed from the group ting of SEQ ID NOs: 23, 154-156. 69. The multispeci?c polypeptide uct of ment 59, wherein the protease is an MlVEP. 70. The peci?c polypeptide construct of embodiment 69, wherein the MMP is MlVIP-2. 71. The multispeci?c ptide construct of any of embodiments 52—70, wherein the cleavable linker comprises the general formula P3 P2 P1 1 P1’ (SEQ ID NO: 157), wherein P3 is P, V or A; P2 is Q or D, P1 is A or N, and P1" is L, I or M. 72. The multispeci?c polypeptide uct of any of embodiments 52—71, wherein the cleavable linker comprises the general formula P3 P2 P1 1 P1’ (SEQ ID NO: 158), wherein P3 is P, P2 is Q or D, P1 is A or N, and P1’ is L or I. 73. The multispeci?c polypeptide construct of any of embodiments 52—72, wherein the cleavable linker comprises the sequence PAGL (SEQ ID NO:24). 74. The multispeci?c polypeptide construct of any of embodiments 52-73, wherein the ble linker comprises an amino acid sequence selected from the group ting of SEQ ID NOsz22-31, 104-114, 117-118, 4, 148, 150-158. 75. The multispeci?c polypeptide construct of any of embodiments 45-74, wherein the multispeci?c polypeptide construct comprises at least (i) a ?rst polypeptide comprising the ?rst Fc polypeptide of the heterodimeric Fc region, the linker and the VH domain of the anti-CD3 antibody or antigen binding fragment; and (ii) a second polypeptide sing the second Fc polypeptide of the heterodimeric Fc region, the linker and the VL domain of the anti-CD3 antibody or antigen binding fragment n one or both of the ?rst and second polypeptide comprise at least one antigen-binding domain that binds to a tumor associated antigen (TAA). 76. The multispecific ptide construct of any of embodiments 1-75, wherein one or more antigen binding domain that binds TAA results in monovalent, bivalent, trivalent, or tetravalent binding to the TAA. 77. The multispecific polypeptide construct of embodiment 75, wherein only one of the ?rst or second polypeptide comprises the at least one antigen-binding domain that binds a TAA. 78. The multispecific polypeptide construct of embodiment 75 or embodiment 77, wherein the at least one antigen binding domain is positioned amino-terminally relative to the Fc region and/or is positioned carboxy-terminally ve to the CD3 binding region of one of the first or second ptide of the multispecific ptide construct. 79. The multispecific polypeptide construct of embodiment 75 or embodiment 77, n the at least one antigen binding domain is positioned amino-terminally relative to the Fc region of the pecific construct and the second antigen binding domain is positioned carboxy-terminally relative to the CD3 binding region of the multispecific uct. 80. The multispecific polypeptide construct of any of embodiments 1-79, wherein the antigen binding domain, or independently each of the antigen binding domains, comprises an extracellular domain or binding fragment thereof of the native cognate binding partner of the TAA, or a t thereof that exhibits binding activity to the TAA. 81. The multispecific polypeptide construct of any of ments 1—79, wherein the antigen binding domain, or independently each of the n g domains, is an antibody or antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, an Fv fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. 82. The multispecific polypeptide construct of embodiment 81, n the antibody or antigen-binding fragment thereof is a Fv, a scFv, a Fab, a single domain antibody , a VNAR, or a VHH. 83. The multispecific polypeptide construct of embodiment 81 or embodiment 82, wherein the antibody or antigen-binding fragment is an sdAb. 84. The multispecific polypeptide construct of embodiment 83, wherein the sdAb is a human or humanized sdAb. 85. The multispecific polypeptide construct of embodiment 83 or embodiment 84, wherein the sdAb is VHH, VNAR, an engineered VH domain or an engineered VK domain. 86. The multispecific polypeptide construct of embodiment 81 or embodiment 82, n the antibody or antigen-binding fragment thereof is an scFv. 87. The multispecific polypeptide construct of embodiment 81 or embodiment 82, wherein the dy or antigen-binding fragment thereof is a Fab. 88. The multispecific polypeptide construct of embodiment 87, wherein the multispeci?c polypeptide construct comprises: (i) a first polypeptide comprising the ?rst PC polypeptide of the heterodimeric Fc region, the linker and the VH domain of the anti-CD3 antibody or antigen binding fragment, (ii) a second polypeptide sing the second Fc polypeptide of the heterodimeric Fc region, the linker and the VL domain of the anti-CD3 antibody or antigen g fragment, and (iii) a third polypeptide comprising a VH-CHl (Fd) or VL-CL of a Fab antibody fragment that binds to a tumor—associated antigen, wherein the ?rst and/or second polypeptide further comprises the other of the VH-CHl (Fd) or VL-CL of the Fab antibody fragment. 89. The multispecific polypeptide uct of embodiment 88, wherein only one of the ?rst or second polypeptide comprises the other of the VH—CHl (Fd) or VL-CL of the Fab antibody fragment. 90. The multispecific polypeptide construct of ment 89, wherein both the ?rst or second polypeptide comprises the other of the VH-CHl (Fd) or VL-CL of the Fab antibody fragment. 91. The multispecific polypeptide construct of embodiment 89 or embodiment 90, wherein the other of the VH-CHl (Fd) or VL-CL of the Fab antibody fragment is positioned amino-terminally relative to the Fc region and/or at the carboxy-terminally relative to the CD3 binding region of one of the ?rst or second polypeptide of the multispeci?c polypeptide construct. 92. The multispecific ptide construct of any of embodiments 89-91, wherein the other of the VH-CHl (Fd) or VL-CL of the Fab antibody fragment is oned terminally relative to the Fc region of the first ptide or second polypeptide and at the y-terminally relative to the CD3 binding region of the other of the ?rst or second polypeptide. 93. The pecific polypeptide construct of any of embodiments 1-92, wherein the antigen binding domain, or independently each of the antigen binding domains, binds to a tumor antigen ed from among FA-3, 5T4, Alpha-4 integrin, Alpha-V integrin, alpha4beta1 integrin, alpha4beta7 integrin, AGR2, Anti-Lewis-Y, Apelin J or, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CD11a, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD40L, CD41, CD44, CD44V6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD137, CD138, CD166, CD172A, CD248, CDH6, CEACAMS (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, en, Cripto, CSFR, CSFR—l, CTLA-4, CTGF, CXCLlO, CXCL13, CXCRl, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL3, DLL4, DPP-4, DSG1, EDA, EDB, EGFR, EGFRViii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein ofRSV, FAP, FGF—2, FGF8, FGFRl, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FROL), GAL3ST1, G—CSF, G—CSFR, GD2, GITR, GLUT1, GLUT4, GM—CSF, GM—CSFR, GP Hb/IIIa receptors, Gp130, GPIIB/IIIA, GPNlV?3, GRP78, eu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, ha, a, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGFlR, IL1B, IL1R, 1L2, IL11, 1L12, 1L12p40, 1L—12R, beta1, IL13, IL13R, IL15, IL17, IL18, IL21, ILZ3, IL23R, ILZ7/IL27R(wsx1), IL29, IL-31R, 1L3 1/IL31R, ILZR, 1L4, IL4R, 1L6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISSl-R, LAG-3, LLF—R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUCl, Mucin-16 (MUC16, CA-125), Na/K ATPase, NGF, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, OX-40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-l, PD-Ll, PD-L2, Phosphatidyl-serine, PlGF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, STEAPl, STEAP2, TAG-72, TAPA1,TEM-8, TGFbeta, TIGIT, TIM-3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, INFR, TNFRS12A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAPl, VCAM-l, VEGF, VEGF-A, , VEGF-C, VEGF-D, VEGFRI, , VEGFR3, VISTA, WISP-l, , and WISP-3. 94. The multispeci?c polypeptide construct of any of embodiments 1-93, wherein multispeci?c antigen binding domain comprises at least a ?rst antigen binding domain and a second antigen binding domain, wherein the ?rst antigen binding domain and second antigen binding domain bind to the same TAA.

WO 91438 2018/027195 95. The multispeci?c polypeptide construct of embodiment 94, wherein the ?rst antigen binding domain and the second n binding domain binds a different epitope of the same TAA. 96. The multispeci?c polypeptide construct of embodiment 94, wherein the ?rst antigen binding domain and the second antigen binding domain binds the same epitope of the same TAA. 97. The multispeci?c polypeptide construct of any of embodiments 1-96, wherein multispeci?c n binding domain comprises at least a ?rst antigen binding domain and a second antigen binding domain wherein the ?rst antigen binding domain and the second antigen binding domain bind a different TAA. 98. The peci?c polypeptide uct of any of embodiments 5—97, wherein the multispeci?c ptide construct comprises a ?rst linking peptide (LPl) n the ?rst n binding domain and the Fc region. 99. The multispeci?c polypeptide construct of any of embodiments 5—98, wherein the multispeci?c polypeptide construct comprises a second linking peptide (LP2) between the CD3 binding region and the second antigen binding domain. 100. The multispeci?c polypeptide construct of any of embodiments 5—99, wherein the multispeci?c polypeptide construct comprises a ?rst linking peptide (LPl) between the ?rst antigen binding domain and the Fc region and a second linking e (LP2) between the CD3 binding region and the second antigen binding domain, and wherein the multi speci?c polypeptide construct has the structural ement from N—terminus to C- terminus as follows: ?rst antigen binding domain — LP1- Fc region —linker —CD3 binding region — LP2 — second antigen binding domain. 101. The multispeci?c ptide construct of embodiment 100, wherein the linker is a cleavable linker. 102. The multispeci?c polypeptide construct of embodiment 100 and embodiment 101, n the two linking peptides are not identical to each other. 103. The multispeci?c polypeptide construct of any of embodiments 98-102, n LPl or LP2 is independently a peptide of about 1 to 20 amino acids in length. 104. The multispeci?c polypeptide of embodiment 103, wherein LPl or LP2 ndently comprise a peptide that is or comprises any Gly-Ser linker as set forth in SEQ ID NOs:10-13,119,135,147,149 or GGS. 105. The multispeci?c polypeptide construct of any of embodiments 41-104, wherein the anti-CD3 antibody or antigen binding fragment is an FV antibody fragment. 106. The pecific polypeptide construct of embodiment 105, wherein the EV antibody fragment comprises a disulfide stabilized anti-CD3 binding FV fragment (dst). 107. The multispecific polypeptide construct of any of embodiments 41-106, wherein the anti-CD3 antibody or antigen-binding nt comprises a VH CDR1 comprising the amino acid sequence TYAMN (SEQ ID NO: 16); a VH CD2 comprising the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17), a VH CDR3 sing the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDR1 comprising the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 19), a VL CDR2 comprising the amino acid sequence GTNKRAP (SEQ ID NO: 20), and a VL CDR3 sing the amino acid sequence ALWYSNLWV (SEQ ID NO: 21). 108. The multispecific polypeptide construct of embodiment 106 or embodiment 107, wherein the anti-CD3 dsFV comprises: a VH having the amino acid sequence of any of SEQ ID NOS: 14 and 32-62 or a sequence that ts at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOS: 14 and 32-62, and a VL having the amino acid sequence of any of SEQ ID NOS: 15 and 63-81 or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOS: 14 and 32-62. 109. The multispecific polypeptide uct of any of embodiments 106-108, wherein the anti—CD3 dsFV comprises the amino acid sequence of SEQ ID NO: 14 and the amino acid sequence of SEQ ID NO: 15. 110. The multispecific polypeptide construct of any of ments 102-104, wherein the anti—CD3 dsFV comprises the amino acid sequence of SEQ ID NO: 44 and the amino acid sequence of SEQ ID NO: 72. 111. The multispecific polypeptide construct of any of embodiments 1-109, n the multispeci?c polypeptide construct is conjugated to an agent. 112. The multispecific polypeptide construct of embodiment 111, wherein the agent is a therapeutic agent, an oplastic agent, a toxin or fragment thereof, a detectable moiety or a diagnostic agent. 113. The multispecific polypeptide construct of embodiment 112, wherein the agent is conjugated to the multispecific polypeptide construct Via a linker. 114. A cleotide(s) encoding the multispeci?c polypeptide ucts of any of embodiments 1-113. 115. A polynucleotide encoding a ptide chain of any of the multispeci?c polypeptide constructs of any of embodiments 1-113. 116. A polynucleotide, compiising a ?rst nucleic acid sequence encoding a ?rst polypeptide of a peci?c construct of any of embodiments 1-115 and a second nucleic acid sequence encoding a second polypeptide of the multispeci?c construct, wherein the ?rst and second nucleic acid sequence are separated by an internal ribosome entry site (IRES), or a nucleic acid encoding a self-cleaving e or a peptide that causes ribosome skipping. 117. The polynucleotide of embodiment 116, wherein the ?rst nucleic acid sequence and second nucleic acid sequence are operably linked to the same promoter. 118. The polynucleotide of embodiment 116 or embodiment 117, wherein the multispeci?c ptide construct ses a third polypeptide chain, and the polynucleotide further comprises a third c acid encoding the third ptide of the multispeci?c uct. 119. The polynucleotide of embodiment 118, wherein the third nucleic acid is separated from the ?rst and/or second polypeptide by an internal ribosome entry site , or a nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping and/or the third nucleic acid sequence is operably linked to the same promoter as the ?rst and/or second nucleic acid sequence. 120. The polynucleotide of any of embodiments 116-119, wherein the nucleic acid encoding a self—cleaving peptide or a peptide that causes ribosome skipping is selected from a T2A, a P2A, a E2A or a F2A. 121. A vector, sing the polynucleotide of any of embodiments 114-120. 122. The vector of embodiment 121 that is an expression vector. 123. The vector of embodiment 121 or 122 that is a viral vector or a eukaryotic vector, optionally wherein the eukaryotic vector is a mammalian vector. 124. A cell, comprising polynucleotide or polynucleotides of—any of embodiments 0, or a vector or vectors of any of embodiments 121-123. 125. The cell of embodiment 124, wherein the cell is recombinant or isolated. 126. The cell of embodiment 125, wherein the cell is a mammalian cell. 127. The cell of embodiment 126, n the cell is a HEK293 or CHO cell. 128. A method of producing a multispeci?c polypeptide construct, the method sing introducing into a cell a polynucleotide or polynucleotides of any of embodiments 114-120 or a vector or vectors of any of embodiments 121-123 and ing the cell under conditions to produce the multispeci?c polypeptide construct. 129. A method of producing a multispecific polypeptide construct, the method comprising culturing the cell of any of embodiments 124-127 under ions in which the multispeci?c polypeptide is produced by the cell. 130. The cell of embodiment 128 or 129, wherein the cell is a mammalian cell. 131. The cell of ment 130, wherein the cell is a HEK293 or CHO cell. 132. The method of embodiment 128 or embodiment 129, further comprising isolating or purifying the multispeciflc polypeptide construct from the cell. 133. The method of any of embodiments 128-132, wherein the multispeci?c ptide construct is a dimer. 134. A multispecific polypeptide construct produced by the method of any of embodiments 128-133. 135. A pharmaceutical ition sing the peci?c ptide construct of any of embodiments 1-113 or embodiment 134 and a pharmaceutically acceptable carrier. 136. The pharmaceutical composition of embodiment 135 that is sterile. 137. A method of stimulating or inducing an immune response, the method comprising contacting a target cell and a T cell with the multispeci?c polypeptide construct of any of embodiments 1-113 or embodiment 134 or the pharmaceutical composition of embodiments 109 or embodiment 110, said target cell expressing a tumor associated antigen ized by the multispeci?c polypeptide construct. 138. The method of embodiment 137, wherein the target cell is a tumor cell expressing the tumor associated n (TAA). 139. The method of embodiment 138 or embodiment 138, wherein the multispeci?c polypeptide construct comprises a cleavage linker that functions as a substrate for a protease and the inducing or stimulating the immune response is increased in the presence of the protease. 140. The method of embodiment 139, wherein the protease is produced by an immune effector cell, by a tumor, or by cells present in the tumor nVironment. 141. The method of embodiment 139 or embodiment 140, wherein the protease is produced by an immune or cell and the immune effector cell is an activated T cell, a natural killer (NK) cell, or an NK T cell. 142. The method of embodiment 141, wherein the immune effector cell is in proximity to cells that express the antigen. 143. The method of any of embodiments 2, wherein the protease is ed by a tumor that is in proximity to cells that express the TAA in a tissue and/or ed by a tumor that is co-localized with TAA in a , and wherein the protease cleaves the cleavable linker in the multispecific polypeptide construct when the multispecific polypeptide construct is exposed to the se. 144. The method of any of embodiments 137-143, wherein the protease is ed from among matriptase, a matrix metalloprotease (MMP), granzyme B, and combinations thereof. 145. The method of embodiment 144, n the protease is granzyme B. 146. The method of any of ments 137-145, wherein the ting is carried out ex vivo or in vitro. 147. The method of any of embodiments 137-145, n the contacting is carried out in vivo in a subject. 148. A method of stimulating or inducing an immune response in a subject, the method comprising administering, to a subject in need thereof, a therapeutically effective amount of the multispecific conjugate of any of embodiments 1-113 or embodiment 134 or the ceutical composition of embodiments 109 or embodiment 110. 149. The method of embodiment, 137-147, and 148, which increases cell-mediated immunity. 150. The method of any of embodiments 137—147, 148, and 149, which increases T-cell activity. 151. The method of any of embodiments 137-147, 148-150, which increases cytolytic T—cell (CTL) activity. 152. The method of any of embodiments 137-147, 148-151, wherein the immune response is increased against a tumor or cancer. 153. The method of any of embodiments 7, 148-152, wherein the method treats a disease or condition in the subject. 154. A method of treating a disease or condition in a subject, the method comprising administering, to a subject in need thereof, a therapeutically effective amount of the multispecific conjugate of any of embodiments l-113 or the pharmaceutical composition of embodiments 135 or embodiment 136. 155. The method of embodiment 153 or embodiment 154, wherein the disease or condition is a tumor or a cancer. 156. The method of any of embodiments 147, 148-155, wherein said subject is a human. 157. A multispeci?c polypeptide construct that, in an inactive state, comprises a ?rst component and a second component, wherein the ?rst and second components are operably linked, wherein each of the ?rst and second components comprises an antigen binding domain that binds a tumor associated antigen (TAA), wherein the ?rst component comprises an Fc region, wherein the second component comprises a CD3-binding region, and wherein the ?rst and second components are coupled by a ble linker. 158. The multispeci?c polypeptide of embodiment 157, wherein, in an inactive state, binding of the nding region to CD3 is inhibited or substantially reduced. 159. The multispeci?c polypeptide of embodiment 157, n in an activated state, the ?rst and second components are not operably linked. 160. The multispeci?c polypeptide of embodiment 157, wherein in an activated state, the second component binds the epsilon chain of CD3 (CD38) and a tumor ated antigen (TAA). 161. A multispeci?c polypeptide construct that, in an activated state binds the epsilon chain of CD3 (CD38) and a tumor associated n (TAA), the multispeci?c polypeptide construct comprising: a ?rst antigen binding domain that binds a ?rst epitope on the TAA; an antibody or antigen g fragment thereof that binds to CD38, an globulin Fc polypeptide region; a second antigen binding domain that binds a second epitope on the TAA; and a cleavable linker coupled to the immunoglobulin Fc polypeptide region and the second antigen binding domain, wherein the cleavable linker is a polypeptide that functions as a substrate for a protease. 162. The multispeci?c polypeptide construct of embodiment 161, wherein the protease is ed by an immune effector cell. 163. The multispeci?c polypeptide construct of embodiment 162, n the immune effector cell is in proximity to cells that express the TAA. 164. The multispeci?c polypeptide construct of any one of embodiments 161 to 163, wherein the protease cleaves the cleavable linker in the multispeci?c polypeptide construct when the multispeci?c polypeptide construct is exposed to the protease. 165. The multispeci?c polypeptide construct of ment 161, wherein the protease is produced by a tumor that is in ity to cells that express the TAA in a tissue and/or ed by a tumor that is co-localized with TAA in a tissue, and n the protease cleaves the cleavable linker in the multispeci?c polypeptide construct when the multispeci?c polypeptide construct is exposed to the protease. 166. The multispeci?c polypeptide construct of embodiment 161, wherein the cleavable linker is a polypeptide of up to 25 amino acids in length. 167. The multispeci?c polypeptide construct of embodiment 161, n the cleavable linker is a substrate for matriptase, a matrix metalloprotease (MMP), granzyme B, and combinations f. 168. The multispeci?c polypeptide construct of embodiment 161, wherein the cleavable linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 24—3 1. 169. The multispeci?c ptide construct of embodiment 161, wherein each of the ?rst antigen binding domain and the second antigen binding domain is an antibody or n—binding fragment thereof selected from the group consisting of a Fab nt, a F(ab')z nt, an FV fragment, a scFV, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. 170. The multispeci?c fusion polypeptide of embodiment 169, wherein the dy or antigen-binding fragment thereof is a FV, a scFV, a Fab, a single domain antibody (sdAb), a VNAR, or a VHH. 171. The multispeci?c fusion polypeptide of embodiment 169, wherein the antibody or antigen-binding nt is an sdAb. 172. The multispeci?c fusion polypeptide of embodiment 171, wherein the sdAb is a human or humanized sdAb. 173. The multispeci?c fusion polypeptide of embodiment 171, wherein the sdAb is VHH, VNAR, an engineered VH domain or an engineered VK domain. 174. The multispeci?c fusion polypeptide of embodiment 161, wherein the immunoglobulin Fc region polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-2. 175. The multispeci?c fusion polypeptide of ment 174, wherein the immunoglobulin Fc region polypeptide comprises at least one modi?cation to enhance FcyR binding. 176. The multispeci?c fusion polypeptide of embodiment 175, wherein the modi?cation is modi?cation at Ser239 or Ile332. 177. The multispeci?c fusion polypeptide of embodiment 174, wherein the globulin Fc glycosylation is modi?ed to enhance FcyR binding as compared to an unmodi?ed Fc region. 178. The multispeci?c fusion polypeptide of embodiment 177, wherein the immunoglobulin Fc glycosylation lacks or has reduced fucose content. 179. The multispeci?c fusion polypeptide of embodiment 174, wherein the globulin Fc region polypeptide ses at least one ation to induce heterodimerization. 180. The multispeci?c fusion polypeptide of embodiment 179, wherein the modi?cation is at a position selected from the group consisting of Thr366, Leu368, and Tyr407, and combinations f. 181. The multispeci?c fusion polypeptide of embodiment 180, wherein the modi?cation is selected from the group consisting of Thr366Ser, Leu368Ala, Tyr407Val, and combinations thereof. 182. The peci?c fusion polypeptide of embodiment 181, further comprising a ation of a non—cysteine residue to a cysteine residue at a position selected from the group consisting of Ser3 54, Y349, and combinations thereof. 183. The multispeci?c fusion polypeptide of embodiment 181, further comprising a modi?cation at residue Ile235. 184. The multispeci?c fusion polypeptide of embodiment 183, n the modi?cation is Ile23 5Arg. 185. The peci?c fusion polypeptide of embodiment 174, wherein the immunoglobulin Fc region polypeptide comprises a modi?cation at residue Ile235. 186. The peci?c fusion polypeptide of embodiment 185, wherein the modi?cation is Ile23 5Arg. 187. The multispeci?c fusion polypeptide of embodiment 174, wherein the immunoglobulin Fc region polypeptide comprises at least one ation to enhance FcRn binding. 188. The multispeci?c fusion polypeptide of embodiment 187, wherein the modi?cation is at a position selected from the group ting of Met252, Ser254, Thr256, Met428, Asn434, and combinations thereof. 189. The multispeci?c fusion polypeptide of embodiment 188, wherein the modi?cation is at a position selected from the group consisting of Met252Y, Ser254T, Thr256E, Met428L, Met428V, Asn434S, and combinations thereof. 190. The multispeci?c fusion polypeptide of embodiment 187, n the modi?cation is at position Met252 and at position Met428. 191. The multispeci?c fusion polypeptide of embodiment 190, wherein the ation is Met252Y and M428L. 192. The multispeci?c fusion polypeptide of embodiment 190, wherein the modi?cation is Met252Y and M428V. 193. The multispeci?c polypeptide construct of embodiment 161, wherein the peci?c polypeptide construct ses a ?rst linking peptide (LP1) between the ?rst n binding domain and the immunoglobulin Fc ptide region. 194. The multispeci?c polypeptide construct of ment 161, n the multispeci?c polypeptide construct ses a second g peptide (LP2) between the anti-CD3 binding domain and the second antigen binding domain. 195. The multispeci?c polypeptide construct of embodiment 161, wherein the multispeci?c polypeptide construct comprises a ?rst linking peptide (LP1) between the ?rst antigen binding domain and the immunoglobulin Fc polypeptide region and a second g peptide (LP2) between the anti-CD3 binding domain and the second antigen binding domain, and wherein the multispeci?c polypeptide construct in the uncleaved state has the structural arrangement from N—terminus to C-terminus as follows: ?rst antigen binding domain — LP1- immunoglobulin Fc polypeptide linker region — cleavable linker — anti-CD3 binding domain — LP2 — second antigen binding domain. 196. The multispeci?c polypeptide construct of embodiment 195, wherein the two linking peptides are not identical to each other. 197. The multispeci?c polypeptide construct of embodiment 195, n each of LP1 and LP2 is a peptide of about 1 to 20 amino acids in length. 198. The peci?c polypeptide construct of embodiment 161, wherein the antibody or antigen binding fragment thereof that binds to CD38 is an FV antibody fragment. 199. The multispeci?c polypeptide construct of embodiment 198, wherein the FV dy fragment comprises a disul?de stabilized anti-CD3 binding FV fragment (dst). 200. The peci?c polypeptide uct of embodiment 199, wherein anti- CD3 dsFV comprises a VH CDRl comprising the amino acid sequence TYAMN (SEQ ID NO: 16), a VH CD2 comprising the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17), a VH CDR3 comprising the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDRl comprising the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 19), a VL CDR2 comprising the amino acid sequence GTNKRAP (SEQ ID NO: 20), and a VL CDR3 comprising the amino acid sequence ALWYSNLWV (SEQ ID NO: 21). 201. The multispeci?c polypeptide construct of embodiment 198, wherein the VH and VL that comprise the anti-CD3 binding FV are linked to opposite sides of a heterodimeric 202. The multispeci?c ptide construct of embodiment 200, n anti- CD3 dsFV comprises the amino acid sequence of SEQ ID NO: 14. 203. The multispeci?c polypeptide construct of embodiment 200, wherein anti— CD3 dsFV comprises the amino acid sequence of SEQ ID NO: 15. 204. The multispeci?c polypeptide construct of embodiment 200, wherein anti- CD3 dsFV comprises the amino acid ce of SEQ ID NO: 14 and the amino acid sequence of SEQ ID NO: 15. 205. The multispeci?c polypeptide construct of embodiment 204, wherein anti- CD3 dsFV comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 32-81. 206. The multispeci?c polypeptide construct of embodiment 204, wherein anti- CD3 dsFV comprises a combination of an amino acid sequence selected from the group consisting of SEQ ID NO: 32-62 and an amino acid sequence selected from the group consisting of SEQ ID NO: 63-81. 207. The multispeci?c polypeptide uct of any one of embodiments 1 to 206, wherein the multispeci?c polypeptide construct is conjugated to an agent. 208. The peci?c polypeptide uct of embodiment 207, wherein the agent is a therapeutic agent, an antineoplastic agent, a toxin or fragment f, a able moiety or a diagnostic agent. 209. The multispeci?c polypeptide construct of embodiment 207, wherein the agent is conjugated to the multispeci?c polypeptide construct Via a linker. 210. A pharmaceutical composition comprising the multispeci?c polypeptide construct of any of one of embodiments 1 to 209 and a carrier. 211. A method of treating or alleviating a symptom of a clinical indication associated with a disorder in a subject, the method comprising stering the multispeci?c polypeptide uct of any one of embodiments 157 to 209 or the pharmaceutical composition of embodiment 210 to a subject in need thereof in an amount suf?cient to alleviate the symptom of the clinical indication associated with the er. 212. The method of embodiment 211, wherein said subject is a human. 213. The method of embodiment 211, wherein the disorder is cancer.

VI. EXAMPLES The ing examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLE 1. Method of producing constrained CD3 binding ns Example 1 bes the generation and expression of multispeci?c polypeptide constructs containing a CD3 binding region that exhibits constrained CD3 g. The multispeci?c constructs were generated in various con?gurations, as shown in FIGS. 4A-4C, FIGS. SA-SE, FIGS. 6A-6B, and to contain a dimeric Fc region of an immunoglobulin coupled by a linker (e.g. a cleavable linker) to the CD3 binding region, and one or more antigen binding domain that binds a tumor associated antigen (TAA) positioned terrninally relative to the Fc region and/or carboxy-terminally relative to the CD3 g region of the multispeci?c polypeptide construct. Exemplary representative constructs with different TAA antigen binding domains and linkers were generated.

Polynucleotides encoding at least a ?rst polypeptide chain and a second ptide chain of the dimeric multispeci?c polypeptide construct were generated and cloned into a plasmid for expression. The ?rst polypeptide chain generally included in order, from the N—terminus to C-terminus, an Fc hole polypeptide (e.g. set forth in SEQ ID N083); a cleavable linker, such as one containing one or more substrate recognition sites for a protease, and a variable light (VL) domain of a dst anti—CD3 antibody (e.g. set forth in SEQ ID NO:72). The second ptide chain generally included in order, from the N- terminus to C-terminus, an Fc knob polypeptide (e.g. set forth in SEQ ID NO: 82), the same cleavable linker as the ?rst polypeptide chain, and a variable heavy domain of a dst anti— CD3 antibody (e. g. set forth in SEQ ID NO:44). Except as noted, the exemplary cleavable linker, GGSGGGGIEPDIGGSGGS (SEQ ID NO: 105) containing a ate recognition site for granzyme B was used in exemplary constructs. A similar linker, TGGSGGGGIEPDIGGSGGS (SEQ ID NO: 148), was used in exemplary construct cx1547 containing FRd. For the exemplary construct cx3 09, the exemplary cleavable linker GSPAGLEADGSRQARVGS (SEQ ID NO: 166) was used. Similar constructs can be generated using other dimeric Fc con?gurations, including other knob-into-hole con?gurations, such as any as described; other linkers, including other cleavable linkers, particularly polypeptide linkers that include a substrate recognition site for a protease, such as granzyme B, matriptase and/or an MMP, and other nding regions, including other anti-CD3 antibodies, including dst or other monovalent fragments, or other TAA antigen- g nts, such as scFv, sdAb or Fab formats.

In some cases, r constructs were generated, except containing a non- cleavable linker. The non—cleavable linker included linkers ranging from 3—18 amino acids in size. Examples of non-cleavable linker used in exemplary generated molecules were GGS (e. g. contained in exemplary construct ), GGSGGS (SEQ ID NO:10, contained in exemplary construct cx1357), GGSGGSGGS (SEQ ID NO:11, contained in exemplary construct cx1358), GGSGGSGGSGGS (SEQ ID NO: 12, contained in exemplary construct cx1359), GGSGGSGGSGGSGGS (SEQ ID NO:13, ned in ary construct ), and GGGGGSGGGGGSGGGGGS (SEQ ID NO:119) or GGSGGGGSGGGGSGGGGS (SEQ ID NO: 147, contained in exemplary construct cx681).

One or both of the polypeptide chains additionally encoded one or more TAA antigen binding domain amino terminal to the Fc domain and/or carboxy terminal to the CD3 binding region, in various con?gurations. When the TAA was provided as a single chain nt, e.g. sdAb or scFv, the TAA antigen binding domain was linked at the N-terminus to one or both polypeptide chains of the Fc heterodimer (e. g. hole and/or knob) by a peptide linker, e. g. PGGGG (SEQ ID NO: 102) and/or was linked at the C-terminus to one or both s (e.g. VH and/or VL) of the CD3 binding region by a e linker, e.g. GGGG (SEQ ID NO: 103). Other similar peptide s can be employed. When the TAA was provided as a Fab, such as in the exemplary construct designated cx3313 or cx3315, an additional polynucleotide encoding the light chain of the Fab was cloned into a plasmid. In this example, the encoded polypeptides included one or more polypeptide chains in which the VH-CHl (Fd) of the Fab was linked at the N—terminus of one or both polypeptide chains of the Fc heterodimer and/or linked at the C-terminus of one or both domains of the CD3 binding region, similar to above. The third polynucleotide encoded the VL-CL of the Fab.

Any n binding domain that binds to a TAA can be employed in the ed multispeci?c polypeptide constructs. ary generated proteins contained an antigen binding domain that binds one of the following tumor ated antigens: Folate Receptor Alpha (FROL), B7H3, EGFR, 5T4, CD20, and DLL3. The ted proteins were either composed of VH and VL sequences assembled as Fabs or scFvs, or were generated to contain the binding domains as single domain antibodies (sdAbs). Various TAA-binding domains where used herein including sdAb, scFv and Fab, including from the following sources: cMet sdAb as set forth in SEQ ID NO: 123 (US. Patent No. 6,884); B7H3 Fab and scFv as set forth in SEQ ID NOS: 127 and 128 and scFv as set forth in SEQ ID NO: 124 (PCT Pub. No.

WO2017030926), 5T4 scFv as set forth in SEQ ID NO: 129, 130, 167, and 168 (US. Patent No. USS,044,178), DLL3 scFv as set forth in SEQ ID NO: 189 (US. Pub. No. US 2017/0037130), CD20 GA101 as set forth in SEQ ID NO: 125, 189, and 190 (US. Pub. No.

US 2005/0123 546). Multispecific polypeptide ucts were generated containing 1, 2, 3 or 4 TAA n binding domain, such as to e for monovalent, bivalent, trivalent, or tetravalent binding. In some cases, the TAA antigen binding domains were the same. In some cases, the TAA antigen binding s were different, such that the generated multispecific polypeptide constructs exhibited specificity for at least two different TAAs, to different epitopes of the same TAA or the same epitopes of the same TAA. For example, exemplary dual targeted multispecific polypeptide constructs were generated containing an antigen binding domain with speci?city for EGFR and cMet (see e.g. and exemplary constructs designated cx2973, cx2979 and cx2977). Further, exemplary multispecific polypeptide constructs were generated containing different TAA antigen binding domains speci?c for the same epitope of B7H3 or for two different epitopes of B7H3 (e. g. and exemplary constructs designated cx2846 and cx3 094, respectively) or for the same epitope of 5T4 (e.g. ary construct cx3252).

Polynucleotides were generated to encode ptide chains of exemplary multispecific polypeptide constructs designated cx1547, cx309, cx1356, , cx1358, cx1359, cx1360, cx681 and cx1762 (each targeting FROL), cx2513 and cx3030 (each targeting EGFR), cx2973, cx2979, cx2977 (each targeting cMET and EGFR), cx3095, cx2846, cx3094, cx33 14 and cx3313 (each ing B7H3), cx3315, cx3265 and cx3262 (each targeting 5T4), cx3309 (targeting CD20); and cx3308 (targeting DLL3), including constructs as depicted in FIGS. 3, 4A(t0p panel)—4C, 5A-5E, 6A-6B, 7, 8, and 9. The constructs were generated to contain a cleavable or eavable linker.

Separate plasmids encoding each chain of the heterodimeric constrained CD3 binding n were transiently transfected at an equimolar ratio into mammalian cells (either HEK293 or CHO) using polyethylenimine. Recombinant protein secreted into the supernatant was collected after 3-7 days, and puri?ed by protein A chromatography, followed by either preparative size exclusion chromatography (SEC) or flow-through hydrophobic ction chromatography (HIC). Heterodimeric protein was selectively puri?ed owing to a mutation designed into one chain of the heterodimeric PC at position 1253R or H43 5R (usually the hole-Fc) such that it did not bind protein A. The second chromatography step on SEC (AKTA with ex-200 resin) or FT-HIC (AKTA with butyl/phenyl sepharose) was used to remove undesired cross-paired species containing two dimeric ch that were more hydrophobic and twice the expected molecular weight.

The method favored production of dimeric multispecific polypeptide constructs, containing properly paired species of heterodimeric Fc and the disul?de stabilized anti-CD3 Fv as described (anti-CD3 VH with the on G44C as set forth in SEQ ID NO: 44 and VL with the mutation GlOOC as set forth in SEQ ID NO: 72). ed heterodimeric constrained CD3 binding protein was stable and did not accumulate cross—paired species upon prolonged incubation at 4°C or increased protein tration.

A shows an image of a SDS-PAGE of the FROt-targeted constrained CD3 engaging construct, , reducing (R) and non—reducing (NR) conditions (expected molecular weight ). FIGS. 10B and 10C shows a chromatogram from size-exclusion analysis of cx1547, demonstrating that a single species with a determined molecular weight of 137.9kDa was observed.

EXAMPLE 2. g to cancer cells and primary T cells by ?ow cytometry This Example describes studies assessing binding of exemplary constructs to T cells or to cancer cells. These studies were carried out in single cultures containing either only the T cells or only the cancer cells in isolation from each other. 1. Binding to Primary T cells in Cleaved and Uncleaved State Binding of an exemplary multispeci?c polypeptide construct of the disclosure, referred to herein as cx309, to CD3 on the e of primary T cells was assessed following proteolytic cleavage of its cleavable linker, GSPAGLEADGSRQARVGS (SEQ ID NO:27), which contains substrate recognition sites for tase, me B, and MMP-2. The tumor n binding domains of cx309 binds the Folate Receptor Alpha (FRoc), which is not expressed on the primary T cells.

Primary T cells were negatively enriched from PBMCs ed from healthy human donor aks. Where noted, cx309 was pre-cleaved prior to addition to cells, with cleavage con?rmed by SDS—PAGE. cally, cx309 was exposed to matriptase (A) or matrix metalloprotease 2 (MMP-Z) 1B) (cleaved) or was not exposed to protease (uncleaved). The cx309 construct, either cleaved or uncleaved, was ed onto cells or added at a , saturating concentration. Bound cx309 was detected with ?uorophore-conjugated secondary antibodies speci?c for either human PC or humanized vhh, and binding was measured by ?ow cytometry. Cells incubated with secondary antibody only served as negative controls.

As shown in A and 11B, cx309 bound to T cells after the construct was cleaved, by either matriptase or MlVEP—Z within the linker between the PC and the CD3 binding domain prior to initiation of the binding assay. No binding to T cells was observed with the uncleaved construct, showing that cx309 was able to bind to T-cells in the cleaved, 1'. e., active state but yed undetectable T—cell binding in the uncleaved form. 2. ison of Binding to T cells vs. Antigen-Expressing Cancer Cells Additional representative FRd-targeting constrained CD3 engaging ucts with various linkers between the Fc and the component of the CD3 binding domains were assessed for binding to T cells as described above and to FROL expressing cells (Ovcar-S). For the studies, lOOnM of each construct, cxl356, cx681 or cxlS47, was used. The additional representative FRd—targeting constrained CD3 engaging constructs with various linkers between the Fc and the ent of the CD3 binding domains were found to bind FRd expressing cells (Ovcar-S) (A and 12C), but lacked the ty to bind T-cells (B and 12D).

In a similar study, a representative EGFR-targeting constrained CD3 engaging construct ted as ntially described in Example 1, cx3030, was found to bind EGFR expressing cells (Colo-205) (A), yet lacked the capacity to bind T-cells (B). 400nM of each construct was used. This observation further demonstrates that the constrained CD3 engaging constructs display attenuated T-cell binding in isolation.

As shown in FIGS. 14A-14D, similar results were observed for representative B7H3-targeting constrained CD3 engagers, cx3313, cx3314 and cx3095. Cx3313 and cx3314 were generated as substantially described in Example 1 and were composed of the same B7H3 VH and VL sequences assembled as Fabs or scFvs, respectively, as described in Example 1. cx3095 ned a B7H3 binding domains that was a single domain antibody.

As shown in FIGS. 14A and 14B, representative B7H3 -targeting constrained CD3 rs were found to bind A375 cells expressing B7H3. However, as shown in FIGS. 14C and 14D, the same constructs were not able to bind to T cells in isolation. In these studies, the binding of the representative B7H3 -targeting ained CD3 engagers, cx3313, cx3314 and cx3095 was compared to Dual-affinity Re-targeting Antibody (DART)—monomeric Fc format targeting B7H3 and CD3 Fc B7H3XCD3, see e.g. W02017030926Al). The DART- Fc B7H3XCD3 contained a B7H3 sequence as set forth in SEQ ID NO: 169, 145, or 146.

Notably only the DART-Fc format was observed to allow for T-cell binding in the e of B7H3 engagement (FIGS. 14C and 14D), whereas, all formats displayed g to B7H3- expressing cells (FIGs. 14A and 14B).

In a further study, similar constrained binding was observed for representative 5T4-targeting constrained CD3 engaging constructs ted as substantially described in Example 1, cx3262 and . The 5T4 binding domains of cx3262 were generated as single domain antibodies, whereas, the 5T4 binding domain of cx33 15 was ted with an scFv derived as set forth in SEQ ID NO: 167 and 168 (See US. Patent No. USS,044,178).

Both entative 5T4-targeting constrained CD3 engaging constructs were found to bind 5T4 expressing cells (Ovcar—5) (A), yet lacked T—cell binding capacities (B). 400nM of each construct was used. This observation further demonstrates that the ained CD3 engaging constructs described herein display attenuated T-cell binding in isolation.

As shown in FIG. D, a representative CD20-targeting constrained CD3 engaging construct, cx3490, was found to bind CD20 expressing cells (Ramos), yet lacks T- cell binding capacities. lOOnM of cx3490 construct was used. The CD20 binding domains of cx3490 were scFvs derived from VH and VL of the CD20 antibody GAlOl as described in Example 1.

EXAMPLE 3. Assessment of CD3 reporter T cell activation using a reporter assay This example describes assessment of the ability of various constructs to activate a CD3 NFAT reporter Iurkat cell line in co-cultures with target antigen-expressing cells.

These assays were used to demonstrate that while T—cell binding via the CD3—binding domain is restricted or inhibited on isolated T-cells (as shown in Example 2), once the multispecifrc polypeptides provided herein are bound to a cognate antigen they are capable of engaging T- cells and mediating T-cell activation. 1. Luciferase Reporter Assay Antigen targeting constrained CD3 engaging constructs were titrated onto co- cultures of target cells and genetically engineered Jurkat cells that s an NFAT—driven luciferase reporter (Promega, USA). In this assay, ment of CD3 results in NFAT signaling and production of intracellular luciferase. Assay plates were incubated at 37°C for approximately 6 hours and then equilibrated to room temperature. Bio—Glo reagent was added to sample wells and luminescence of supematants was measured using a SpectraMax L microplate reader.

As shown in , a representative rgeting constrained CD3 engaging uct, cx309, displayed signi?cantly enhanced capacity to te T-cells when cleaved at the linker between the Fc and the CD3 binding domain. Herein, cx309 was pre-cleaved with tase prior to assay initiation. y T—cell activation was only observed in the ce of the FROL ve Ovcar-S cell line. Some T-cell activation was observed with the uncleaved cx309. This result is consistent with the ability of the constrained CD3 engaging constructs to exhibit CD3 binding upon binding to its antigen, with increased CD3 engagement after proteolytic cleavage. 2. GFP Reporter Assay n targeting constrained CD3 engaging constructs were titrated onto co- cultures of target cells and engineered Jurkat cells that express NFAT-driven green ?uorescence protein (GFP). Engagement of CD3 results in NFAT signaling and production of green fluorescence. For reporter assays utilizing adherent target cells, target cells were seeded, allowed to settle at room temperature for uniform distribution, and incubated for several hours at 37°C to permit adherence prior to addition of reporter cells and n targeting constrained CD3 engaging constructs. Assay plates were serially imaged using an IncuCyte ZOOM system and CD3 reporter cell activation was ined by measuring total green object integrated intensity.

FIGS. 18 and 19A-19D show constructs targeting Folate Receptor (FRd), A-20D shows ucts targeting EGFR or EGFR and cMET; FIGS. 21A-21B and 22A- 22F show constructs targeting B7H3; FIGS. 23A-23B and 24 show constructs targeting 5T4; shows a construct targeting CD20, and shows a construct targeting DLL3.

As shown in all ?gures, each of the tested representative constructs were able to induce antigen dependent T-cell tion in the presence of a target-expressing cells as shown by increased GFP signal. FIGS. 22A-F show that the degree of activation is similar to or, in some cases, greater than the comparator molecule DART-Fc: B7H3xCD3 described in Example 2.

Notably A-19D trate the enhanced T-cell activating capacity that is achieved when the Fc portion of the constrained CD3 engaging constructs is removed, allowing ricted T-cell engagement. The PC of these constrained CD3 engaging ucts may be removed via proteolysis if proteolytic cleavable linkers are included between the Fc and the CD3 binding domain. cx3238 ents the fully cleaved C-terminal portion and was produced via co-expression of two plasmids encoding l) the D3 VH linked to a C-terminal FRd—binding sdAb and 2) the anti-CD3 VL linked to a inal FRa-binding sdAb. This result is consistent with the oning of the Fc domain as aining the ability of the CD3 binding region to bind CD3.

EXAMPLE 4. Assessment of linker length on activity The effect of various length linkers between the PC and the ent domains (VH and VL) that comprise the CD3 binding region on T-cell activating capacity was tested using the Jurkat reporter assay described in Example 3. FROt-targeting ained CD3 engaging constructs, generated as described in Example 1 containing GlySer-based linkers of varying lengths as listed in Table E1 were used in these assays.

Table E1: Tested Linker Len_ths Linker _-s3: GGS s6: GGSGGS s9: GGSGGSGGS _s12: GGSGGSGGSGGS s15: GGSGGSGGSGGSGGS 119 gs18: GGGGGSGGGGGSGGGGGS 147 s18: GGSGGGGSGGGGSGGGGS As shown in FIGs. 27A-27F the length of the linker and T-cell activating capacity were positively correlated. T-cell activating capacity was shown to directly relate to linker length, indicating shorter linkers restrict CD3 binding to a greater extent.

Importantly, T-cell engagement of the constructs is dependent on nding, as these constructs did not demonstrate a T-cell binding capacity in isolation (e.g. solution form when unbound to target TAA) as shown above in Example 2 (A-12D). Together, these ucts displayed restricted or inhibited binding to CD3, yet were capable of activating T- cells in a target ent manner.

EXAMPLE 5. Assessment of functional activity This Example describes the assessment and characterization of the tested constrained CD3 engaging constructs in human primary T cell in vitro assays. 1. T cell-mediated cytotoxicity Target cells were fluorescently labeled with CytoID red. For cytotoxicity assays utilizing adherent target cells, target cells were seeded, allowed to settle at room temperature for uniform distribution, and incubated for several hours at 37°C to permit adherence prior to addition of other assay components. y T cells were negatively enriched from PBMCs isolated from healthy human donor leukopaks and added at a 1021-4021 T cell-to-target cell ratio. Green caspase-3/7 reagent was added, which ?uorescently labeled nuclear DNA of cells undergoing apoptosis, Antibodies were titrated onto the co-culture and assay plates were serially imaged using an IncuCyte ZOOM . Target cell death was determined by measuring total red/green overlap object area.

As shown in A-28C, cx1547, a FRd-targeted constrained CD3 engaging construct induced potent T-cell-mediated cytotoxicity of antigen ve but not antigen negative cell lines, tent with the capacity to potently induce antigen—dependent T—cell activation. Similarly, B7H3 -targeting constrained CD3 ng constructs induced potent T- ediated xicity of antigen positive but not antigen negative cell lines, as shown in A-29F and 30. These constructs displayed similar potencies to an alternative format, DART-Fc B7H3xCD3. These observations support that the n-targeted constrained CD3 format provided herein compared to other CD3 engaging formats known in the art, lack or exhibit reduced T—cell binding in isolation while maintaining potent antigen—dependent T— cell cytotoxicity inducing capacities.

As shown in A-31F, a construct representative of a C-terminal proteolytic product containing only the CD3 binding domain operably linked to TAA—binding domains, designated cx2190 (see ) displayed enhanced antigen-dependent T-cell cytotoxicity inducing capacity compared to the ved FROt-targeted constrained CD3 engaging construct, designated cxl762 (see ).

As shown in , a representative 5T4-targeted constrained CD3 engaging construct, cx3315 induced speci?c T-cell xicity toward a 5t4 expressing cell line, Ovcar—S, but not toward a 5T4 negative cell line, CCRF—CEM. 2. T cell activation To assess T cell activation, suspension cells from T cell-mediated cytotoxicity assays were collected and stained with a live/dead stain and ?uorophore—conjugated anti— CD4, anti-CD8, anti-CD25, and/or anti-CD71 antibodies. Cells were analyzed using a SONY SA3 800 al analyzer and CD4+ or CD8+ T cell activation was determined by measuring expression levels of CD25 or CD71 or percent CD25— or CD71—positive. shows T cell activation as measured by incubating cleaved cx3 O9 and uncleaved, l'.e., inactive CX3O9 constructs for 20 hours in a co-culture of T-cells and Ovcar5 cells. As shown, only cleaved cx309 was capable of mediating FRoc-dependent T-cell activation via CD3 binding. T-cell activation was monitored by ?ow tric is of the CD25% of CD4 and CD8 populations.

Additionally, a construct containing B7H3 TAA was also tested. As shown in FIG. H, B7H3 -targeting constrained CD3 engaging construct also mediated B7H3- dependent T-cell activation via CD3 binding. Similar potencies of T-cell activation by the constrained CD3 engaging constructs and the DART-Fc format were observed e the signi?cant differences in T-cell binding by these two formats (FIG. l4A-14D).

Thus, the results demonstrated that the n-target constrained CD3 engaging constructs tested induced potent antigen-dependent tion of both CD4 and CD8 T-cells. 3. T cell cytokine production [ELISA] Supernatants from T cell-mediated cytotoxicity assays were analyzed for lFNy content by sandwich ELISA (BioLegend, USA). The manufacturer’s ctions were followed and a standard curve was generated from which cytokine concentration values of supernatant samples were interpolated. s that had absorbance values below the lower limit of detection were assigned a cytokine concentration equal to half that of the lowest standard concentration. shows that a representative B7H3 —targeted constrained CD3 engaging construct was observed to elicit IFNy tion by T-cells in an antigen dependent manner. 4. T cell cytokine production [FluoroSpot] FluoroSpot membranes were coated with IFNy and IL—2 capture antibodies overnight at 4°C. Membranes were washed with PBS and antibody titrations, target cells, and PBMCs or T cells vely enriched from PBMCs were added. For target cell: PBMC co- culture, cells were seeded at a 1:20 ratio. For target cell:T cell co-culture, cells were seeded at a 1:10 ratio. Assay plates were incubated for ~24 h at 37°C and membranes were prepared according to the manufacturer’s (C.T.L.) instructions. Membranes were imaged using a CTL- ImmunoSpot S6 Universal Analyzer. Cytokine spot count was measured using uniform exposure time and intensity settings among assay wells. A-36B and 37 depicts the ability of the antigen-targeted constrained CD3 engaging construct to elicit cytokine production from s in FRd or B7H3-dependent manner, tively.

. Dissociated tumor cell killing An ovarian cancer dissociated tumor cell sample (Conversant) was stained with Zombie Red and ?uorophore-conjugated anti-CD45 and anti-EpCAM antibodies to identify tumor cells (CD45-/EpCAM+) and tumor in?ltrating immune cells (CD45+/EpCAM—) by ?ow cytometry. Unstained cells were seeded in a 96-well tissue culture plate and entative FROL-constrained CD3 engaging constructs and recombinant human IL-2 were added at 20 nM and 10 ng/mL ?nal concentrations. Following culture at 37°C for 6 days, supernatant ts were collected for analysis of IFNy content by sandwich ELISA (described above) and remaining supernatants ning non-adherent cells were removed.

Adherent cells were gently washed with PBS to remove residual suspension cells and debris, media was added to cells, and assay wells were imaged using an IncuCyte ZOOM system to visualize tumor cell con?uency. An equal volume of ter-Glo viability reagent was added to sample wells and luminescence was measured using a aMaX L microplate reader. A-38D depicts the capacity of the antigen-targeted ained CD3 ng construct to activate T-cells that had previously in?ltrated a tumor sample and mediate cytotoxicity and tumor cell elimination.

Other Embodiments While the invention has been described in conjunction with the ed description thereof, the foregoing description is intended to rate and not limit the scope of the disclosure, which is de?ned by the scope of the appended claims. Other aspects, advantages, and modi?cations are within the scope of the following claims.

SEQUENCE TABLE SEQ ID SEQUENCE DESCRIPTION PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV IgGl Fc DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP ISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVNIH EALHNHYTQK SLSLSPGK PAPGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV LHQD WLNGKEYKCK PAPI EKTISKAKGQ PREPQVYTLP PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE NNYK DSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL KSLS LSPGK PAPPVAGPSV FLFPPKPKDT PEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDISVE WESNGQPENN YKTTPPMLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK GGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFKWYV DGVEVHNAKT KPREEQYNST FRVVSVLTVL GKEY KCKVSNKALP APIEKTISKT KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESSGQPEN NYNTTPPMLD SDGSFFLYSK LTVDKSRWQQ GNIFSCSVIVIH EALHNRFTQK SLSLSPGK PAPEFLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRVVSVLTVL HQDWLNGKEY KGLP ISKA KGQPREPQVY TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE SV1V1H EALHNHYTQK SLSLSLGK 6 PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD LYSR LTVDKSRWQE GNVFSCSVNIH EALHNHYTQK SLSLSLGK EPKSSDKTHTCPPC Hinge -10 CW -11 GGSB —12 (W 13 AAA(ms I14 EVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVARI anti-CD3 HV RSKYNNYATYYADSVKDRFTISRDDSQSILYLQMNNLKTEDTAMYYCVRHG NFGNSYVSWFAYWGQGTLVTVSA I]i15QAV V | QESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGG D3 LV TNKRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNLWVFGGGT KLTVL anti-CD3 VH 17 NNYATYYADSVKD anti-CD3 VH 18 HGNFGNSYVSWFAY anti-CD3 VH 19 RSSTGAVTTSNYAN anti-CD3 VL GTNKRAP anti-CD3 VL 2 1 ALWYSNLWV anti-CD3 VL 22 Granzyme B substrate 23 Granzyme B 24 PAGL MMP substrate TGLEADGSPAGLGRQARVG Linker 26 TGLEADGSRQARVGPAGLG Linker 27 TGSPAGLEADGSRQARVGS Linker 28 GLEADGSRQARVG Linker 29 TGRQARVGLEADGSPAGLG Linker TGSRQARVGPAGLEADGS Linker 31 TGPAGLGSRQARVGLEADGS Linker 32 EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRI D 3 VH 1 YATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAV Y Y CVRHG \FG\SYVSWFAYWGQGTLVTVSS U.) U.) EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARI anti-CD3 VH2 RSKY\\YATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS U.) EVKLVESGGGLVKPGRSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARI anti-CD3 VH3 RSKY\\YATYYADSVKDRFTISRDDSKSILYLQWMKEDTAMYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS DJ EVKLVESGGGLVKPGRSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARI anti-CD3 VH4 RSKY\\YATYYADSVKDRFTISRDDSKSILYLQMBSLKTEDTAMYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS U) EVKLVESGGGLVKPGRSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARI anti-CD3 VH5 RSKY\\YATYYADSVKDRFTISRDDSKSILYLQWSLKTEDTAMYYCVRHG VSWFAYWGQGTLVTVSS U.) EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMI\WVRQAPGKGLEWVSRI anti-CD3 VH6 RSKY\\YATYYADSVKGRFTISRDDSKNTLYLQM\SLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS U.) EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVGRI anti-CD3 VH7 RSKY\\YATYYADSVKGRFTISRDDSKNTLYLQM\SLRAEDTAVYYCVRHG \FGDSYVSWFAYWGQGTLVTVSS EVQLVESGGGLVQPGGSLKLSCAASGFTF\KYAM\WVRQAPGKGLEWVAR anti-CD3 VH8 IRSKYBNYATYYADSVKDRFTISRDDSKNTAYLQMVNLKTEDTAVYYCVRH GNFG\ SYISYWAYWGQGTLVTVS EVQLVESGGGLVQPGGSLRLSCAASGFTF\TYA\/f\WVRQAPGKGLEWVARI anti-CD3 VH9 RSKY\\YATYYADSVKGRFTISRDDSKNTLYLQNIRSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTTVTVSS ,_i EVQLVESGGGLVQPGGSLRLSCAASGFTF\TYAV[\WVRQAPGKGLEWVARI anti-CD3 VH10 RSKY\\YATYYADSVKGRFTISRDDSKNTLYLQNIBSLRAEDTAVYYCVRHG \FG\SYVSYFAYWGQGTTVTVSS SGGGLVQPKGSLKLSCAASGFTF\TYA\/f\WVRQAPGKGLEWVARI anti-CD3 VHll RSKY\\YATYYADSVKDRFTISRDDSQSILYLQMNVLKTEDTAMYYCVRHG \FG\SYVSWFAYWGO GTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTF\TYAVRWVRQAPGKGLEWVARI anti-CD3 VH12 RSKY\\YATYYADSVKGRFTISRDDAKNTLYLQMSSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVKP EVQLVESGGGLVQPGGSLRLSCAASGFTF\TYAVD.WVRQAPGKCLEWVARI anti-CD3 VH13 RSKY\\YATYYADSVKGRFTISRDDAKNTLYLQMSSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVKP EVQLVESGGGLVQPGGSLRLSCAASGFTF\TYAV[\WVRQAPGKGLEWVARI anti-CD3 VH14 YATYYADSVKGRFTISRDDAK\TLYLQVISSLRAEDTAV Y Y CVRHG \FG\SYVSWFAYWGCGTLVTVKP 46 EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVARI anti-CD3 VH15 RSKY\\YATYYADSVKGRFTISRDDAK\TLYLQVISSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVSRI anti-CD3 VH16 RSKY\\YATYYADSVKGRFTISRDDAK\TLYLQVISSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRI anti-CD3 VH17 RSKY\\YATYYADSVKGRFTISRDDAK\TLYLQVISSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKCLEWVARI anti-CD3 VH18 RSKY\\YATYYADSVKGRFTISRDDAK\TLYLQVISSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKCLEWVSRI anti-CD3 VH19 RSKY\\YATYYADSVKGRFTISRDDAK\TLYLQVISSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKCLEWVSRI D3 VHZO RSKY\\YATYYADSVKGRFTISRDDAK\TLYLQVISSLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKCLEWVGRI anti-CD3 VH21 RSKY\\YATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKCLEWVARI anti-CD3 VHZZ RSKY\\YATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVKLVESGGGLVKPGRSLRLSCAASGFTFNTYAMNWVRQAPGKCLEWVARI anti-CD3 VH23 RSKY\\YATYYADSVKDRFTISRDDSKSILYLQWMKEDTAMYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVKLVESGGGLVKPGRSLRLSCAASGFTFNTYAMNWVRQAPGKCLEWVARI anti-CD3 VH24 YATYYADSVKDRFTISRDDSKSILYLQMBSLKTEDTAMYYCVRHG \FG\SYVSWFAYWGO GTLVTVSS EVKLVESGGGLVKPGRSLRLSCAASGFTFNTYAMNWVRQAPGKCLEWVARI D3 VHZS RSKY\\YATYYADSVKDRFTISRDDSKSILYLQMI\SLKTEDTAMYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMI\WVRQAPGKCLEWVSRI anti-CD3 VH26 RSKY\\YATYYADSVKGRFTISRDDSKNTLYLQM\SLRAEDTAVYYCVRHG \FG\SYVSWFAYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKCLEWVGRI anti-CD3 VH27 RSKY\\YATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHG \FGDSYVSWFAYWGO GTLVTVSS SGGGLVQPGGSLKLSCAASGFTFNKYAM\WVRQAPGKCLEWVAR anti-CD3 VH28 IRSKYLNYATYYADSVKDRFTISRDDSKMAYLQWMKTEDTAVWCVRH GNFGNSYISYWAYWGQGTLVTVS SGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKCLEWVARI anti-CD3 VH29 RSKYNWATWADSVKGRFTISRDDSKNTLYLQMBSLRAEDTAVYYCVRHG NFGNSYVSWFAYWGQGTTVTVSS O\ H EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKCLEWVARI anti-CD3 VH30 RSKYNWATYYADSVKGRFTISRDDSKNTLYLQMBSLRAEDTAVYYCVRHG NFGNSYVSYFAYWGQGTTVTVSS O\N EVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKCLEWVARI anti-CD3 VH31 ATWADSVKDRFTISRDDSQSILYLQMNNLKTEDTAMYYCVRHG NFGNSYVSWFAYWGQGTLVTVSS QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGG D3 VLl TNKRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNLWVFGGGT KLTVL 64 QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGG anti-CD3 VL2 TNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGCG TKLEIK QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGG anti-CD3 VL3 T\KRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGG QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGG anti-CD3 VL4 T\KRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGT KLTVL QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGG anti-CD3 VL5 T\KKAPGVPARFSGSILGNKAALTITGAQADDESIYFCALWYSNLWVFGGGT- KLTVL QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGG anti-CD3 VL6 T\KRAPGVPARFSGSILGNKAALTITGAQADDESDYYCALWYSNLWVFGGG TKLTVL QAVV 1 QEPSLTVSPGGTVTLTCGSSTGAVTTS\YANWVQEKPGQAFRGLIGG anti-CD3 VL7 T\KRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGG TKLTVL \]O QT V V I QEPSLTVSPGGTVTLTCGSSTGAVTSG\YPNWVQQKPGQAPRGLIGG D3 VL8 TKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL \] H QAV V l QEPSLTVSPGGTVTLTCGSSTGAVTTS\YANWVQQKPGQAFRGLIGG anti-CD3 VL9 T\KRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGG TKLEIK QAV V l QEPSLTVSPGGTVTLTCGSSTGAVTTS\YANWVQQKPGQAFRGLIGG anti-CD3 VL 10 T\KRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGCG TKLEIK QAV V l QEPSLTVSPGGTVTLTCGSSTGAVTTS\YANWVQQKPGQCFRGLIGG anti-CD3 VLl 1 T\KRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGEG TKLEIK \]4; QAV V | QESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGG anti-CD3 VL 12 T\KRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNLWVFGCGT KLTVL QAV V I QEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGG anti-CD3 VL13 GVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGKLEIK %O§j/OCJ%OAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGG anti-CD3 VL 14 \KRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGC TKLTVL AVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGG anti-CD3 VL15 KRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGT AVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGG anti-CD3 VL16 \KRAPGVPARFSGSILGNKAALTITGAQADDESIYFCALWYSNLWVFGCGT OAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGG anti-CD3 VL17 \KRAPGVPARFSGSILGNKAALTITGAQADDESDYYCALWYSNLWVFGCG KLTVL "IOAV V l QEPSLTVSPGGTV'ILTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGG D3 VL18 TPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGCG TKLTVL QT V V I QEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGG anti-CD3 VL19 TKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGCG TKLTVL 00N DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV Knob FC KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPT DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMRSRTPEVTCVVVDVSHEDPEV Hole FC KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPT 004; DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH EALHNHYTQKSLSLSPT DKTHTCPPCPAPGGPSVFLFPPKPKDTLMRSRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPT PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMRSRTPEVTCVWDVSHEDPEV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPS ESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPG 00 00 DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH EALHNHYTQKSLSLSPG DKTHTCPPCPAPGGPSVFLFPPKPKDTLMRSRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV MHEALHNRYTQKSLSLSPT \O H DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHE TQKSLSLSPT DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV MHEALHNRYT OKSLSLSPG \O LA) DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNRYTQKSLSLSPG \0J; DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVTCVVVDVSHEDPEVK Knob Fc FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVV HEALHNHYTQKSLSLSPT \0 U1 DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPEVTCVVVDVSHEDPEVKFN Knob Fc EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVVH EALHNHYTQKSLSLSPT DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVV HEALHNHYTQKSLSLSPG O\l DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVVH EALHNHYTQKSLSLSPG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVVH EALHNRYTQKSLSLSPT DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVVHE ALHNRYTQKSLSLSPT DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS PIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVVH EALHNRYTQKSLSLSPG DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAV QPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVVHE ALHNRYTQKSLSLSPG i 13 nkn ?—* 14 LEADGSRQARVG Linker ,_i ,_i 5 GGEGGGGSGGSGGGS Linker 116 GSSAGSEAGGSGQAGVGS Linker 1 17 GGSGGGGLEAEGSGGGGS Linker 118 GGSGGGGIEPDPGGSGGS Linker GGGGGSGGGGGSGGGGGS Linker SGGGLVQPGGSLRLSCAASGFTLDNYAIGWFRQAPGKEREGVSCIS FR alpha sdAb SSDGSTYYADSVKGRFTISRNNAKGTVYLLMNSLKPEDTAV Y Y CATELVPAC TYSNGRGPLDGMDYWGKGTQVTVKP 121 EVQLLESGGGEVQPGGSLRLSCAASGSIFSIDATAWYRQAPGKQRELVAIITSS FR alpha sdAb GSTNYPESVKGRFTISRDNAKNTVYLQMSSLRAEDTAVYYCNAITRYGGSTY DFWGQGTLVTVKP SVKGRFTISSDFARNTVYLQMNSLRAEDTAVYYCNTGAYWGQGTLVTVKP 123 EVQLVESGGGLVQPGGSLRLSCAASGFILDYYAIGWFRQAPGKEREGVLCID cMETsdAb ASDDITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTGVYYCATPIGLSSS CLLEYDYDYWGQGTLVTVKP EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYI B7H3 scFV SSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENI YYGSRLDYWGQGTTVTVSSSGGGGSGGGGSGGGGSDIQLTQSPSFLSASVGD RVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGT DFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGR CD20 scFV DTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFD GYWLVYWGQGTLVTVSGSGGGGSGGGGTGGGGSDIVMTQTPLSLPVTPGEP ASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSG SGTDFTLKISRVEAEDVGVYYCAONLELPYTFGGGTKVEIK QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYVYY DLL3 scFV SGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFD LVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERVTLSCRA SQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR LEPEDFAVYYCQQYDRSPLTFGGGTKLEIK EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYI B7H3 Fd SSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENI YYGSRLDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSC DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSAS B7H3 LC YRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR EVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVARI RSKSNNYATYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRQ WDYDVRAMNYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVEPKSC DIVMTQSHIFMSTSVGDRVSITCKASQDVDTAVAWYQQKPGQSPKLLIYWAS TRLTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPYTFGGGTKLE IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYI YYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNY FDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSC EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGAS TRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKV EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS FNRGEC QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMAW DLL3 Fd INTYTGEPTYADDFKGRFAFSLETSASTASLQIINLKNEDTATYFCARIGDSSPS DYWGQGTTLTVSSSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSC SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVVWYQQKPGQSPKLLIYYAS DLL3 LC NRYTGVPDRFAGSGYGTDFSFTISTVQAEDLAVYFCQQDYTSPWTFGGGTKL EIRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS FNRGEC Linker Linker IEPDG Linker Linker Linker Linker _Linker IEPDP Linker QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGG Second TNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGG Polypeptide GTKLTVLGGGGSGGGGEVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMH Chain of B7-H3 WVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSL X CD3 Bispecific RDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSSGGCGGGKVAALKEK DART-A VAALKEKVAALKEKVAALKE Diabody DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV Third KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK Polypeptide PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPS Chain of B7-H3 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV X CD3 ific MHEALHNRYTQKSLSLSPGK GGSGGGGSGGGGSGGGGS TGGSGGGGIEPDIGGSGGS X1X2X3X4X5(P4P3P2P1¢P1) X1= I, L, Y, M, F, V, orA; (P4=I, L,Y M F, V,or A) X2=A, G, S,V,E,D,Q,N,0rY; (P3=A G, S, V,E,D, Q,N,0rY) Linker consensus X3=H,P,A,V,G,S,orT;(P2=H,P, ,AV,,G S,oraT) K4=DorE;(Pl=DorE) X5=1,L,Y,M,F,V,T, S,GorA(Pl’=I,,YM,,FV,TSGorA) X1EX3DX5 (P4 P3 PZPIiPl’) X1=IorL;(P4=IorL) (P3 = E) Linker consensus K3— PorA (P2— PorA) K5=I, V, T, S, orG(Pl’=I, V, T S, orG) LEADG XlQARX5 (P1QARi(A/V)) X1 = any amino acid; (P1 is any amino acid) Linker consensus X5: A or V RQARK5 (RQAR(A/V)) X1X2 X3 X4 (P3 P2 P1 1 P1’) X1 =P,VorA; (P3 =P,VorA) X2 = Q or D; (P2 = Q or D) Linker consensus X3 =AorN;(P1=AorN) X4 =L,IorM (131’ =L,IorM) PX2X3X4 (P3 P2 P1 1 P1’) (P3 = P) X2 = Q or D; (P2 = Q or D) Linker consensus X3 =AorN;(P1isAorN) X4=LorI Pl’isLorI) 162 n2A 163 EGRGSLLTCGDVEENPGP TZA 164 LEGGGEGRGSLLTCGDVEENPGPR T2A GGAGAATCCCGGACCC k66 nkn 167 EVQLVESGGGL VQPKGSLKLS TFNT YAMNWVRQAP VARI RSKSNNYATY YADSVKDRFT ISRDDSQSlVIL anti-5T4 VH YLQMNNLKTE DTAMYXCVRQ WDYDVRAMNY WGQGTSVTVS S SHIF MSTSVGDRVS ITCKASQDVD TAVAWYQQKP LIYW GVPD RFTGSGSGTD FTLTISNVQS anti-5T4 VL EDLADYFCQQ TFGG GTKLEIK DIQLTQSPSF LSASVGDRVT ITCKASQNVD TNVAWYQQKP GKAPKALIYS ASYRYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNNYPFTFGQ GTKLElKGGG SGGGGEVQLV ESGGGLVQPG GSLRLSCAAS GFTFSTYAMN WVRQAPGKGL EWVGRIRSKY YADS VKDRFTISRD First Polypeptide YLQM NSLKTEDTAV YYCVRHGNFG NSYVSWFAYW Chain of B7-H3 GQGTLVTVSS GGCGGGEVAA LEKEVAALEK EVAALEKEVA X CD3 Bispecific ALEKGGGDKT HTCPPCPAPE AAGGPSVFLF PPKPKDTLMI SRTPEVTCVV DART-A VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV Diabody SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SREEMTKNQV SLWCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL wherein n is 0 to 10 wherein n is 1 to 4 wherein n is 1 to 5 174 GlyXXaa-Glyy-Xaa-GlyZ Linker Xaa is independently selected from A, V, L, I, M,F, W, P, G, S, T, C, Y, N,Q, K, R, H, D, or E X, and z are each inte_ers in the rane from 1-5 Gly-Gly-Gly-Xaa—Gly-Gly-Gly-Xaa—Gly-Gly-Gly Linker Xaa is independently selected from A, V, L, I, M,F, W, P, G, S, T, C, Y, N,Q, K, R, H, D, or E 176 ATTTGSSPGPT Linker 177 C-GGGGG Linker 178 (EAAAK)n Linker n=2-20 180 AS-(EAAAK)n—GT n=2-20 n=2-20 n=2-20 183 (AGGGS)n n=2-20 184 GKSSGSGSESKST)n—GGS n=2-20 185 (SSSSG)n n=1-9 186 SSSASASSA 188 QVQLQESGPG LVKPSETLSL TCTVSGGSIS SYYWSWIRQP PGKGLEWIGY DLL3 scFV V Y Y SGTTNYN PSLKSRVTIS QFSL KLSSVTAADT AV Y Y CASIAV TGFYFDYWGQ GTLVTVSSGG GGSGGGGSGG GGSEIVLTQS PGTLSLSPGE RV'ILSCRASQ RVNNNYLAWY QQRPGQAPRL SRAT GIPDRFSGSG SGTDFTLTIS RLEPEDFAVY YCQQYDRSPL TFGGGTKLEI K QVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA CD20 VH PGQGLEWMGR IFPGDGDTDY NGKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNV FDGYWLVYWG QGTLVTVSS 190 DIVMTQTPLS LPVTPGEPAS ISCRSSKSLL HSNGITYLYW YLQKPGQSPQ CD20 VL LLIYQMSNLV SGVPDRFSGS TLKI SRVEAEDVGV YYCAQNLELP YTFGGGTKVE IKRTV

Claims (9)

1. A multispecific polypeptide construct, the multispecific polypeptide construct comprising a first component comprising a heterodimeric immunoglobulin Fc region and a second component comprising a CD3-binding region, wherein: the CD3-binding region is an D3 antibody or antigen-binding nt thereof that is a disulfide stabilized anti-CD3 binding Fv fragment (dsFv) sing a variable heavy chain region (VH) and a variable light chain region (VL), wherein the VH of the Fv antibody fragment is linked to one polypeptide of the Fc region, and the VL of the Fv antibody fragment is linked to the other polypeptide of the heterodimeric Fc region; the first and second components are coupled by a linker, wherein the Fc region is positioned N-terminal to the CD3-binding region; and one or both of the first and second components ses an antigen binding domain that binds a tumor associated antigen (TAA); and the CD3-binding region is not able to, or is not ntially able to, bind or engage cell surface CD3 unless at least one antigen binding domain is bound to its TAA.

2. The multispecific polypeptide uct of claim 1, wherein the nding region binds CD3 (CD3e).

3. The multispecific construct of claim 1 or claim 2, wherein the antigen binding domain is positioned amino-terminally relative to the Fc region and/or positioned carboxyterminally ve to the CD3-binding region of the multispecific ptide construct.

4. The multispecific polypeptide construct of any of claims 1-3, wherein the first component comprises a first antigen binding domain and the second component comprises a second antigen binding domain, n each of the antigen binding domains bind a tumor associated antigen (TAA).

5. The multispecific polypeptide construct of claim 4, wherein the first antigen binding domain is positioned amino-terminally relative to the Fc region of the multispecific polypeptide construct and the second antigen binding domain is positioned carboxy-terminally relative to the CD3-binding region of the multispecific construct.

6. The multispecific polypeptide construct of any of claims 1-5, wherein the Fc region is an Fc region of a human IgG1, a human IgG2, a human IgG3, or a human IgG4, or is an immunologically active fragment thereof.

7. The multispecific polypeptide construct of any of claims 1-6, n the Fc region comprises: a polypeptide sing the amino acid sequence set forth in SEQ ID NO: 1 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,

99. % sequence identity to SEQ ID NO:1; a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,

99% sequence identity to SEQ ID NO:2; a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,

99% sequence identity to SEQ ID NO:4; or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 5 or a ce of amino acids that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,

99% ce identity to SEQ ID NO:5.

8. The multispecific polypeptide construct of any of claims 1-7, wherein one or both Fc polypeptide of the heterodimeric Fc region ses at least one modification to promote heterodimerization compared to a ptide of a homodimeric Fc region, ally compared to the Fc polypeptide set forth in SEQ ID NO:1 or an immunologically active fragment thereof.

9. The multispecific polypeptide construct of claim 8, wherein each of the Fc polypeptides of the heterodimeric Fc comprise a knob-into-hole modification or se a charge mutation to increase electrostatic complementarity of the polypeptides.

10. The multispecific fusion polypeptide of claim 8 and claim 9, wherein the first Fc polypeptide of the dimeric Fc comprises the modification ed from among Thr366Ser, Leu368Ala, Tyr407Val, and combinations thereof and the second Fc polypeptide of the heterodimeric Fc comprises the modification T366W and optionally wherein the first and second Fc polypeptides further comprises a modification of a non-cysteine residue to a ne e, wherein the modification of the first polypeptide is at one of the position Ser354 and Y349 and the modification of the second Fc polypeptide is at the other of the position Ser354 and Y349.

11. The multispecific polypeptide construct of claim 9, wherein the amino acid modification is a charge mutation to increase electrostatic complementarity of the polypeptides.

12. The pecific ptide construct of any of claims 1-11, wherein the Fc region comprises a polypeptide comprising the modification Ile253Arg or His435Arg.

13. The multispecific polypeptide construct of any of claims 1-12, wherein the Fc region ses a polypeptide comprising at least one cation to enhance FcRn binding.

14. The multispecific fusion polypeptide of claim 13, wherein the modification is at a position selected from the group consisting of Met252Y, Ser254T, Thr256E, Met428L, Met428V, Asn434S, and combinations thereof.

15. The multispecific polypeptide construct of any of claims 1-14, wherein the first polypeptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS: 82, 86, 94 or 96, and the second polypeptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS:83, 87, 90, 92, 98 or 100.

16. The multispecific polypeptide construct of any of claims 1-15, wherein the Fc region comprises a polypeptide comprising at least one amino acid modification that reduces effector function and/or reduces binding to an effector molecule selected from an Fc gamma receptor or C1q.

17. The multispecific polypeptide construct of claim 16, n the one or more amino acid modification is on of one or more of Glu233, Leu234 or .

18. The multispecific polypeptide construct of any of claims 1-14, 16, and 17, wherein the first polypeptide of the heterodimeric Fc comprises the ce of amino acids set forth in any of SEQ ID NOS: 84, 88, 95 or 97 and the second polypeptide of the heterodimeric Fc comprises the sequence of amino acids set forth in any of SEQ ID NOS: 85, 89, 91, 93, 99 or

19. The multispecific polypeptide construct of any of claims 1-18, wherein the CD3 binding region is monovalent.

20. The multispecific polypeptide uct of any of claims 1-19, wherein the linker is a polypeptide linker.

21. The multispecific polypeptide construct of any of claims 1-20, wherein the linker is a cleavable linker.

22. The multispecific polypeptide construct of claim 21, wherein binding of the CD3- binding region to CD3 is substantially reduced when the multispecific polypeptide construct is in an uncleaved state compared to a cleaved state.

23. The multispecific ptide construct of claim 21 or 22, wherein the cleavable linker is a polypeptide that functions as a substrate for a protease.

24. The multispecific polypeptide construct of claim 23, n the protease is produced by an immune effector cell, by a tumor, or by cells present in the tumor microenvironment.

25. The multispecific polypeptide construct of claim 23 or claim 24, wherein the protease is selected from among matriptase, a matrix metalloprotease (MMP), granzyme B, and combinations f.

26. The multispecific polypeptide construct of claim 25, wherein the protease is granzyme B.

27. The multispecific polypeptide construct of any of claims 21-26, wherein the cleavable linker comprises an amino acid sequence of the general formula P4 P3 P2 P1 ? P1’ (SEQ ID NO: 150), n P4 is amino acid I, L, Y, M, F, V, or A; P3 is amino acid A, G, S, V, E, D, Q, N, or Y; P2 is amino acid H, P, A, V, G, S, or T; P1 is amino acid D or E; and P1’ is amino acid I, L, Y, M, F, V, T, S, G or A, optionally an amino acid sequence of the general formula P4 P3 P2 P1 ? P1’ (SEQ ID NO: 151), wherein P4 is amino acid I or L; P3 is amino acid E; P2 is amino acid P or A; P1 is amino acid D; and P1’ is amino acid I, V, T, S, or G.

28. The multispecific ptide construct of any of claims 21-27, wherein the cleavable linker comprises the amino acid sequence IEPDI (SEQ ID NO:136), LEPDG (SEQ ID NO:152, LEADT (SEQ ID NO:137), IEPDG (SEQ ID NO:138), IEPDV (SEQ ID ), IEPDS (SEQ ID NO:140), IEPDT (SEQ ID ) or LEADG (SEQ ID NO:153).

29. The multispecific polypeptide uct of any of claims 21-28, wherein the cleavable linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:22, 105-112, 136-141, 148,150-153.

30. The multispecific polypeptide construct of claim 25, wherein the protease is matriptase.

31. The multispecific polypeptide construct of any of claims 21-30, wherein: the cleavable linker comprises the sequence P4QAR? (A/V) (SEQ ID NO: 154), wherein P4 is any amino acid; ally the sequence RQAR(A/V) (SEQ ID NO: 155) or the sequence RQARV (SEQ ID NO: 156).

32. The multispecific polypeptide construct of any of claims 21-31, wherein the cleavable linker comprises an amino acid sequence ed from the group consisting of SEQ ID NOs: 23, 154-156.

33. The pecific polypeptide construct of claim 25, wherein the se is an MMP; optionally MMP-2.

34. The multispecific polypeptide construct of any of claims 21-33, wherein the cleavable linker comprises the general formula P3 P2 P1 ? P1’ (SEQ ID NO: 157), wherein P3 is P, V or A; P2 is Q or D; P1 is A or N; and P1’ is L, I or M, optionally the l formula P3 P2 P1 ? P1’ (SEQ ID NO: 158), wherein is P; P2 is Q or D; P1 is A or N; and P1’ is L or I, optionally the sequence PAGL (SEQ ID NO:24).

35. The multispecific polypeptide construct of any of claims 21-34, wherein the cleavable linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:22-31, 104-114, 117-118, 136-144, 148, 150-158.

36. The multispecific polypeptide construct of any of claims 19-35, wherein the multispecific ptide construct ses at least (i) a first polypeptide comprising the first Fc polypeptide of the heterodimeric Fc , the linker and the VH domain of the anti-CD3 antibody or antigen binding fragment; and (ii) a second polypeptide sing the second Fc polypeptide of the heterodimeric Fc region, the linker and the VL domain of the anti-CD3 antibody or antigen binding fragment , wherein one or both of the first and second polypeptide comprise at least one antigen-binding domain that binds to a tumor associated antigen (TAA).

37. The multispecific polypeptide construct of any of claims 1-36, n the one or more antigen binding domain that binds a TAA results in monovalent, bivalent, trivalent, or tetravalent binding to the TAA.

38. The multispecific polypeptide construct of claim 36 or claim 37, wherein: the at least one antigen binding domain is positioned amino-terminally relative to the Fc region and/or is positioned carboxy-terminally relative to the CD3 g region of one of the first or second polypeptide of the multispecific polypeptide uct; or the first antigen binding domain is positioned amino-terminally relative to the Fc region of the multispecific construct and the second antigen binding domain is positioned carboxyterminally relative to the CD3 binding region of the multispecific construct.

39. The multispecific polypeptide construct of any of claims 1-38, wherein the antigen binding domain, or independently each of the antigen binding domains, is an antibody or antigen-binding fragment f ed from the group consisting of a Fab fragment, a F(ab')2 fragment, an Fv fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody.

40. The multispecific polypeptide construct of claim 39, wherein the antibody or antigen-binding nt thereof is a Fv, a scFv, a Fab, a single domain antibody (sdAb), a VNAR, or a VHH.

41. The multispecific polypeptide construct of claim 39 or claim 40, wherein the antibody or antigen binding fragment is a Fab and the multispecific polypeptide construct comprises: (i) a first polypeptide comprising the first Fc polypeptide of the heterodimeric Fc region, the linker and the VH domain of the anti-CD3 antibody or antigen g nt; (ii) a second polypeptide comprising the second Fc polypeptide of the heterodimeric Fc region, the linker and the VL domain of the anti-CD3 antibody or antigen binding fragment, and (iii) a third polypeptide comprising a VH-CH1 (Fd) or VL-CL of a Fab antibody fragment that binds to a tumor-associated antigen, wherein the first and/or second polypeptide further comprises the other of the VH-CH1 (Fd) or VL-CL of the Fab antibody fragment.

42. The multispecific polypeptide construct of claim 41, wherein: only one of the first or second polypeptide comprises the other of the VH-CH1 (Fd) or VL-CL of the Fab antibody fragment; or both the first and second polypeptide comprises the other of the VH-CH1 (Fd) or VL-CL of the Fab antibody fragment.

43. The multispecific polypeptide construct of claim 41 or claim 42, wherein: the other of the VH-CH1 (Fd) or VL-CL of the Fab antibody fragment is positioned amino to the Fc region and/or at the y to the CD3 binding region of one of the first or second ptide of the multispecific polypeptide construct; or the other of the VH-CH1 (Fd) or VL-CL of the Fab dy fragment is positioned amino to the Fc region of the first polypeptide or second polypeptide and at the carboxy to the CD3 binding region of the other of the first or second polypeptide.

44. The multispecific polypeptide construct of any of claims 1-43, wherein the antigen binding , or independently each of the antigen binding domains, binds to a tumor ated antigen (TAA) selected from among 1LFA-3, 5T4, Alpha-4 integrin, Alpha-V integrin, alpha4beta1 integrin, beta7 integrin, AGR2, Anti-Lewis-Y, Apelin J receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, , (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CD11a, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD40L, CD41, CD44, CD44v6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD137, CD138, CD166, CD172A, CD248, CDH6, CEACAM5 (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, , CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL3, DLL4, DPP-4, DSG1, EDA, EDB, EGFR, EGFRviii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FRa), 1, G-CSF, GCSFR , GD2, GITR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP IIb/IIIa ors, Gp130, GPIIB/IIIA, GPNMB, GRP78, HER2/neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGF1R, IL1B, IL1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbeta1, IL13, IL13R, IL15, IL17, IL18, IL21, IL23, IL23R, IL27/IL27R (wsx1), IL29, IL-31R, IL31/IL31R, IL2R, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged s, Jagged 1, Jagged 2, KISS1-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPD1, MCSP, elin, MRP4, MUC1, Mucin-16 (MUC16, CA-

125. , Na/K ATPase, NGF, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, OX-40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidyl-serine, P1GF, PSCA, PSMA, PSGR, RAAG12, RAGE, 4, Sphingosine 1 Phosphate, STEAP1, STEAP2, TAG-72, TAPA1, TEM-8, TGFbeta, TIGIT, TIM-

3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, TNFR, TNFRS12A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAP1, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, VISTA, WISP-1, WISP-2, and WISP-3.

45. The multispecific polypeptide construct of any of claims 1-44, wherein the pecific polypeptide uct comprises at least a first antigen binding domain and a second antigen binding domain, n the first antigen binding domain and second antigen binding domain bind to the same TAA.

46. The multispecific polypeptide construct of any of claims 1-45, wherein the multispecific polypeptide construct comprises at least a first antigen binding domain and a second antigen binding domain n the first n binding domain and the second antigen binding domain bind a different TAA.

47. The multispecific polypeptide construct of any of claims 1-46, wherein the multispecific polypeptide construct comprises a first linking peptide (LP1) between the first antigen binding domain and the Fc region and a second linking peptide (LP2) between the CD3 g region and the second antigen binding domain, and wherein the multispecific polypeptide construct has the structural arrangement from N-terminus to C-terminus as follows: first n binding domain – LP1- Fc region r –CD3 binding region – LP2 – second antigen binding domain.

48. The multispecific polypeptide construct of any of claims 1-47, wherein the anti- CD3 antibody or antigen-binding fragment comprises a VH CDR1 comprising the amino acid sequence TYAMN (SEQ ID NO: 16); a VH CD2 comprising the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17); a VH CDR3 comprising the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDR1 sing the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence P (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence ALWYSNLWV (SEQ ID NO: 21).

49. The multispecific polypeptide construct of claim 48, wherein the anti-CD3 dsFv comprises: a VH having the amino acid ce of any of SEQ ID NOS: 44 and 49-62 or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOS: 44 and 49-62; and a VL having the amino acid sequence of any of SEQ ID NOS: 64, 72, 74, 76, or 78-81 or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOS: 64, 72, 74, 76, or 78-81.

50. The multispecific polypeptide construct of claim 48 or 49, n the anti-CD3 dsFv comprises: a VH having a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%,

97. %, 98% or 99% sequence identity to SEQ ID NO: 44; and a VL having a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%,

97%, 98% or 99% sequence identity SEQ ID NO: 72.

51. The multispecific polypeptide construct of any of claims 48-50, wherein the anti- CD3 dsFv comprises the amino acid sequence of SEQ ID NO: 44 and the amino acid sequence of SEQ ID NO: 72.

52. The multispecific polypeptide construct of any of claims 1-51, wherein the pecific polypeptide construct is conjugated to an agent, optionally wherein the agent is a therapeutic agent, an antineoplastic agent, a toxin or fragment thereof, a detectable moiety or a diagnostic agent.

53. A polynucleotide(s) ng any one of the multispecific polypeptide constructs of any of claims 1-52.

54. A polynucleotide encoding a polypeptide chain of any one of the multispecific polypeptide constructs of any of claims 1-52.

55. A polynucleotide, comprising a first nucleic acid sequence encoding a first polypeptide of a pecific uct of any of claims 1-52 and a second nucleic acid sequence encoding a second polypeptide of the multispecific construct of any of claims 1-52, wherein the first and second c acid sequence are separated by an internal me entry site (IRES), or a nucleic acid encoding a self-cleaving e or a peptide that causes ribosome skipping.

56. The polynucleotide of claim 55, wherein the multispecific ptide construct comprises a third polypeptide chain, and the polynucleotide further comprises a third nucleic acid encoding the third ptide of the multispecific construct, optionally wherein the third nucleic acid is separated from the first and/or second polypeptide by an internal ribosome entry site (IRES), or a nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping and/or the third nucleic acid ce is operably linked to the same promoter as the first and/or second nucleic acid sequence.

57. A vector, comprising the polynucleotide of any of claims 53-56.

58. An isolated cell, comprising a polynucleotide or polynucleotides of any of claims

53-56, or a vector of claim 57.

59. A method of producing a multispecific polypeptide construct, the method comprising introducing into a cell a polynucleotide or polynucleotides of any of claims 53-56 or a vector of claim 57 and culturing the cell under conditions to produce the multispecific ptide construct.

60. A method of producing a multispecific polypeptide construct, the method comprising culturing the cell of claim 58 under ions in which the multispecific polypeptide is produced by the cell.

61. A multispecific polypeptide construct produced by the method of claim 59 or claim 60.

62. A ceutical composition comprising the multispecific polypeptide construct of any of claims 1-52 and claim 61 and a pharmaceutically acceptable carrier.

63. A method of stimulating or inducing an immune response, the method comprising contacting an isolated target cell and an isolated T cell with the pecific polypeptide construct of any of claims 1-52 and claim 61 or the pharmaceutical composition of claim 62, said target cell expressing a tumor associated n recognized by the multispecific polypeptide construct.

64. The method of claim 63, wherein the target cell is a tumor cell expressing the tumor associated antigen (TAA).

65. The method of claim 63 or claim 64, wherein the multispecific polypeptide uct comprises a ge linker that functions as a substrate for a protease and the inducing or stimulating the immune response is increased in the presence of the protease.

66. The method of any of claims 63-65, wherein the protease is selected from among matriptase, a matrix metalloprotease (MMP), granzyme B, and ations thereof.

67. The method of any of claims 63-66, n the contacting is carried out ex vivo or in vitro.

68. Use of a therapeutically effective amount of the multispecific conjugate of any of claims 1-52 and claim 61 or the pharmaceutical composition of claim 62 for the manufacture of a medicament for the treatment of a disease or condition in a subject in need thereof.

69. The use of claim 68, n the treatment of a disease or ion in a subject comprises stimulation of an immune response in the subject.

70. The use of claim 68 or claim 69, wherein the disease or condition is a tumor or a cancer.

71. The use of claim 69, wherein the immune response is increased against a tumor or cancerUmmain mi U Region Binding Linker 'E “E Binding Antigen Pentide ‘D

4...: {I} Linker

3: C03 % i % termmu: terminua % N {I m \\\\\\\ " ”In..\\\\\\\\ \\\\\\\\\ \\\\\\\\ -- Illll" \\\\\\\\ " ""III \\\\\\\\ * till“,\?m \\\\\\\ \\ “ll“ll'"“II’ \\\\\\\\ FIG“:W «uni \\\\\\\ *— :IIIII’ , \\\\\\\\

33:54.3, an mt ?mum?uud\?m>mm_u EmEam‘ comma EmEon Ha g“5:353 WW, Emson?au imn-mau,§& BE mgmc?é? an nwmnuxm EmEon EwEon ?u Na Emcoquu \xx»m?m?amwmaxw “cmcanau um~m>$um§_\ww:mm_u:3 m:_u:_a-«é an mmmwwo?u??cm 3% Egg magma Na EmEom W * mgncai?ww4.99¢ W 99¢ \\~ 99* mgmga?p m Q mtEgan um‘wm$3M 92: QC_EE&E EmEon .mzm Himugmauécd gEE?com m gm??m mE?z?w LEE“ $3?me as“? $me €35“ E mmmm?n?m g m3§mmE52 ??gimavwgtmmzm mmmmwoi “Em‘g £355 mu dam?” vzoz NQ

8. :3 Emm?mmgw £3 g4? mamxu ”mam V .mm?? 3: ”mam um u”........\W ”mmu ?w?sm Q V Nwm?xu mmz??cou :oEcmouE \n R AW, \ ““amaf‘meu?éwmg?? ‘mmmws \,vE .0QEKMVAWMQ Q mmcmm?ceu Emcg

343. .. 3.3%E,

3qu Mm?? mmummg?amm mumhmnzm £3 mm”imousé E:

39:3; mmmmwaa EVE: £35 ?uaxm E“magma, w?gmwwu m3 E $3on Q mm ?gmm?scoz £3 ?g n33 ga?m m m E: QQEVTUHH HOE aocxl? ....................:>,m8§< c cmmgu NW :3...er gimouécq Q v» 3%+ Q5&% Eu @ Eggm?u maqmw a x‘x BEQQER a, E.“ EEC @V \?“ Av has mwoxaum AEEE: SEQ HQ ,5 Q ,2, mmar?i gd?m a ........gimm £3 5mm (53:: &...................;3:: ?g 3.3ch

5m“SEE 3m m mm?mxxmmmu Eagmwmuscaz .6.”— mmmmwQ‘E

85. $ng,30 mwMM>m $523? Umwmxu %:img 33m gun.%@ mawéUuq ”mmmmxu m?u ”0&me :mmU UUEQ EUR mUpUEUmmE :pwmauiscq 33%,

335. $: m um”.

25Emgu

303. Maw Qa?m n33 m 21m mm, SE m aging N UEd Emgu 5%

595. ,\ w. :mmgu. cmmgu 54;.U) Aw, H $036; mam} n33 mé? QUE,mam@mibm mmmgu 54$ ‘w :UwVEUU 3:4 dam mmexm? :3ch :cq 6% m?ua?cd 63 w?gmwwu m?gm Sq, weuw.GE $mean .9”

290. $ .GE ?EEom 88?“$§§E§$t: ngmm&m %®, mmmm \:\.x» ii ®® xi Qmomxu mag mag Emmgmbmb @15me §:< ”?ammmmmm mm gmm? aecx?m magmm? £3........mmim Ewm vigxsa.%® .Qm mwmwxu Emmmzm mmcgém 2.3%: mow .WE £3 mBmkrmmU E8 Amxc; swan...” Eu 305$qu mamémmumwum “m2“«£me

31u ...1

3...: In:§® 3% ......mm 0&3 Emma Emmm?coE Emwmgcowa ASE“ EVE: .6.» wwaasum aq Ewm guimév $3 ao?m? wEgmwwu gmmwu E3 mwmm mm 3:16 HwEu Ewm A.m3%®y «23% A..EVE;gig”: m3$£ farms:.xiwauzgq £3 mhmmxu Emmmgm Ewwmzm £43mm3 ad? E8 5.2.9 wagging; $33 EON w?gmwwo mama SEN.» 'un $8 .3 xv“Um éN® .533 WA..at

6E LEE.mmuzsc? 33%, Emwm‘éccm‘a «:wmmam m?agzum @366 am $me .EE m?mxfmm? ?inm mmnouam ?n mmow?w mxwm an mu ?cmmmu an Qd?m mmomxuH?mwmxxmm an vacuum wmmcmm a?um aqnm wwwmxu E?mam 3.3 vmamxu ”mam 3qu “5“?ng 05 $3,, mth mrmm mrnm mrhm $3 35

5mm E\W R” \HV,.

1 35Ava? mi ?gigmauéé% \izmmus?cd Q mm E m8

343 $3 mrmm mxmm Ea EVE; 2% E mBmxrmmU an Exam“ Nu 5’3; Qanm I> $35 NEE m5 :> 3un Egan m mrhm m .......mznm m8 SEQ Q m?uécéwg mrhm ??é mygm?u: équg $3 @oszm 33?me \va \W 5ME3 VQ kw x.“x 3Q .m

5 Ewan“ “?nkWA ‘,.I@.......wmmOIém ......EVE: ,3 mwor‘um gags: Ma .3 Mt mEmpmm? m?ux?cd $3173 ......wamC: wwgm>mmwu mauéc? gamma m?gmwmo £43 .mer mrmm

35m 3mm mrnm 383m mrhm ?um 83am mxmm #Hmmxu Emmmzm EmEm mxmm mmmmxo Emmgmm mmmcmm on??iimnu?é Eum n3 mxnm mrmm EVE: $meng $an c?mzua? mxmm €575 w?gmwwu M mimm mmu .......mim\ gacxém .......v: ma?mauéci £30 vw Q__M\\\\ » x\ v\\ m\u w &‘ .......Emcu .......mworag «avian mowic? Eum SEQ ’M: gazing gmxcz mums mrhm mrmm mwgmxfmmwu - mm max/mm? EEG

43m 333m EM mnou?w Em 333m

3mm, m?mmxu Em?gm gmgm g mmmmxu Em?am mmmcmm mmmmxu “Egg ”mam

3 £3 Nu m 9a £9,

3m Qdmm “3E E@33me 5mm“ 3,m% i mgxi m8,_§ onSEE onmewwEd Emzu $5: 6,3; u: E g umwv?c: E v I) .E Na N Em 33:23 23ng xpxmguéé QR WE £3 .......Smmam £3 33% v $33339: Emr? E Sm «?rm m>mmwu E \V Sud gocg‘? \«W ....r>,maué:4 V E V“, NWn} QQ ?EA.....i§§ ,3 “an“ Emzw A E mworém SEE ’8

3m $316 :5 w .,,,.....;mvm§ 69 m?gmm? : A::::._mw..vwcww m m3 maux?c? Egg 3?? 3030”,“ wm?m>mwwu maus?c?

9....—